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ABSTRACT 
 
 Due to its robustness, genetic tractability, and industrial relevance, the budding yeast 
Saccharomyces cerevisiae was selected as study model of the aromatic amino acid biosynthetic 
pathway. This pathway houses a wide diversity of economically important metabolites ranging 
from polymer precursors to pain-management drugs, whose productions have been highly 
sought-after in biotechnological research. However, tight regulations at the transcriptional, 
translational, and allosteric levels surround the aromatic amino acid pathway, protecting the 
microbial factories (e.g. S. cerevisiae) from unnecessary energy expenditures. By making use 
of computational metabolic engineering tools such as Flux Balance Analysis and Metabolic 
Flux Analysis, together with fast and reliable synthetic biology techniques, the flux into the 
aromatic amino acid pathway was exploited. Initially, the flux distribution in the central carbon 
metabolism was studied through 13C-metabolic flux analysis and carbon tracing experiments. 
Important insights regarding the partition between glycolysis and the pentose phosphate 
pathway were obtained and correlated with the production of aromatic amino acid derivatives. 
For the first time, the pentafunctional enzyme, ARO1, composing the core of the shikimic acid 
pathway was subjected to site-directed mutagenesis to reveal its active domains.  This resulted 
in the development of new variants with disrupted activities specifically designed for 
increasing production of the two target molecules, namely, muconic acid and shikimic acid. 
Further analysis with OptForce simulations revealed that overexpressing the ribose-5-
phosphate ketol-isomerase gene, RKI1, can enhance carbon funneling into the aromatic amino 
acid pathway. A multilevel engineering strategy was established to explore novel 
transcriptional regulators that tightly control the carbon flux into the pathway. Deleting the 
x 
 
 
gene RIC1, involved in efficient protein localization of trans-Golgi network proteins, increased 
the titers of shikimic acid and muconic acid. These non-intuitive interventions, in combination 
with the previous genetic platforms, increased the production titers over 3-fold compared to 
the base strains. The shikimic acid strains produced 1.9 g L-1, while muconic acid and 
intermediates were accumulated up to 1.6 g L-1, both being the highest reported in S. 
cerevisiae, in batch fermentations. Future research should focus on devising more dynamic 
genome engineering strategies that rely on modulating the activity of essential genes while 
ensuring a good compromise with biomass formation.  
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CHAPTER 1 INTRODUCTION  
1. Motivation 
The environmental impact caused by exploiting the natural sources of fossil fuels has led to 
extensive research in the biotechnology industry. The fermentation of cheap carbon sources 
through engineered microorganisms has proven to constitute a promising alternative to classic 
chemical synthesis processes that otherwise employ petrochemical feedstocks. For example, 
the manipulation of microorganisms like Escherichia coli and Saccharomyces cerevisiae has 
rendered powerful microbial factories for the production of a wide array of chemicals with 
diverse applications. Potentially, this reduces the exploitation of non-renewable fossil 
resources, and for several specialty chemicals, it removes the dependency of cumbersome 
extraction processes from plant tissues. In this light, fermentation with metabolically 
engineered microorganisms stands as a strong alternative with great potential to contribute 
towards diminishing worldwide economic and environmental issues. 
Utilizing microbes for the production of chemicals is an endeavor with decades of intense 
research. Since the conception of metabolic engineering over three decades ago, the budding 
yeast Saccharomyces cerevisiae has been an exceptional model organism for the discovery and 
conceptualization of entire production routes. Nowadays, with the development of state-of-
the-art technology, it is possible to model the yeast’s physiology from a molecular to a system-
wide level. Starting from the genetic landscape, whole genome sequencing, as well as powerful 
techniques like RNA-seq, have allowed exploiting of the concept of synthetic biology. 
Furthermore, knowing the genetic makeup of the cell permits its reconstruction into metabolic 
pathways for mathematical modeling of fluxes. The techniques denominated Flux Balance 
Analysis (FBA) and Metabolic Flux Analysis (MFA) are key to perform in silico simulations 
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for predictions of complicated metabolic states. Moreover, recent technologies for genome 
engineering have opened the door to unprecedented advances in the establishment of 
industrial-scale microbial platforms. For example, the discovery and repurposing of the 
prokaryotic adaptive immune system, composed of Clustered Regularly Interspaced Short 
Palindromic Repeats and CRISPR-associated genes (CRISPR-Cas), has unlocked a whole new 
era of powerful gene-editing tools.  
The system-wide concept of metabolic engineering has been put into practice with 
exemplary results. Some success stories in S. cerevisiae include the establishment of metabolic 
routes that challenge and revolutionize the concept of simple alcoholic fermentation. One great 
example is the production of the antimalarial drug artemisinin, and most recently the de novo 
production of the aromatic alkaloids. In this last case, however, it was clear that despite the 
intensive metabolic engineering applied, the yields still remained far from industrial-scale 
consideration.  
The family of aromatic amino acid derivatives is of particular interest to many sectors of 
the chemical industry. It encompasses a millionaire market including molecules that range 
from polymer precursors (e.g. muconic acid), drug precursors (e.g. shikimic acid), 
nutraceuticals (e.g. naringenin and resveratrol), and potent alkaloids (e.g. morphine). Yet, the 
scenarios of low product yields have evidenced a need to approach the engineering from 
different and more innovative perspectives. In this light, this thesis contains a comprehensive 
set of studies that combines the implementation and discovery of new metabolic engineering 
approaches towards establishing yeast microbial platforms for the biosynthesis of compounds 
derived from the aromatic amino acid pathway. Such approaches can be repurposed and 
expanded for other chemical derivatives of industrial importance.   
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2. Objectives 
The central goals supporting the core of this thesis were accomplished through the 
establishment of the following key objectives: 
• Evaluate the metabolic impact and connectivity of the aromatic amino acid pathway in 
relationship to the key pathways composing the central carbon metabolism in S. 
cerevisiae 
o Combine computational simulation with experimental calculations to predict 
carbon distributions among glycolysis, pentose phosphate pathway, and the 
aromatic amino acid pathway 
o Determine the minimal genetic elements required to engineer the central carbon 
metabolism to direct flux into production of aromatic chemicals 
o Determine the most suitable yeast expression host to enhance production titers 
• Establish multilevel engineering strategies to rationally engineer the production of 
aromatic amino acid derivatives 
o Identify and engineer endogenous enzymatic catalysts to allow carbon 
channeling for desired products  
o Identify transcriptional regulators that specifically target the family of genes in 
the aromatic amino acid pathway 
o Identify new metabolic interventions through implementing in silico systems-
wide genetic reconstruction models 
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3. Approach 
To enhance product formation deriving from the aromatic amino acid pathway in S. cerevisiae, 
computational and experimental metabolic engineering tools were implemented. It is important 
to mention that although the application for production of aromatic derivatives is case specific, 
the approach for pathway visualization and engineering can be adopted for any other product 
deriving from the same pathway or from a distinct one. Initially, the approach consisted of 
partitioning the aromatic pathway in different modules to localize the perturbations of interest. 
This allowed directing the attention toward targeting specific bottlenecks for a step-by-step 
resolution of the overall pathway. New versions of the pentafunctional enzyme Aro1 were 
developed to enable the accumulation of target compounds. To explore novel genetic 
interventions, in silico simulations of gene perturbations were employed through Metabolic 
Flux Analysis in combination with Flux Balance Analysis. Shikimic acid served as the 
molecular marker to track the titer improvements achieved by implementing the novel 
engineering strategies. By establishing a minimal genetic pathway for shikimic acid 
accumulation, a strain-dependent approach for metabolic engineering was successfully 
devised. This approach provides important insights into key regulatory points in the pathway 
of interest from comparing wildtype strains belonging to the same species but with slightly 
different genetic makeups. Moreover, this minimal genetic platform permitted the exploration 
of transcriptional regulator targets that negatively impact the production of aromatic 
compounds. 
Collectively, these strategies compile a series of efforts that led to the construction of 
competitive aromatic derivative production strains. A direct application of this work 
encompassed expanding the aromatic pathway toward the production of a heterologous 
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compound, namely muconic acid. Furthermore, a full production cycle was demonstrated 
where coupling the biological- and electrocatalysis allowed closing a common gap observed 
in the efforts of converting cheap sugars to industrially relevant products.  
The manipulations presented here for the production of aromatic derivatives have also been 
adopted for the production of similar compounds in the non-conventional yeast Pichia stipitis 
which possesses higher yield capabilities. This demonstrates that the innovative engineering 
rationale established in this thesis can serve as an engine for knowledge generation and can be 
easily be adapted for establishing microbial factories with industrial capabilities beyond the 
model organism S. cerevisiae. 
 
4. Report Organization 
An introduction to the aromatic amino acid biosynthetic pathway is presented in Chapter 2. 
This comprehensive review introduces several aromatic compounds, their economic 
importance, and their industrial application. Moreover, it covers the most recent metabolic 
engineering strategies to enable the production of aromatic compounds in S. cerevisiae. Next, 
Chapter 3 is devoted to constructing the highest producing strain of muconic acid reported in 
the literature. This project was done in collaboration with the Tessonnier group and the 
Cochran group (ISU, Chemical Engineering) for the diversification of muconic acid for 
applications in the polymer industry. Chapter 4 contains the first evidence of high production 
of shikimic acid in yeast and presents a minimal genetic approach to engineering the carbon 
entrance into the aromatic amino acid pathway. Moreover, in this chapter, the carbon flux into 
the aromatic pathway was studied through 13C MFA and carbon tracing. Chapter 5 is dedicated 
to fully engineering the precursor module of the pathway in a multilevel approach. This 
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included the discovery of new genetic targets for deletion and overexpression from OptForce 
simulations, as well as one of the firsts attempts to unravel transcriptional regulations in the 
pathway. Chapter 6 describes several new strategies toward rewiring gluconeogenesis to 
enhance the production of aromatic compounds. Furthermore, it includes preliminary work on 
engineering S. cerevisiae and P. stipitis for the production of plant secondary metabolites. The 
conclusions of this thesis and future perspectives are also included in this final chapter.  
Lastly, synthetic biology techniques for DNA assembly and optimization of pathways were 
highly used throughout this thesis. Hence, an appendix is included at the end of this document 
where synthetic biology techniques and computation tools are described to serve as a reference 
for the construction and optimization of any metabolic pathway. 
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CHAPTER 2 
 
YEAST FACTORIES FOR THE PRODUCTION OF AROMATIC COMPOUNDS: FROM 
BUILDING BLOCKS TO PLANT SECONDARY METABOLITES 
 
A review manuscript published in the Journal of Industrial Microbiology and Biotechnology  
 
Authors: Miguel Suástegui1 and Zengyi Shao 1 
 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 
 
Abstract 
The aromatic amino acid biosynthesis pathway is a source to a plethora of commercially 
relevant chemicals with very diverse industrial applications. Tremendous efforts in microbial 
engineering have led to the production of compounds ranging from small aromatic molecular 
building blocks all the way to intricate plant secondary metabolites. Particularly, the yeast 
Saccharomyces cerevisiae has been a great model organism given its superior capability to 
heterologously express long metabolic pathways especially the ones containing cytochrome 
P450 enzymes. This review contains a collection of state-of-the-art metabolic engineering 
work devoted towards unraveling the mechanisms for enhancing the flux of carbon into the 
aromatic pathway. Some of the molecules discussed include the polymer precursor muconic 
acid, as well as important nutraceuticals (flavonoids and stilbenoids), and opium-derived drugs 
(benzylisoquinoline alkaloids).  
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1. Introduction 
During the past two decades, the biotechnological production of petroleum-derived 
compounds has attracted worldwide attention, leading to extraordinary research for the 
construction and optimization of microbial factories capable of utilizing renewable feedstocks 
as starting materials (Becker and Wittmann, 2015; Borodina and Nielsen, 2014; Jullesson et 
al., 2015). Given the richness and variety of biological pathways, bio-based production by 
engineered microorganisms has expanded from just biofuels to the realm of specialty 
chemicals and secondary metabolites (Dai et al., 2014; Facchini et al., 2012). This group of 
chemicals has garnered special attention due to the cumbersome processes required for their 
production through classical chemical synthesis or the immense amounts of plant tissues 
required for extraction. Amongst the core metabolic pathways that lead to the production of 
specialty compounds, the aromatic amino acid biosynthetic pathway outstands for its unique 
diversity.  
The aromatic, or arene, chemicals are recognized as cyclic six-carbon structures with 
delocalized electrons that generally possess a sweet or pleasant aroma, the property from 
which this class of molecules gets its name. This vast family of compounds is of great 
importance to the chemical industry; benzene, for instance, serves as the aromatic building 
block of many other chemicals such as toluene, phenol, and other polycyclic aromatics. 
Unfortunately, using petroleum-derived benzene as the starting molecule compromises the 
sustainability and the safety of the process. Acute and chronic exposure to benzene has proven 
to be carcinogenic (Sonawane et al., 2000); furthermore, the synthesis of benzene derivatives 
usually entails the release of toxic gases into the environment (Niu et al., 2002b). For these 
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reasons, the production of aromatic compounds in microbial systems has become more 
attractive.   
The family of aromatic compounds comprises a vast number of molecules. In nature, the 
aromatic amino acids, namely, L-tryptophan (L-trp), L-phenylalanine (L-phe), and L-tyrosine 
(L-tyr), serve as building blocks for the biosynthesis of polypeptides. In several plants, these 
amino acids serve also as the precursors for the production of highly sought-after 
nutraceuticals, fragrances, and drugs. Although these secondary metabolites encompass a 
market in the billion-dollar range (Pandal, 2014), extraction from plant tissues requires high 
amounts of biomass and cumbersome separation processes, leading to very low yields. Hence, 
the implementation of microbial factories, engineered with the heterologous biosynthetic 
pathways of aromatic secondary metabolites, represents a great solution to this problem. This 
ensures not only higher yields but also sustainable and greener processes. With the advent of 
recombinant DNA technology, genome editing tools, and synthetic biology, this solution has 
proven to be feasible (Becker and Wittmann, 2015; Borodina and Nielsen, 2014; Jullesson et 
al., 2015), albeit, optimization of the microbial hosts to increase the carbon yields still remains 
as a limiting factor.  
This review summarizes the metabolic engineering efforts to manipulate the biosynthesis 
of aromatic compounds in microbial systems with exclusive attention directed to 
Saccharomyces cerevisiae. Yeast hosts have a greater potential in the production of secondary 
aromatic compounds due to their greater capability of expressing membrane-bound 
cytochrome P450 oxidases, which are key catalysts in these metabolic pathways (Jiang and 
Morgan, 2004; Schoch et al., 2001; Szczebara et al., 2003). 
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2. The Aromatic Amino Acid Biosynthetic Pathway 
The aromatic amino acid biosynthetic pathway is present in many microorganisms and plants; 
it is responsible for the de novo synthesis of L-tyr, L-phe, and L-trp. This pathway is sectioned 
into three main parts: (i) the shikimic acid pathway, (ii) the L-trp branch, and (iii) the L-tyr and 
L-phe branches (Figure 1). The energetic expenditure of synthetizing aromatic acids requires 
twice the ATP cost than most of other amino acids (Bender, 2012). Therefore, it is expected to 
encounter strict regulation at the transcriptional and allosteric levels throughout the pathway.  
 
2.1. Initiation, shikimic acid pathway, and aromatic amino acid branches 
The initiation of the synthesis of aromatic amino acids requires two precursors from distinct, 
yet closely related pathways. Erythrose-4-phosphate (E4P) and phosphoenolpyruvate (PEP) 
are the two starter units; the former derives from the pentose phosphate pathway (PPP) and the 
latter from glycolysis. A balanced ratio between these two molecules would be optimal to 
enhance the carbon entrance into the aromatic pathway. However, given the intrinsic functional 
differences between these parallel pathways, the available fluxes of these individual precursors 
differ drastically. Metabolic flux analysis in S. cerevisiae has shown that the available E4P 
flux is at least an order of magnitude lower than the PEP flux (Suastegui et al., 2016a). Hence, 
as described in the subsequent sections, efforts have been directed towards engineering of PPP 
as well as the lower end of the glycolytic pathway to enhance the production of precursors to 
enter the aromatic pathway. 
The enzyme 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase (isoenzymes 
ARO3/4) is in charge of condensing the two precursors to initiate the biosynthesis of aromatic 
compounds. Following this reaction, the pentafunctional ARO1 enzyme catalyzes five out of 
  
11 
the six steps in the shikimic acid pathway, from DAHP to 5-enolpyruvyl-3-shikimate 
phosphate (EPSP). This enzyme is exemplary in yeast since all five subunits are encoded 
within one open reading frame (ORF), resulting in single multi-domain protein, unlike its 
homologues in bacteria and plants, where each subunit is encoded separately. Finally, the 
enzyme chorismate synthase ARO2 converts EPSP into chorismate, which is the common 
precursor to the biosynthesis of L-trp, L-phe, and L-tyr (Braus, 1991). Chorismate can enter 
the L-trp branch composed of five steps (TRP1 to TRP5) or enter the L-tyr/L-phe branches 
which share the first catalytic step, from chorismate to prephenate, catalyzed by the enzyme 
chorismate mutase ARO7. Following this step, the pathway branches into the synthesis of 
phenylpyruvate (PP), catalyzed by prephenate dehydratase (PHA2); and the synthesis of 4-
hydroxyphenylpyruvate, (4-HPP) catalyzed by prephenate dehydrogenase (TYR1). Finally, 
two aromatic amino transferases, ARO8 and ARO9, catalyze the transfer of an amine group to 
each of the previous molecules to yield L-phe and L-tyr (Braus, 1991) (Figure 1).  
2.2. Transcriptional regulation 
It is well known that transcription factors (TFs) can globally regulate the transcription rates of 
a network of genes. TFs bind to specific promoter regions of structural genes to up- or down-
regulate the transcription of such genes (Zhu et al., 2009). GCN4p is a TF that has been 
associated with transcriptional activation of amino acid biosynthesis genes in response to 
nutrient starvation (Hinnebusch, 1988; Hinnebusch and Natarajan, 2002). This regulatory 
protein contains a leucine-zipper structure that is commonly found in DNA-binding 
polypeptides. As expected, several GCN4p binding sequences have been found in the promoter 
sequences of the aromatic amino acid biosynthesis genes such as ARO1, ARO3, ARO4, ARO9, 
TRP2, and TRP3 (Braus, 1991). It has been demonstrated that certain metabolites can control 
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the transcription rates of specific genes in the pathway. For instance, the transcription of TYR1 
can be regulated by the concentrations of L-phe (Mannhaupt et al., 1989). Another example is 
the influence of excess L-trp in the activation of ARO9 and ARO10, which can initiate the 
process of aromatic amino acid degradation (Lee and Hahn, 2013). The implementation of a 
global transcriptional regulation approach to increase the production of aromatic compounds, 
although promising, is naturally challenging. For instance, the starvation of aromatic amino 
acids will not only trigger a GCN4p-dependent transcriptional increase response on the genes 
from the corresponding pathway, but other genes involved in the biosynthesis of histidine, 
arginine, isoleucine, leucine, and other amino acids will also be activated, preventing the 
possibility of conducting a controllable localized up-regulation (Hinnebusch and Natarajan, 
2002). This creates intricate regulatory networks that have to be explored from a global 
perspective (Moxley et al., 2009).  
2.3. Allosteric regulation 
There are three major allosteric checkpoints occurring at the branching points of the aromatic 
pathway. Engineering these control points in S. cerevisiae is the most straightforward approach 
and thus has enabled the heterologous production of aromatic compounds from the three main 
tiers in the pathway. The first one occurs at the level of the DAHP synthase isoenzymes ARO3 
and ARO4 (Luttik et al., 2008b). These catalyze the first committed step in the biosynthesis of 
aromatic amino acids, and both ARO3 and ARO4 are sensitive to the feedback inhibition posed 
by L-phe or L-tyr, respectively (Figure 1). Thus, the presence of these two amino acids can  
block the entrance of carbon into the pathway, dramatically decreasing the production of any 
of the downstream metabolites. 
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Figure 1: The aromatic amino acid biosynthetic pathway, the heterologous muconic acid 
(MA) pathway, and the heterologous vanillin pathway. Abbreviation of metabolites – E4P, 
erythrose-4-phosphate; PEP, phosphoenolpyruvate; DAHP, 3-deoxy-D-arabinoheptulosonate-
7-phosphate; DHQ, dehydroquinoate; DHS, dehydroshikimate; SA, shikimic acid; S3P, 
shikimate-3-phosphate; EPSP, 5-enolpyruvyl-3-shikimate phosphate; CA, chorismic acid; PP, 
phenylpyruvate; 4-HPP, p-hydroxyphenylpyruvate; L-PHE, L-phenylalanine; L-TYR, L-
tyrosine; AA, anthranilic acid, N-PRAA, N-(5-phospho-D-ribosyl)-anthranilate; CPdRibP, 1-
(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate; I3GP, indole-3-glycerol 
phosphate; L-TRP, L-tryptophan; PCA, protocatechuic acid; PAL, protocatechuic aldehyde; 
VG, vanillin-b-D-glucoside. Abbreviation of enzymes – ARO3/4, DAHP synthase isoenzymes; 
ARO1, aromatic pentafunctional enzyme; subunits – C: DHQ synthase, E: DHQ dehydratase, 
D: DHS dehydrogenase, B: SA kinase, A: ESPS synthase; ARO2, chorismate synthase; ARO7, 
chorismate mutase; PHA2, prephenate dehydratase; TYR1, prephenate dehydrogenase; 
ARO8/9; aromatic amino transferases; TRP2, anthranilate synthase; TRP3, indole-3-glycerol-
phosphate synthase; TRP4, anthranilate phosphoribosyl transferase; TRP1, 
phosphoribosylanthranilate isomerase; TRP5, tryptophan synthase; AROZ and 3DSD, 3DHS 
dehydratase; AROY, PCA decarboxylase; HQD, catechol 1,2-dioxygenase; ACAR, aromatic 
carboxylic acid reductase; OMT, O-methyl transferase; UGT, UDP glycotransferase. 
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The second allosteric control occurs on the enzymes anthranilate synthase (TRP2) and 
indole-3-glycerol-phosphate synthase (TRP3), whose activities are repressed by the presence 
of L-trp. Simultaneously, L-trp can act as an activator of the enzyme chorismate mutase 
(ARO7), which catalyzes the conversion of chorismate into prephenate, initiating the 
production of L-tyr and L-phe (Figure 1). A third recognized allosteric control occurs at high 
concentrations of L-tyr. This causes feedback inhibition of ARO7, potentially switching the 
carbon flux towards production of L-trp to maintain a balanced production of aromatic amino 
acids (Braus, 1991).  
 
3. Metabolic Engineering Strategies for the Production of Aromatic Compounds 
 
3.1. Engineering the shikimic acid pathway  
The shikimic acid pathway has been a focal point in S. cerevisiae to engineer the production 
of three important metabolites: muconic acid, shikimic acid, and vanillin.  
3.1.1. Muconic acid 
Muconic acid is the unsaturated precursor of adipic acid and terephthalic acid, which are the 
building units for the plastics Nylon 6,6 and polyethylene terephthalate (PET) with an annual 
market value greater than $22 million (Lu et al., 2016; Niu et al., 2002b; Picataggio and 
Beardslee, 2012). The classic chemical processes to produce these derivatives are not 
environmentally friendly, thus stressing the need for development of microbial fermentation 
alternatives.  Curran et al. (Curran et al., 2012a) engineered the first S. cerevisiae strain capable 
of accumulating this compound by introducing a 3-gene heterologous pathway which diverted 
carbon from the shikimate pathway at the node of dehydroshikimate (DHS) (Figure 1). The 
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metabolic engineering rationale included the removal of the feedback inhibition loop by 
overexpressing the L-tyr insensitive DAHP synthase variant, ARO4K229L (Figure 2a).  
Furthermore, to increase the precursor availability, flux balance analysis (FBA) was 
performed. The results suggested that the PPP had to be rewired to force the carbon entrance 
through the non-oxidative PPP branch, allowing a higher E4P pool to enter the aromatic 
pathway. The overexpression of the transketolase gene (TKL1) and the deletion of glucose-6-
phosphate-1-dehydrogenase (ZWF1) were the key predicted manipulations to achieve this goal 
(Figure 2b). These manipulations translated into an increase in muconic acid titer from 40 mg 
L-1 to ~60 mg L-1 (Curran et al., 2012a). Overexpression of the rate-limiting step, 
protocatechuic acid (PCA) decarboxylase (AROY), led to a final strain producing 141 ± 8 mg 
L-1 (3.9 mg g-1glucose) (Table 1). A second study demonstrated that overexpressing the mutant 
ARO1D1409A, capable of halting the conversion of DHS to shikimic acid, increased the titer to 
235 mg L-1 (Figure 2c). Coupling this strategy with a controlled oxygen fermentation to relieve 
the oxygen sensitivity of the AROY isolated from the anaerobic bacterium Klebsiella 
pneumoniae increased the muconic acid titer to 559.5 mg L-1, the highest reported titer and 
yield to date in S. cerevisiae (Suastegui et al., 2016b) (Table 1). 
3.1.2. Shikimic acid  
Shikimic acid is the fourth intermediate in the shikimate pathway, and serves as the precursor 
of the commercial anti-influenza drug Tamiflu® (Adelfo Escalante et al., 2014). It is commonly 
extracted from plants (the genus Illicium), however, the low yield, long cultivation cycle, and 
susceptibility of open-field crop growth to environmental factors pose the microbial production 
as a preferred alternative.  
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The engineering key to enable the accumulation of shikimic acid in S. cerevisiae is the 
overexpression of the mutant enzyme ARO1D920A, which has the shikimate kinase subunit 
disrupted and hence cannot convert shikimic acid into shikimate-3-phosphate (S3P) (Figure 1 
and 2c). A recent study compared the capacity of four distinct S. cerevisiae strains to 
accumulate SA as an approach to model the carbon entrance into the aromatic amino acid 
pathway (Figure 2d). It was demonstrated that the four equally engineered strains, containing 
the same set of episomal plasmids for gene overexpression, differed dramatically in their titers. 
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Table 1: De novo production of the most significant aromatic amino acids-derived 
compounds in S. cerevisiae. 
 
 Compound Strain Substrate Titer mg L-1 
Yield 
mg g-1 
Fermentation 
Type Ref 
Sh
ik
im
ic
 a
ci
d 
pa
th
w
ay
 Shikimic acid INVSc1-SA3 Glucose 380  19  Batch 
(Suastegui 
et al., 
2016a) 
 
 Muconic acid MA-12 Glucose 141  3.9  Batch 
(Curran et 
al., 2012a) 
INVSc1-
MA2 
Glucose 559.5 14 Batch 
(mini reactor with 10-
20% dissolved oxygen) 
(Suastegui 
et al., 
2016b) 
Vanillin VG2 Glucose 500  32  
Continuous 
chemostat 
(dilution rate = 0.015 h-
1) 
(Brochado 
et al., 
2010) 
L
-t
yr
 / 
L
-p
he
 b
ra
nc
h 
L-tyrosine TY1041M Glucose 350 
 
(cytosolic) 17  Batch 
(Gold et 
al., 2015) 
Coumaric acid ST4058 Glucose 1930 N.S. Fed batch 
(FIT media) 
(Rodriguez 
et al., 
2015c) 
Naringenin IMX106 Glucose 108 5.4 Batch 
(Koopman 
et al., 
2012b) 
trans-Resveratrol ST4152 
Glucose 415.6 N.S. 
Fed-batch (Li et al., 2015) Ethanol 531.4 N.S. 
Thebaine CSY1064 Glucose 0.0064 0.00032  Batch (Galanie et 
al., 2015) Hydrocodone Pcs2765 Glucose 0.0003 0.000015 Batch 
L
-t
rp
 
br
an
ch
 N-Acetylserotonin 
SCE-Il3-
HM-60 Glucose ~ 45 N.S. 
Fed-batch 
(FIT media) (Germann 
et al., 
2015) Melatonin SCE-Il3-HM-60  Glucose 14.5 N.S. 
Fed-batch 
(FIT media) 
 
N.S.: Not specified 
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Metabolic flux analysis (MFA) coupled with quantitative PCR (Qpcr) enabled the 
establishment of an appropriate engineering rationale that allowed titer increases in all four 
strains. This strategy consisted of grouping the genes encoding TKL1, ARO4K229L, and 
ARO1D920A together in a low-copy plasmid, demonstrating that the aromatic amino acid 
pathway is sensitive to the burden of excessive protein expression (Suastegui et al., 2016a). 
The highest shikimic acid titer in batch fermentation reached 380 mg L-1 in the diploid strain 
INVSc1 (Table 1).  
3.1.3. Vanillin 
The production of aromatic flavors or aromas is predominant in several industries. The two 
most popular benzenoid flavors are vanillin and 2-phenylethanol (derived from L-phe, section 
3.3.1); the market of these two compounds together make 44.4% of the total benzenoid market, 
which as to 2014 was $2.8 billion, and is expected to increment to $3.4 billion by 2019 (Pandal, 
2014). Vanillin is the most extensively used flavoring compound in industry. Its global market 
in 2019 is expected to reach $800 million, which represents the highest increase among all the 
benzenoid flavors. This plant-derived secondary metabolite can be extracted from the seedpods 
of the flower Vanilla planifolia. However, due to extremely low yields and laborious 
cultivation schemes that lead to a cost-ineffective process, nearly 99% of vanillin is obtained 
from a biochemical synthesis processes involving the breakdown of lignocellulosic biomass or 
from a petroleum derived precursor (Priefert et al., 2001).  
Microbial production of vanillin from glucose has also been reported in S. cerevisiae via 
expression of a heterologous pathway that diverts the carbon from the shikimic acid pathway 
at the node of DHS. This pathway consisted of four steps, namely, DHS dehydratase (3DSD) 
from Podospora pausiceta, an aromatic carboxylic acid reductase (ACAR) from Nocardia sp., 
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a phosphopantetheinyl transferase (PPTase) from Escherichia coli to activate ACAR, and an 
O-methyl transferase (OMT) from Homo sapiens (Figure 1). The introduction of this pathway 
in S. cerevisiae resulted in the accumulation of 45 mg L-1 of vanillin after 48 h of small-scale 
batch fermentation (Hansen et al., 2009b). A further study addressed the toxicity of vanillin by 
overexpression of a glycotransferase (UGT) from Arabidopsis thaliana in the previously 
reported strain, yielding a strain capable of producing 100 mg L-1 of vanillin b-D-glucoside 
(VG) after 90 h of fermentation (Brochado et al., 2010). Furthermore, the same group 
investigated engineering strategies to increase the carbon flux into the aromatic pathway by 
means of in silico metabolic modeling. The FBA prediction suggested that the knockout of 
GHD1 encoding glutamate dehydrogenase could enhance the production of VG. This was 
supported by the fact that deletion of this gene increased the pool of NADPH, 
thermodynamically favoring the activity of ACAR.  
However, this prediction did not result in higher vanillin titers due to a reduced biomass 
yield on glucose. A second knockout target was the gene PDC1 encoding pyruvate 
decarboxylase, whose deletion could reduce the overall pyruvate decarboxylase activity by 
~30%, ensuring that less carbon was directed towards production of ethanol while maintaining 
cellular growth (Figure 2b). This resulted in a 2-fold increased production of VG compared to 
the parental strain from 250 to 500 mg L-1 in a very low dilution rate chemostat fermentation 
(Brochado et al., 2010) (Table 1). 
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3.2.  Engineering the L-tyr and L-phe branches 
In plants, the L-tyr and L-phe metabolic branches provide precursors to a great amount of 
aromatic secondary metabolites such as flavonoids, stilbenoids, and alkaloids. The application 
of these molecules ranges from the food and nutraceutical industries to the pharmaceutical 
industry. For instance, the pain management pharmaceuticals, a group of drugs that contain the 
L-tyr-derived alkaloids, are expected to reach a global market of $40.8 billion by 2020 (Elder, 
2015). Extraction of these compounds from plant tissues, however, is strongly dependent on 
environmental factors that can cause production instability in the farming processes. Hence, 
the production of secondary metabolites derived from L-tyr and L-phe has been intensively 
studied in microbial platforms in the past decade.  
To enable its microbial production, research has been directed mostly towards engineering 
the aromatic amino acid pathway for accumulation of L-tyr. The work by Gold et al. (Gold et 
al., 2015) described a metabolomics approach aided by in silico analysis for the construction 
of a yeast platform for overproduction of L-tyr. To construct the base strain, the feedback 
inhibition points were removed by overexpression of the S. cerevisiae feedback insensitive 
enzymes ARO4K229L and ARO7G141S (Figure 2a), and the byproduct formation was removed by 
knocking out phenylpyruvate decarboxylase ARO10 (Figure 2c). Especial attention was 
directed towards engineering the central carbon metabolism to enhance the production of 
precursors. Deletion of ZWF1 encoding glucose-6-phosphate dehydrogenase was attempted 
with the hypothesis of linking NADPH deficiency and subsequent regeneration in the L-tyr 
pathway by the action of overexpressed NADP+-dependent prephenate dehydrogenase TYR1. 
The L-tyr concentrations were improved to 192 Mm (~350 mg L-1) when L-methionine was 
added into the medium to recover the growth deficiency caused by deletion of ZWF1 because 
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L-methionine reduces the cellular demand for NADPH during amino acid synthesis (Table 1). 
Finally, to increase availability of PEP, a mutant version of the major pyruvate kinase 
(CDC19T21E) (Figure 2b), with impaired activity was knocked in to substitute the wildtype 
gene. However, no increase of carbon flux into the aromatic amino acid pathway was observed. 
Even though the mutant still possessed low pyruvate kinase activity, the decreased cellular 
fitness made the cells unviable in the absence of L-methionine and caused the L-tyr production 
to drop significantly. 
3.2.1. 2-Phenylethanol 
Phenethyl alcohol (2-PE) is a benzene-derived chemical with an ethylic group widely used in 
industry due to its particular floral odor. Altogether, its market is expected to reach $700 
million by 2019 (Pandal, 2014), yet its current production process is based on chemical 
synthesis (alkylation of benzene) which yields undesired side products, making the separation 
processes costly (Etschmann et al., 2002). Production of 2-PE has also been studied in 
microbial systems. As a naturally occurring molecule in S. cerevisiae, it provides organoleptic 
features to fermented beverages like sake and beer. This compound can be produced de novo 
through the conversion of glucose to L-phe. The latter amino acid undergoes transamination, 
decarboxylation, and dehydrogenation to finally yield 2-PE (a mechanism known as the 
Ehrlich pathway) (Figure 3). Work has been directed towards increasing the de novo 
production of 2-PE. For instance, Fukuda et al. (Fukuda et al., 1992) subjected S. cerevisiae to 
inhibitory concentrations of fluorophenylalanines, which act as competitive inhibitors of L-phe 
synthesis. The recovered spontaneous mutants, those with higher tolerance to the inhibitors 
could also accumulate 6-fold higher 2-PE (1.3 g/L) than the parental strain (Fukuda et al., 
1990b). Analysis of the mutant strain revealed a mutation on the L-tyr-inhibited DAHP 
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synthase (ARO4) causing its release from the feedback inhibition and resulting in higher carbon 
flux towards production of L-tyr, L-phe and 2-PE (Fukuda et al., 1990a). 
Biotransformation of L-phe to produce 2-PE has also been extensively studied in S. 
cerevisiae as an alternative to overcome the low yields of de novo synthesis. This process 
requires the addition of L-phe into the fermentation medium, usually accompanied by a poor 
nitrogen source, forcing the cells to catabolize the aromatic amino acid. Concentrations as high 
as 4.8 g L-1 have been obtained in yeast (Kim et al., 2014a), albeit product toxicity remained 
as the limiting factor. In situ product recovery has thus been crucial in the production of 2-PE, 
with the most successful technique being two-phase extraction using oleic acid as the 
extractant, which elevated the production to 12.6 g L-1 (Stark et al., 2003; Stark et al., 2002). 
3.2.2. Coumaric acid 
The production of the important nutraceutical group of flavonoids and stilbenoids initiates with 
the common precursor p-coumaric acid (Phca). This compound can be derived directly from 
L-tyr through the enzyme L-tyr ammonia lyase (TAL), or from L-phe, through the sequential 
action of two enzymes: phenylalanine ammonia lyase (PAL) and cinammate-4-hydroxylase 
(C4H) (Vannelli et al., 2007) (Figure 3).  
Recently, Jendresen et al. (Jendresen et al., 2015) characterized several TALs from various 
microbial sources, resulting in the finding of two enzymes, from the bacteria Herpetosiphon 
aurantiacus and Flavobacterium johnsoniae, with increased catalytic activity and high product 
specificity (barely any cinnamic acid was observed). The latter enzyme (FjTAL) was 
incorporated in the subsequent research by Rodriguez et al. (Rodriguez et al., 2015c) with the 
goal of constructing a S. cerevisiae platform for high accumulation of Phca. Unlike the work 
described by Gold et al. (Gold et al., 2015), the focus was only directed to manipulate the 
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aromatic amino acid pathway without altering precursor supply through tailoring the central 
carbon metabolism 
 Similar strategies were implemented: removal of L-tyr feedback inhibition 
(overexpression of ARO4K229L and ARO7G141S), removal of competitive pathways leading to 
phenylacetaldehyde (PAA) and 4-hydroxyphenylacetaldehyde (4-HPAA) (ARO10 and 
pyruvate decarboxylase PDC5; Figure 2c), and channeling of carbon flux towards L-tyr 
(overexpression of TYR1, Figure 1). Finally, to study the push of carbon flux through the 
pathway, the complete shikimate pathway from S. cerevisiae (ARO1 and ARO2) and the 
orthologous genes from E. coli were independently integrated into the genome under the 
control of strong constitutive promoters. Overexpression of the E. coli SA kinase II alone 
(aroL) demonstrated the biggest improvement, indicating that this step could be rate-limiting 
in the pathway. The highest producing strain accumulated 1.93 g L-1 of Phca in microplate 
fermentation and 1.89 g L-1 in bioreactors, both using synthetic Feed-In-Time (FIT) fed-batch 
media that gradually release glucose from higher polysaccharides within the medium solution 
under the action of supplemented hydrolase (Table 1).  
. 
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Figure 2: Common metabolic engineering strategies implemented in S. cerevisiae to 
increase the production of compounds deriving from the aromatic amino acid 
biosynthetic pathway. A) Removal of feedback inhibition points has been achieved by 
overexpression of the tyrosine insensitive enzymes ARO4K229L, which deregulates the first 
committed step in the aromatic biosynthesis pathway; and ARO7G141S, which controls the lower 
branching point to the production of the L-phe and L-tyr. B) Increasing the availability of the 
main precursor E4P has been achieved by overexpression of the transketolase 1 gene (TKL1) 
in combination with deleting the glucose-6-phosphate-1-dehydrogenase gene (ZWF1) to force 
the entrance of carbon into the non-oxidative section of PPP. Reducing the activity of the 
catalytic steps in the lower portion of glycolysis (pyruvate kinase mutant CDC19T21E and 
PDC1) has been attempted to increase the availability of PEP. C) Blocking competing 
pathways has been demonstrated by overexpressing mutant versions of the ARO1 enzyme to 
halt the conversion of intermediates in the shikimate pathway. Deletion of ARO10 and PDC5 
increases precursor availability. D) A strain-dependent pathway balancing approach was 
implemented to establish a strong yeast platform for the production of the common precursor 
shikimic acid. E) Recycling of the cofactor BH4 (tetrahydrobiopterin) is essential in the 
production of secondary aromatic compounds. Abbreviations – DHB, dihydrobiopterin; 6-
PTH, 6-pyruvoyl-tetrahydropterin; DHP, dihydroneopterin triphosphate; GTP, guanosine 
triphosphate; PCBD, pterin-4-alpha-carbinolamine dehydratase; DHPR, dihydropteridine 
reductase; SPR, sepiapterin reductase; PTS, 6-pyruvoyl-tetrahydropterin synthase; GCH1, 
GTP cyclohydrolase I. The dash lines represent multiple steps.  
 
ARO4K229L
a) Removal of Feedback Inhibition Points
E4P
PEP
HO OPO32- HO
CH2OPO32-
O
OH
HO OPO32- HO
CH2OPO32-
O
OH
O
HO
O OH
OH
OH
O
-2O3P
DAHP
ARO7G141S
CA Prephenate
L-tyr
ARO4
ARO7
b) Increase of Precursor Availability c) Blocking Competing Pathways
ARO1D1409A
ARO1D920A
O
HO
O OH
OH
OH
O
-2O3P
DAHP
DHS
SA
L-TYR
Flavonoids
Stilbenoids
PEP
Pyr
CDC19T21E
Acetaldehyde
Ethanol
ATP
ADP
PDC1
Aromatics
E4P
ARS/CEN
1 2 3ARS/CEN 2µ
1 2 3
d) Strain Dependent Pathway Balancing
a
b
g
d
Shikimate
Shikimate
Shikimate
Strain characterization
MFA
qPCR
Platform reconstruction
High producing platform
Low producing platform
e) Cofactor Recycling and Biosynthesis
L-TYR
L-TRP
TyrH
TPH
BH4
HN NH2
O
OH
HO
5-HTP
L-DOPAHTHB
DHB
HTHB
6-PTH DHP GTPGCH1PTSSPR
BIAs
Melatonin
Serotonin
PCBD
PCBD DHPR
Pyruvate kinase 
with low activity
ZWF1
TKL1
Aromatics
G6P
F6P
X5P
TKL1
G3P
S7P
E4P
R5P
F6P
TAL
Ri5P
Glucose
L-PHE
ARO10
PDC5
4-HPAA PAA
ARO8/9
ARO10
PDC5
4-HPP PP
O
OH
2µ
1 2 3
O
OH
OHO
OH
O
OH
O
O
OHO
OH
OH
OH
O
OHO
OH
OH
HO
OHO
HO O
O
OH
O
O
OH
NH2
O
OH
NH2
O
OH
HO
O
NH2
O
OH
HO
HO
OH
NH2
O
HO
HN NH2
O
OH
G3P
  
25 
3.2.3. Flavonoids and stilbenoids 
Jiang et al. reported the production of the flavanone nutraceutical naringenin in S. cerevisiae 
(Jiang et al., 2005). This work was further extended by Trantas et al. (Trantas et al., 2009) via 
constructing a series of strains capable of converting L-phe to a palate of flavonoids and 
stilbenoids, namely, trans-resveratrol, naringenin, genistein, kaempferol, and quercetin. To 
convert L-phe into the aforementioned products, initially, a strain overexpressing PAL, C4H 
(cytochrome P450 enzyme) and CPR (cytochrome P450 reductase) was constructed to 
accumulate Phca. Although S. cerevisiae contains a copy of CPR, overexpression of a Glycine 
max (soybean) CPR increased the accumulation of Phca by 4-fold. All of the subsequent strains 
contained a 4-coumaric acid ligase gene (4CL) to convert Phca to 4-coumaroyl CoA. To enter 
the stilbenoids pathway, the type III polyketide synthase (resveratrol synthase, RS) was 
overexpressed to produce trans-resveratrol. To construct the flavonoid-producing strains, the 
chalcone synthase (CHS) and the chalcone isomerase (CHI) were overexpressed, leading to 
production of naringenin. Further strains diverting naringenin into genistein (isoflavone) or 
flavonols (kaempferol and quercetin) were obtained by expression of the isoflavone synthase 
(IFS), or the flavanone 3-hydroxylase (F3H/F3’H) together with the flavonol synthase (FLS) 
(Figure 3). Although low titers were obtained, all the products were observed in the medium 
when L-phe or any of the downstream metabolites were fed into the medium. This indicated 
that all the plant genes were functional in S. cerevisiae but that pathway optimization was 
required to remove bottlenecks and enable higher conversion efficiencies.  
Metabolic engineering strategies for de novo production of naringenin were investigated 
by Koopman et al. (Koopman et al., 2012b). The common strategies for removal of feedback 
inhibition and byproduct formation were implemented in this work. Additionally, expressing 
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the corresponding ammonia lyase enzymes (TAL or PAL) to increase precursor availability 
enhanced the production of Phca. The bottleneck step downstream was partially removed by 
integrating into the genome additional copies of CHS, leading to a production of 134.5 µM 
naringenin (36 mg L-1) in batch fermentation. Optimization of the fermentation process in a 
bioreactor led to a maximal production of 400 µM (108 mg L-1) (Table 1). 
Resveratrol is a stilbenoid that is highly sought-after due to its nutraceutical properties. The 
production in S. cerevisiae has been achieved by whole cell conversion of Phca (Becker et al., 
2003; Trantas et al., 2009) or in complex media containing L-tyr (Shin et al., 2012; Wang et 
al., 2011). Although one of the highest-producing strains on record could accumulate up to 391 
mg L-1 resveratrol, it also required the supplementation of Phca (Sydor et al., 2010). Recently, 
a S. cerevisiae strain was constructed for the de novo production of resveratrol in minimal 
media without the supplementation of L-tyr or L-phe (Li et al., 2015). This entailed the 
expression, under strong constitutive promoters, of the heterologous TAL gene (tyrosine 
ammonia lyase) from Herpetosiphon aurantiacus, the ST1 gene (resveratrol synthase) from 
Vitis vinifera, the 4CL from Arabidopsis thaliana, and the acetyl-CoA carboxylase variant 
ACC1S659A, S1157A (post-translational de-regulated mutant) from S. cerevisiae to increase the 
availability of malonyl-CoA. These manipulations, together with the removal of L-tyr feedback 
inhibition led to the production of 235 mg L-1 resveratrol. Furthermore, production in fed batch 
mode using glucose or ethanol as feeding substrates after initial carbon depletion led to the 
production of 415.65 mg L-1 and 531.41 mg L-1 resveratrol, respectively, representing the 
highest productions reported to date (Table 1).  
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3.2.4. Benzylisoquinoline alkaloids 
Benzylisoquinoline alkaloids (BIAs) compose a large group of plant secondary metabolites 
that include the opioid chemicals. Used for the treatment of severe pain, this group of 
molecules, which also contains codeine, morphine, oxycodone, and hydrocodone, represents 
the largest global market of pain management pharmaceuticals (Elder, 2015). Other BIAs like 
berberine and sanguinarine can be implemented as antibacterial agents (Fossati et al., 2014). 
Papaver somniferum, commonly named opium poppy, is the primary source of natural and 
semisynthetic opioids. Industrial farming of this plant to satisfy its huge demand, however, is 
prone to commercial instabilities due to its dependence on environmental factors. Hence, 
efforts to decipher the natural enzymatic pathways and construct microbial factories to produce 
these important metabolites to ensure a more controllable production scheme have been a work 
in progress for the last couple of decades (Beaudoin and Facchini, 2014; Hagel and Facchini, 
2013; Ziegler et al., 2009). Eukaryotic microorganisms like S. cerevisiae have been central in 
this research, given their outstanding ability to express challenging heterologous enzymes, 
especially cytochrome P450s, whose activities require the presence of an electron donor 
protein (CPR) as well as a compartmentalized cellular environment provided by endoplasmic 
reticulum membranes (Ro et al., 2002). 
One of the biggest breakthroughs of 2015 was the demonstration of the complete 
biosynthesis of BIAs from glucose in yeast. This work, published by Galanie et al. (Galanie et 
al., 2015), is a product of over a decade of work from several research groups that intensively 
worked on reconstructing the entire pathway leading to the production of thebaine (an 
important precursor of morphinan opioids) and hydrocodone (an important semisynthetic 
opioid) from glucose. The biosynthesis of the initial intermediate (S)-reticuline was targeted 
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first, which started from the heterologous expression of a repression insensitive L-tyr 
hydroxylase variant (TyrHR37E, R38E, W166Y) from Rattus norvegicus coupled with four enzymes 
from the same source for the biosynthesis of the electron carrier co-substrate 
tetrahydrobiopterin (BH4) and its recycling and salvage enzymes to synthesize L-DOPA 
(Figure 3 and Figure 2e). Central carbon metabolism was further modified following the 
examples presented in the previous sections, namely, derepression of feedback inhibition by 
expressing L-tyr insensitive ARO4 and ARO7 (ARO4Q166K and ARO7T226I), expression of TKL1 
and deletion of ZWF1. To convert L-DOPA to (S)-reticuline, seven heterologous genes and the 
endogenous ARO10 for production of 4-HPAA were overexpressed. The genes were isolated 
from different plants and bacteria, including the L-DOPA decarboxylase (DODC), a 
norcoclaurin synthase (NCS), three methyltransferases characterized in previous works 
(Hawkins and Smolke, 2008; Minami et al., 2008a), and one cytochrome P450 enzyme 
(NMCH) associated with CPR (Trenchard et al., 2015).  
Completion of the pathway to produce thebaine required the determination of the key 
enzymatic step responsible for the stereochemical conversion of (S)-reticuline to I-reticuline. 
This goal was achieved by three independent groups, which opened the gate to the complete 
biosynthesis of morphine (Farrow et al., 2015; Galanie et al., 2015; Winzer et al., 2015), 
leading to the discovery of 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase 
fusion enzymes (DRS-DRR) (Figure 3). The conversion of I-reticuline to thebaine was 
followed by expression of an engineered salutaridine synthase (SalSyn, bottleneck step) in 
which the N-linked glycosylation was avoided by replacement of the SalSyn a-helices with 
those from cheilanthifoline synthase (CFS), which is homologous to SalSyn but will not be 
glycosylated when expressed in yeast (Galanie et al., 2015). Furthermore, codon-optimized 
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salutaridine reductase (SalR) and salutaridinol acetyltransferase (SalAT) (Higashi et al., 2010; 
Ziegler et al., 2009) were expressed to complete the pathway to thebaine. Finally, the 
expression of thebaine 6-O-demethylase (T6ODM) and morphine reductase (morB) led to the 
construction of a strain capable of accumulating hydrocodone at a titer of ~0.3 µg L-1 after 120 
hours of fermentation directly from sugars (Table 1, Figure 3). 
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Figure 3: The metabolic pathways (native and heterologous) for production of L-tyr- or 
L-phe-derived aromatic compounds in S cerevisiae. Abbreviation of metabolites – PAA, 
phenylacetaldehyde; 2-PE, 30ccession3030ol; Phca, coumaric acid; L-DOPA, L-3,4-
dihydroxyphenylalanine; 4-HPAA, 4-hydroxyphenylacetaldehyde. Abbreviation of enzymes  
– ARO10, phenylpyruvate decarboxylase; PDC1,5,6,10, pyruvate decarboxylase isoenzymes; 
ADH4,5, alcohol dehydrogenase isoenzymes; SFA1, bifunctional ADH and formaldehyde 
dehydrogenase; PAL, phenylalanine ammonia lyase; TAL, tyrosine ammonia lyase; 4CL, 4-
coumaric acid-CoA ligase; RS, resveratrol synthase; CHS, chalcone synthase; CHI, chalcone 
isomerase; IFS, isoflavone synthase; F3H/F3’H, flavanone 3-hydroxylase; FLS, flavonol 
synthase; TyrH*, tyrosine hydroxylase repression insensitive mutant, DODC, L-DOPA 
decarboxylase; morB, morphine reductase. The following enzymes require cytochrome P450 
reductase (CPR): C4H, cinammate-4-hydroxylase; NCS, norcoclaurine synthase; 6OMT, 
norcoclaurine 6-O-methyltransferase; CNMT, coclaurine N-methyltransferase; 4’OMT, 3’-
hydroxy-N-methylcoclaurine 4’-O-methyltransferase; NCMH, N-methylcoclaurine 
hydroxylase; BBE, berberine bridge enzyme; DRS, 1,2-dehydroreticuline synthase; DRR, 1,2-
dehydroreticuline reductase; SalSyn, salutaridine synthase; SalR, salutaridine reductase; 
SalAT, salutaridinol acetyltransferase; T6ODM, thebaine 6-O-demethylase; COR, codeinone 
reductase; CODM, codeine demethylase. The dash lines represent multiple steps.  
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3.3. Engineering the L-trp branch 
The biosynthesis of L-trp initiates with the conversion of chorismate to anthranilate by action 
of the enzymatic complex TRP2 and TRP3. The entrance of carbon into this branch of the 
aromatic amino acid pathway can be regulated by the concentrations of L-tyr and L-trp. L-tyr 
feedback inhibits ARO7, whereas L-trp counteracts this inhibition but feedback inhibits TRP2 
and TRP3, therefore allowing carbon flux to be appropriately split between two branches 
(Brown and Dawes, 1990) (Figure 1). Although L-trp is an important metabolite and key in 
the production of natural products (e.g. indole alkaloids) as well as mammalian 
neurotransmitters like melatonin and serotonin, so far there are no reports of a S. cerevisiae 
strain capable of overproducing L-trp.  
3.3.1. Monoterpene indole alkaloids 
Monoterpene indole alkaloids (MIAs) are a group of secondary metabolites found in many 
plants with diverse medicinal properties (Pasquali et al., 2006). Two common MIAs are the 
Catharanthus roseus-derived vinblastine and vincristine, which have been approved for 
anticancer treatment (Gobbi et al., 2003). Engineering the main MIA precursor strictosidine in 
yeast has been achieved by direct supplementation of the precursors tryptamine (a derivative 
of L-trp) and secologanin in a strain carrying the C. roseus strictosidine synthase, leading to a 
titer of 2 g L-1 strictosidine (Geerlings et al., 2001). De novo production of strictosidine has 
also been recently demonstrated. This work was devoted to engineering the mevalonate 
pathway for increased availability of geranyl pyrophosphate (GPP) followed by heterologous 
expression of 14 plant genes encoding the synthesis of secologanin. No evident engineering 
work was done on the aromatic amino acid pathway to increase the supply of L-trp for 
production of tryptamine (L-trp was supplemented in the amino acid mix of the growth 
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medium) (Brown et al., 2015). To date, engineering the production of L-trp has yet to be 
demonstrated. 
3.3.2. Melatonin  
Melatonin is a naturally occurring, L-trp-derived hormone in mammals that regulates the 
circadian cycle, and it is popularly known due to its nutraceutical properties as a sleeping aid 
as well as an antioxidant compound (Buscemi et al., 2004; Kamei et al., 2000). Although 
melatonin is commonly extracted from the pineal gland of mammalian organisms, it can also 
be naturally produced by S. cerevisiae during alcoholic fermentation. The production is highly 
dependent on the concentration of L-trp in the media, the different nitrogen sources, and the 
strain used (Rodriguez-Naranjo et al., 2012). As a GRAS (generally recognized as safe) 
microorganism, de novo production of melatonin in yeast could be preferred over extraction 
from animal tissues or from chemical synthesis which involved very toxic compounds (He et 
al., 2003).  
Two groups have recently demonstrated the production of 5-hydroxytryptophan (5-HTP), 
which is the first intermediate in the synthesis of melatonin. Zhang et al. (Zhang et al., 2016) 
studied the action of three types of hydroxylases, i.e. L-trp hydroxylase (T3H or T5H), and L-
phe hydroxylase P4H, on the conversion of L-trp to 5-HTP. Expression of Oryctolagus 
cuniculus T5H in combination with the biosynthesis pathway of the cofactor BH4 (Figure 2e) 
resulted in a strain producing around 7.3 µg L-1 starting from 2 g L-1 of L-trp.  
A second group achieved de novo production of 5-HTP and also demonstrated the 
production of melatonin (Germann et al., 2015). The highest producing strain was constructed 
by integrating into the yeast’s Ty2 retrotransposon sites multiple copies of L-trp hydrolysase 
from Schistosoma mansoni (smTPH), H. sapiens 5-HTP decarboxylase (HsDDC), Bos 32ccess 
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serotonin acetyltransferase (BsAANAT), and finally H. sapiens acetylserotonin O-
methyltransferase (HsASMT) (Figure 4). BH4 was also recycled by expression of P. 
aeruginosa pterin-4-alpha-carbinolamine dehydratase (PaPCBD1), and R. norvegicus 6-
pyruvoyl-tetrahydropterin synthase (RnDHPR) (Figure 2e). The highest producing strain 
accumulated melatonin at a titer of 14.5 mg L-1 in fed batch mode (Table 1). It is important to 
mention, however, that several strategies implemented in this work could not significantly 
elevate the production of melatonin; for instance, the external supplementation of L-trp did not 
show a significant increase. A potential approach suggested by the success in E. coli could be 
expression of the novel salicylate 5-hydroxylase, which can convert anthranilate into 5-
hydroxyanthranilate. This molecule could further be processed through the promiscuous L-trp 
biosynthesis genes in S. cerevisiae leading to the direct production of 5-HTP, eliminating the 
usage of the unstable T5H and the requirement of expressing the enzymes for BH4 recycling 
(Figure 2e) (Sun et al., 2015). Given the minuscule titers observed from these previous 
examples, it is evident that engineering of the L-trp biosynthesis branch in S. cerevisiae is still 
in its infancy.  
 
 
Figure 4: The heterologous metabolic pathway for production of L-trp-derived melatonin 
in S. cerevisiae. Abbreviation of metabolites – 5-HTP, 5-hydroxytryptophan. Abbreviation of 
enzymes – TPH, tryptophan hydroxylase; DDC, 5-hydroxy-L-tryptophan decarboxylase; 
AANAT, serotonin N-acetyltransferase; ASMT, N-acetylserotonin O-methyltransferase. 
  
34 
4. Remarks and Future Direction 
 
The advent of synthetic biology, inexpensive DNA sequencing tools, and various 
bioinformatics tools has enabled the elucidation of complex aromatic amino acid-derived 
natural product pathways as well as the establishment of such pathways into microbial hosts 
for more efficient and sustainable production processes. However, it is evident that the yields 
and titers in S. cerevisiae, using a renewable sugar as the sole carbon source, are still far from 
meeting the market demands. As discussed in this review, the manipulations on the pathways 
to increase the carbon flow are merely limited to the removal of the feedback inhibition points 
(ARO4 and ARO7) (Figure 2). Thus far, engineering availability of the precursor E4P has been 
modestly demonstrated by expression of TKL1, but altering the lower glycolytic pathway to 
enable higher accumulation of PEP for the production of DAHP remains as a great challenge. 
Furthermore, the examination of potential transcriptional regulators that could help rewire the 
carbon distribution in order to boost the carbon entrance into the aromatic pathway remains 
uninvestigated.  
The most updated market analyses for aromatic compounds forecast considerable increases 
in national and worldwide demands in all major commercial segments, from food and 
nutraceuticals to drugs and pain management medications. This emphasizes the strong need 
for quick development of microbial hosts to gradually reduce the utilization of non-renewable 
resources as the main feedstocks. This goal can be accomplished by developing efficient (i) 
high-throughput screening methods, (ii) co-culture systems, and (iii) genetic tools for 
engineering non-conventional yeast.  
The development of high-throughput screening methods allows exploration of large 
combinatorial spaces (strain libraries) for selection of improved phenotypes. Such methods can 
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be tied with a growth response (Du et al., 2012a) or an optical or electrochemical response 
(Bermejo et al., 2011; Heiskanen et al., 2013). One example of a biosensor to improve 
production of aromatic secondary metabolites was developed recently (DeLoache et al., 2015). 
It was based on screening a library of L-tyr hydroxylase mutants from Beta vulgaris 
(CYP74AD1) with enhanced activity. By coupling this enzyme with the L-DOPA dioxygenase 
from Mirabilis jalapa, L-DOPA was converted to a yellow fluorescent pigment betaxanthin. 
An identified mutant had a 2.8-fold improvement in activity, which translated into a 7.4-fold 
improvement in dopamine titer. This new mutant enzyme can be used to streamline the 
production of many valuable BIAs.  
Co-culturing systems have garnered attention in recent years as an alternative to efficiently 
produce biorenewable chemicals (Zhang et al., 2015c). One advantage of such systems is the 
partitioning of large metabolic pathways into two or more microbial hosts, in order to reduce 
the metabolic burden imposed on a monoculture system, as well as to facilitate modular 
optimization. In the realm of aromatic compounds, Jones et al. (Jones et al., 2016) implemented 
an E. coli co-culturing process to improve the production of flavonoids. By dividing the 
pathway into two strains (malonyl-CoA requiring upstream and NADPH requiring 
downstream), and optimizing culturing conditions through computational modeling, they 
obtained a system with 65% improved titer in flavan-3-ols. Such an approach could also be 
implemented in yeast cultures with the advantage of a more efficient expression of cytochrome 
P450 enzymes.  
Finally, although S. cerevisiae has been greatly domesticated and serves as a model for 
quick and robust engineering, a major disadvantage stems from being a Crabtree positive yeast. 
This entails the elevated production of ethanol, rather than biomass precursors, under aerobic 
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respiration in high glucose concentrations. As a result, lower titers for value-added compounds 
such as aromatic chemicals are observed. Although research has been devoted to diminish this 
effect in S. cerevisiae (Oud et al., 2012), a potential alternative solution is to engineer Crabtree 
negative non-conventional yeasts. Such yeasts include but are not limited to Yarrowia 
lipolytica and Scheffersomyces stipitis. Special attention should be directed to the latter species, 
since it possesses a highly efficient xylose utilization pathway. As a result, it is expected to 
carry a higher carbon flux into the PPP, which could ultimately lead to an enhanced production 
of aromatic compounds due to an elevated availability of the precursor E4P.  
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Abstract 
Biorefineries aim to convert biomass to a spectrum of products ranging from biofuels to 
specialty chemicals. To achieve economically sustainable conversion, it is crucial to streamline 
the catalytic and downstream processing steps. Here we report a route that integrates bio- and 
chemical catalysis to convert glucose into bio-based unsaturated nylon 6,6. An engineered 
strain of Saccharomyces cerevisiae, with the highest reported muconic acid titer of 559.5 mg 
L-1 in yeast, was used as the initial biocatalyst to convert glucose into muconic acid. Without 
any separation, muconic acid was further electrocatalytically hydrogenated to 3-hexenedioic 
acid with 94% yield, despite the presence of all the biogenic impurities. Bio-based unsaturated 
nylon 6,6 (unsaturated polyamide 6,6) was finally obtained by polymerization of 3-hexenedioic 
acid with hexamethylenediamine, demonstrating the integrated design of bio-based 
polyamides from glucose. 
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1. Introduction 
Biomass emerges as an alternative feedstock to petroleum to grow a more sustainable chemical 
industry and alleviate the concerns about fossil resources. The transition from fossil to 
renewable feedstocks is also expected to revitalize the chemical industry by providing building 
blocks with new functionalities (Hernandez et al., 2014). Since the U.S. Department of 
Energy’s report on top value-added chemicals from biomass (Bozell and Petersen, 2010), 
extensive research has been carried out to establish biological, chemical, or hybrid pathways 
for converting cellulosic sugars (Choi et al., 2015; Corma et al., 2007; Schwartz et al., 2014b). 
Over the past few years, it has become evident that the diversification of building blocks 
requires the combination of biological and chemical transformations (Corma et al., 2007; 
Linger et al., 2014; Nikolau et al., 2008; Schwartz et al., 2014b; Vardon et al., 2015; 
Vennestrøm et al., 2010), i.e. biomass is first biologically converted using microbes to platform 
molecules that are further diversified using chemical catalysis. However, previous attempts to 
implement chemical and biological processes have led to low conversion rates due to catalyst 
deactivation by the residual biogenic impurities (Schwartz et al., 2014a; Zhang et al., 2008).  
The ideal biorefinery pipelines, from biomass to the final products, are currently disrupted 
by a gap between biological conversion and chemical diversification. In this work, we report 
a strategy to bridge this gap by integrating fermentation and electrocatalytic processing. We 
illustrate this concept with the conversion of glucose to unsaturated polyamide 6,6 (UPA 6,6). 
The process entails the fermentation of glucose to muconic acid (MA), followed by 
electrocatalytic hydrogenation (ECH) to 3-hexenedioic acid (HDA), and subsequent 
polycondensation with 1,6-hexamethylenediamine (HMDA) to yield the desired UPA 6,6 
(Figure 1). The overall integration in this study is ensured through the utilization of a 
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metabolically engineered yeast and substitution of conventional high-pressure hydrogenation 
by direct ECH without separation using the broth water, salts, and impurities as an electrolyte 
and hydrogen source. With this integration, we demonstrate that a bio-based polymer can be 
produced using a combined bio- and electrocatalytic process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hybrid conversion of glucose to UPA 6,6. The catalytic integration was enabled 
by the compatibility of the process parameters. Replacing conventional high-pressure 
hydrogenation by direct ECH promoted a seamless flow between the processes, allowing the 
use of the broth water, salts, and impurities as an electrolyte and hydrogen source 
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2. Materials and Methods 
 
2.1. Strains and media 
The yeast strains used in this study are listed in Table 1. Cells were grown in YPAD (1% yeast 
extract, 2% peptone, 0.01% adenine, and 2% dextrose) or synthetic complete media (0.5% 
ammonium sulfate, 0.16% yeast nitrogen without amino acid and ammonium sulfate, 2% or 
4% dextrose) lacking the corresponding auxotrophic nutrient (uracil, tryptophan, leucine, 
histidine, or in combination). Escherichia coli BW25141 was cultured in Luria Bertani (LB) 
media supplemented with 100 g ml-1 ampicillin. Bacteria and yeast were cultured in an orbital 
shaker incubator at 250 rpm, 37 °C and 30 °C, respectively. 
2.2. Plasmid and strain construction 
The primers used for gene knockout are listed in Supplementary Table 1. Gene knockouts 
were performed by homologous recombination of a functional ura3 cassette. Selection in 
SC+Ura+FOA medium, after transformation of a DNA fragment composed of contiguous 
upstream and downstream homologs to the original target, resulted in colonies with the desired 
knockout. All the plasmids assembled in this work derive from the pRS shuttle vector series 
(New England BioLabs, Ipswich, MA) and were constructed following the DNA Assembler 
technique(Shao et al., 2009). The genes conforming MA pathway were obtained from the 
previous work in S. cerevisiae (Curran et al., 2013) and codon-optimized by GenScript 
(Piscataway, NJ), including Podospora 48ccessio Pa_5_5120 (AROZ), encoding 3-
dehydroshikimate dehydratase; Klebsiella pneumoniae AROY, encoding protocatechuic acid 
decarboxylase, and Candida albicans (HQD2), encoding 1,2-catechol dioxygenase. 
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Endogenous genes were amplified from S. cerevisiae YSG50 genomic DNA. A detailed list of 
the plasmids assembled in this work is presented in Table 2.  
2.3. Flux balance analysis.  
Flux balance analysis calculations were performed using MATLAB (Mathworks, Natick, MA) 
and the COBRA toolbox add-in (Schellenberger et al., 2011). The yeast genome-scale model 
Imm904 was utilized for the analysis (Mo et al., 2009). The heterologous pathway to produce 
MA was added to the Imm904 model as described elsewhere (Curran et al., 2013). The glucose 
and oxygen uptake rates were set to 20 and 2 mmol Gdw-1 h-1, respectively (Mo et al., 2009). 
The solution to the linear problem was calculated with the gurobi linear solver. Initially, the 
linear system was optimized to maximize the production of biomass. This theoretical value 
was then set as constraint and flux variability analysis (FVA) was carried out (yielding WT 
scenario). To simulate the production of MA, the flux to biomass was constrained to 20% of 
the theoretical maximum, and MA was set as the target. FVA was performed with the new 
constraints (yielding MA scenario) and the flux through each reaction was compared to the 
WT scenario.  
2.4. ARO1 variants construction 
The residues K1370 and D1409 of ARO1 were substituted to alanine by PCR. Two different 
plasmids were assembled, each containing a different aro1 mutant, namely, pRS426 aro1K1370A 
and pRS426 aro1D1409A. In parallel, the E. coli genes aroB and aroD, encoding the enzymes 
DHQ synthase and DHQ dehydratase, were also assembled in a pRS426 vector, together, and 
in combination with the aro1 mutants.  
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Table 1: Engineered InvSc1 strains for production of MA. 
Strain Genotype Plasmid Parent strain 
InvSc1 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 None None 
InvSc1 Dpdc1 
MATa his3D1 leu2 trp1-289 ura3-52 
MAT his3D1 leu2 trp1-289 ura3-52 
Dpdc1 
None InvSc1 
InvSc1 
aro1::aroY 
MATa his3D1 leu2 trp1-289 ura3-52 
MAT his3D1 leu2 trp1-289 ura3-52 
aro1::aroY 
None InvSc1 
InvSc1 pRS414 
aroY 
MATa his3D1 leu2 trp1-289 ura3-52 
MAT his3D1 leu2 trp1-289 ura3-52 pRS414 aroY InvSc1 
InvSc1 MA1 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
InvSc1 
InvSc1 MA2 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 WT aro1 
InvSc1 MA1 
InvSc1 MA3 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1K1370A 
InvSc1 MA1 
InvSc1 MA4 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1D14090A 
InvSc1 MA1 
InvSc1 MA5 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 hdqs-hdqd 
InvSc1 MA1 
InvSc1 MA6 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1K1370A-hdqs-
hdqd 
InvSc1 MA1 
InvSc1 MA7 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1D14090A-hdqs-
hdqd 
InvSc1 MA1 
InvSc1 MA8 
MATa his3D1 leu2 trp1-289 ura3-52 
MAT his3D1 leu2 trp1-289 ura3-52 
aro1::aroY 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1D14090A 
InvSc1 aro1::aroY 
InvSc1 MA9 MATa his3D1 leu2 trp1-289 ura3-52 MAT his3D1 leu2 trp1-289 ura3-52 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1D14090A-pc-
ppck 
InvSc1 MA1 
InvSc1 MA10 
MATa his3D1 leu2 trp1-289 ura3-52 
MAT his3D1 leu2 trp1-289 ura3-52 
Dpdc1 
pRS425 Sc MA 
pRS413 aro4K229L-tkl1 
pRS426 aro1D14090A –pc-
ppck 
InvSc1 Dpdc1 
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Table 2: Plasmids constructed harboring the genetic platforms for MA production. 
 
 
 
 
 
 
Production 
plasmids Genetic elements Description 
pRS413 Single-copy vector for use in S. cerevisiae for selection in media lacking histidine. 
pRS425 Multiple copy vector for use in S. cerevisiae for selection in media lacking 
leucine or uracil, respectively.  pRS426 
pRS425 Sc MA pRS425- PYK1p-AROZ / GPD1p-HQD2 / TEF1p-AROY 
Plasmid containing the heterologous 
MA pathway 
pRS413 aro4K229L-
tkl1 
pRS413- TP1p-aro4K229L-THD1t / 
ADH1p-TKL1-ADH1t 
Plasmid harboring the mutant aro4 
gene to remove tyrosine feedback 
inhibition. It also contains the tkl1 
gene to increase the flux in the non-
oxidative portion of pentose 
phosphate pathway 
pRS426 aro1 pRS426- GPDp-ARO1-PYK1t Plasmid harboring the 
pentafunctional gene ARO1 and its 
mutant variants aro1K1370A and 
D1409A, to stop the conversion of 
DHS to shikimic acid. 
pRS426 aro1K1370A pRS426- GPDp-aro1K1370A-PYK1t 
pRS426 aro1D1409A pRS426 GPDp-aro1D1409A-PYK1t 
pRS426 dhqs-
dhqd 
pRS426 TEF1p-dhqs-HXT7t / PYKp-
dhqd-ADH2t 
Plasmid containing the E.coli genes 
dehydroquinoate synthase and 
dehydroquinoate dehydratase alone 
and in combination with the mutant 
versions of ARO1.  
pRS426 aro1K1370A-
dhqs-dhqd 
pRS426- GPDp-aro1K1370A-PYK1t / 
TEF1p-dhqs-HXT7t / PYKp-dhqd-
ADH2t 
pRS426 
aro1D1409A-dhqs-
dhqd 
pRS426 GPDp-aro1D1409A-PYK1t / 
TEF1p-dhqs-HXT7t / PYKp-dhqd-
ADH2t 
pRS426 
aro1D1409A-PC-
PPCK 
pRS426 GPDp-aro1D1409A-PYK1t / 
TEF1p-PC-HXT7t / PYKp-PPCK-
ADH2t 
(Plasmid harboring the mutant aro1 
gene, as well as pyruvate 
carboxylase and 
phosphoenolpyruvate carboxykinase 
for pyruvate recycling to PEP)   
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2.5. In vivo PCA decarboxylase activity assay 
The activity of PCA decarboxylase was assessed at different levels of dissolved oxygen. Three 
different oxygen scenarios were tested: a) aerobic b) oxygen-limited, and c) anaerobic. The 
oxygen-limited and anaerobic cultures were carried out in 100 Ml serum bottles containing 60 
Ml media with shaking at 150 rpm and 30 °C. The oxygen-limited flasks were covered with 
aluminum foil, whereas the anaerobic cultures were cap-sealed. A plasmid containing only the 
aroY cassette was assembled in pRS414 plasmid and transformed into strain InvSc1. After 24 
hours of growth, the cultures were spiked with 1 Mm PCA. After 18 hours, samples were taken 
to measure the conversion of PCA to catechol.  
2.6. Small-scale and bioreactor fermentations  
An Applikon Biotechnology mini-fermenter system (Netherlands) equipped with a 250 Ml 
vessel was implemented for scale-up fermentation to optimize MA production with strain 
InvSc1 MA4. 4 Ml of initial culture was used as a seed to inoculate the fermenter at a starting 
OD600 of 0.2 (working volume was 200 Ml). Temperature was maintained at 30 °C, the 
agitation was set to 500 rpm, and the percentage of dissolved oxygen was controlled by 
pumping air. All the parameters were manipulated with a built-in process control software my-
control. Control of Ph was not required for these experiments. The BioXpert Lite software was 
used for online monitor and data acquisition. All cultures were carried out for 5 days and 
samples were collected every 24 hours. 
2.7. Metabolite detection 
An ACQUITY Ultra Performance Liquid Chromatography from Waters (Millford, MA) 
equipped with a BEH-C18 column (Waters) and a PDA detector was used for detection of MA 
and the pathway intermediates from the fermentation samples. Samples were prepared by 
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centrifugation of 1 Ml of fermentation broth at 5,000 rpm for 5 minutes. The supernatant was 
diluted 10 times in nanopure water and filtered with a 2 µm syringe filter. The mobile phase 
consisted of 0.2% formic acid in nanopurewater (Solution A) and 0.2% formic acid in 
acetonitrile (Solution B). The method was as follows: 0.6 ml min-1 of 3% Solution A and 97% 
Solution B for 1.5 minutes, followed by ramping A to 100% (0% B) in 1 minute. From 3 to 
3.1 minutes, Solution A was lowered to 3% (97% B) and maintained until minute 5. The 
column was maintained at 50 °C and the sample reservoir at 4 °C. 
Standard solutions for protocatechuic acid (MP Biomedicals, Santa Ana, CA), catechol 
(Acros Organics, New Jersey, US) and MA (Sigma, St. Louis, MO) were prepared for 
quantification. Retention times of PCA, catechol, and MA were 0.7 min, 1.1 min, and 1.5 min, 
respectively. PCA and MA were detected at 259 nm; catechol was detected at 275 nm.  
 
3. Results 
Muconic acid is the unsaturated synthetic precursor of adipic acid and terephthalic acid, which 
are the corresponding monomers constituting Nylon and polyethylene terephthalate (PET), 
with a total market value greater than $22 billion (Burk et al., 2011; Niu et al., 2002a; 
Picataggio and Beardslee, 2012). The traditional benzene-derived synthetic routes for adipic 
acid and terephthalic acid are environmentally unfriendly (Alini et al., 2007), warranting the 
need to develop a sustainable and green production platform. For large-scale fermentation, 
yeast is the preferred microbial host in industry with unique economic advantages such as the 
greater ease in maintaining phage-free culture conditions and by selling biomass byproducts 
as animal feeds (In et al., 2005; Jeffries, 2006; Nielsen, 2015; Nielsen et al., 2013).  
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3.1 Establishing muconic acid production in S. cerevisiae 
Two previous reports showed the heterologous production of MA in S. cerevisiae with titers 
of 1.56 mg L-1 (Weber et al., 2012) and 141 mg L-1 (Curran et al., 2013). The low production 
was caused by a combination of low precursor availability, active competing pathway(s), and 
the existence of rate-limiting enzyme(s). To address these individual issues, we performed flux 
balance analysis (FBA) to obtain a list of target genes for genetic manipulations (Figure 2a). 
Figure 2b depicts the metabolic pathway with the key manipulations for enhancing MA 
production. The three genes previously characterized in yeast to produce MA from 3-
dehydroshikimic acid (DHS), namely AroZ from Podospora 54ccessio, AroY from Klebsiella 
pneumoniae, and HQD2 from Candida albicans, were cloned in a multiple-copy plasmid. 
Furthermore, the tyrosine-insensitive DAHP synthase (ARO4K229L) was overexpressed to 
remove feedback inhibition caused by the aromatic amino acids in the growth medium. 
Following our FBA analysis and previous reports to increase the carbon flux into the aromatic 
amino acid biosynthetic pathway (Cui et al., 2014; Li et al., 1999; Luttik et al., 2008), the 
transketolase gene (TKL1) was overexpressed to increase the pool of the precursor erythrose-
4-phosphate (E4P). 
Initial fermentations produced 132 mg L-1 MA (strain InvSc1 MA1* in Figure 3), similar 
to the titer of the previously highest yeast producer MuA12, but the yield was increased almost 
2-fold. We reasoned that this increase is mostly due to the intrinsic difference in the genetic 
backgrounds of the host strains. Strain dependency in metabolic engineering has also been 
reported previously (Du et al., 2012b; Kummel et al., 2010). In this case the strain InvSc1 is a 
diploid whereas the strain MuA12 derives from the haploid S. cerevisiae BY4741. 
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3.2 Improving the synthetic flux towards DHS via a novel mutant  
To further force the carbon flow towards DHS, the flux through the two initial reactions in the 
aromatic amino acid pathway needs to be increased (Figure 2b). Suggested by the FBA 
(Figure 2a), the flux through the DHQ dehydratase had to be increased 60-fold to maximize 
MA production. In yeast, these two reactions are catalyzed by the pentafunctional ARO1 
enzyme (Braus, 1991), unlike the self-standing SA pathway enzymes from bacteria and plants. 
By sequence alignment of ARO1 with the characterized SA dehydrogenases from various 
species (Figure 4), it was concluded that the residues K1370 and D1409 could potentially 
serve as catalytic residues. 
A panel of plasmids was created to enhance the flux towards DHS and avoid conversion 
into SA. Overexpression of the mutant ARO1D1409A (InvSc1 MA4) increased the production of 
MA to 235 mg L-1 (strain InvSc1 MA4), confirming that the residue D1409 is essential in the 
catalytic activity of the SA dehydrogenase subunit of ARO1. To ensure that no carbon was 
being diverted to SA, we deleted both copies of aro1 (InvSc1 MA8 in Figure 3), but the MA 
production unexpectedly decreased to 25 mg L-1 and the strain’s fitness was also affected even 
when aromatic amino acids were supplemented. 
To increase the availability of phosphoenolpyruvate (PEP), we overexpressed PC 
(pyruvate carboxylase) and PPCK (phosphoenolpyruvate carboxykinase) in strain InvSc1-
MA4, as well as in the strain InvSc1Δpdc1 (resulting in strains InvSc1 MA9 and InvSc1 
MA10, respectively). However, the MA titers decreased by around 60% and 74%, respectively 
(Figure 3). Recirculation of pyruvate to PEP has been successfully applied in Escherichia coli 
to increase the yield of aromatic compounds. (Patnaik and Liao, 1994a; Zhang et al., 2015a) 
In S. cerevisiae, the failure of this strategy might be attributed to the inaccuracy of FBA 
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modeling to predict the compartmentalization fluxes, enzyme kinetics, and the metabolic 
burden on the cells caused by overexpression of highly regulated genes.  
3.3 Controlling oxygen to alleviate the PCA bottleneck  
Despite the aforementioned genetic manipulations, the production of MA was still limited by 
the accumulation of the intermediate protocatechuic acid (PCA). The enzyme PCA 
decarboxylase is known to be oxygen sensitive (He and Wiegel, 1996; Weber et al., 2012); we 
observed that the conversion of PCA to catechol increased more than 2-fold when growing the 
cells in an oxygen-limited culture (Figure 5a). This improved the ratio of MA to PCA to 2.5, 
which is almost 5-fold higher than the previously highest MA yeast producer. The highest MA 
titer reached 559.5 mg L-1, representing a 4-fold improvement in both titer and yield over strain 
MuA12 (Figure 5b). 
The MA platform consisted in establishing the heterologous pathway in a diploid yeast strain, 
with overexpression of the novel mutant ARO1D1409A, and alleviation of the PCA bottleneck 
with a controlled oxygen environment in the fermentation. 
The yield of 14 mgMA gglucose-1 represents the highest one among the aromatic amino acid-
based metabolites that have been produced in yeast in batch fermentation. Given the strong 
industrial interest in muconic acid (Horwitz et al., 2015; Rogers et al., 2013), substantial 
improvement should be expected in the next several years. Mutagenesis of AroY to remove its 
oxygen sensitivity (Stapleton and Swartz, 2010) and global genetic perturbations (DiCarlo et 
al., 2013; Si et al., 2015) coupled with molecular sensors (Chugani et al., 1998; Ezezika et al., 
2006) are potential strategies that will enable yeast to reach higher yields as observed in the E. 
coli platforms (Niu et al., 2002a; Zhang et al., 2015a) 
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Figure 2: Metabolic engineering rationale for overproduction of MA in S. cerevisiae. A) 
In silico modeling of MA in S. cerevisiae. Flux variability analysis was performed under two 
different scenarios. WT represents the flux through selected reactions targeting maximal 
biomass production. Similarly, the MA scenario represents the flux through the selected 
reactions having maximal MA as target while maintaining 20% of the maximum theoretical 
biomass. B) Three main strategies were studied: removing the feedback inhibition by aromatic 
amino acids, increasing the pool of the precursors PEP and E4P, and increasing the pull of 
carbon into the shikimic acid pathway. Abbreviation of metabolites – G6P, glucose-6-p; F6P, 
fructose-6-p; Ru5P, ribulose-5-p; Ri5P, ribose-5-p; S7P, sedoheptulose-5-p; X5P, xylulose-5-
p; G3P, glyceraldehyde-3-p; AcCoA, acetyl-CoA; PEP, phosphoenolpyruvate; OAA, 
oxaloacetate; DAHP, 3-Deoxy-D-arabinoheptulosonate 7-p; DHQ, 3-dehydroquinate; DHS, 3-
dehydroshikimic acid; SA, shikimate; S3P, shikimate-3-p; EPSP, 5-enolpyruvylshikimate-3-
p; PCA, protocatechuic acid. White and black arrows represent up and downregulated 
reactions, respectively. 
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Figure 3: Characterization of MA production in engineered InvSc1 strains. MA 
accumulation in strains grown in glass tubes containing 15 Ml of selective media. Maximum 
MA acid was observed at 96 h of aerobic fermentation. 
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Figure 4: Sequence alignment of ARO1D with DHS dehydrogenases from various species. 
The ARO1 pentafunctional enzyme from S. cerevisiae (gi: 392300242) was aligned with 
sequences from Deinococcus maricopensis (gi: 319756227), Pseudomonas viridiflava (gi: 
755354730), Arabidopsis thaliana (gi: 332640860), and E. coli (gi: 300847985). The residues 
K1370 and D1409 in ARO1 (yellow) showed 100% homology among all the species. 
 
gi|392300242 1314 KPIGHSRSPILHNTGYEILGLPHKFDKFETESAQLVKEKLLDGNKNFGGAAVTIPLKLDI 
gi|319756227   24 DPAAHSLSPRMHAAAFRFAGLDATYDAVRVPAADLPGAIAALRAPDVLGANLSLPHKAAA 
gi|755354730    9 NPIGHSKSPLIHRLFAEQTGQALDYQASLAPLDDFTAFAQAFFQ-QGRGANVTVPFKEEA 
gi|332640860  331 KPVSHSKSPIVHNQAFKSVDFNGVYVHLL--VDNLVSFLQAYSSSDFAGFSCTIPHKEAA 
gi|300847985    9 NPIAHSKSPFIHQQFAQQLNIEHPYGRVLAPINDFINTLNAFFRAGGKGANVTVPFKEEA 
 
 
gi|392300242 1374 MQYMDELTDAAKIIGAVNTVI-PLGNKKFKGDNTDWLGIRNALINN----GVPEY----- 
gi|319756227   84 LPHLDALTPAARAIGAVNTVI-H-ADGTLTGDNTDAPGLLAALRDA----HAP------- 
gi|755354730   68 FRLADRLTERAQRAGAVNTLS-KLDDGSVLGDNTDGAGLVRDLTIN---CGVR------- 
gi|332640860  389 LQCCDEVDPLAKSIGAVNTILRRKSDGKLLGYNTDCIGSISAIEDGLRSSGDPSSVPSSS 
gi|300847985   69 FARADELTERAALAGAVNTLK-RLEDGRLLGDNTDGIGLLSDLERL---SFI-------- 
 
 
gi|392300242 1424 --VGHTAGLVIGAGGTSRAALYALHSLG-CKKIFIINRTTSKLKPLIESLPSEFNIIGIE 
gi|319756227  131 --AGG-VSVVLGAGGAARAAVWALRAEG-R-DVLILNRTLDNARALARDLGG----TAV- 
gi|755354730  117 --LRGQRILLLGAGGAVRGALEPLLAQQPL-ALVIANRTVEKAERLAQEFAD----LGPV 
gi|332640860  449 SPLASKTVVVIGAGGAGKALAYGAKEKG-A-KVVIANRTYERALELAEAIGG----KAL- 
gi|300847985  117 --RPGLRILLIGAGGASRGVLLPLLSLD-C-AVTITNRTVSRAEELAKLFAH----TGSI 
 
 
gi|392300242 1481 STKSIEEIKE-HVGVAVSCVPAD-------KPLDDELLSKLERFLVKGAHAAFVPTLLEA 
gi|319756227  181 TREDVPWL---DITLIVNASSAGLGD-PDATPLPDPPA------LA---RG---ALVYDM 
gi|755354730  170 FASSFDWL-QESVDVIINATSASLAG--ELPPISP-SL------IE---PG--NTFCYDM 
gi|332640860  502 SLTDLDNYHPEDGMVLANTTSMGMQPNVEETPISK-DA------LK---HY---ALVFDA 
gi|300847985  169 QALGMDELEGHEFDLIINATSSGISG--DIPAIPS-SL------IH---PG---IYCYDM 
 
 
gi|392300242 1533 AYKPSVTPVMTISQDKYQWHVVPGSQMLVHQGVAQFEKWTGFKAPFKAIFDAVTK---E 
gi|319756227  225 VYKPRDTRLMRDARARGA-RTANGLGMLAHQARLAFTAWTGADVPAHVFLNALED---A 
gi|755354730  215 MYGKEPTAFCRWATEQGAAQSVDGLGMLVEQAAEAFLLWRGVRPDSAPVLAELRRQLAG 
gi|332640860  549 VYTPRITRLLREAEESGA-ITVSGSEMFVRQAYEQFEIFTGLPAPKELYWQIMSK---Y 
gi|300847985  214 FYQKGKTPFLAWCEQRGSKRNADGLGMLVAQAAHAFLLWHGVLPDVEPVIKQLQEELSA 
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Figure 5: Variation of fermentation conditions. PCA decarboxylase activity assay under 
different oxygen environments. A) The strain InvSc1 pRS414 aroY was cultured in three 
different oxygen conditions and spiked at 24 h with 1 Mm PCA.  The conversion percentages 
were calculated based on the samples collected at 18 h after PCA supplementation. B) Strain 
InvSc1MA4 in mini reactor fermentations with controlled dissolved oxygen. The highest MA 
accumulation was observed when the dissolved oxygen was maintained between 10 to 20% 
during the first 24 h. After this period, the dissolved oxygen was set to 20% until the end of 
the fermentation (4 days). 
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3.4 Electrochemical hydrogenation 
The fermentation broth was subsequently hydrogenated in a three-electrode electrochemical 
cell (Figure 6). Electrocatalysis was preferred over conventional high-pressure hydrogenation 
as hydrogen is produced in situ by water splitting, the reaction occurs under ambient 
temperature and pressure, and the charge on the electrode surface can mitigate poisoning 
(Chapuzet et al., 1998). In this configuration, hydrogen production and MA hydrogenation take 
place simultaneously at the cathode (Eq. 1-2), allowing a seamless ECH. 
H(+) + e- + * à H* [Eq. (1)] 
2H* + C6H6O4 + * à C6H8O4 [Eq. (2)] 
Lead (Pb) was chosen as a catalyst based on its Earth abundance, low cost, common use in 
industrial electrosynthetic applications, metallic state under cathodic potentials, and stability 
in the presence of sulfur (Joyner et al., 1978; Pletcher and Walsh, 1993). The expected 
resistance to impurities allowed us to significantly simplify the hydrogenation reaction by 
placing the fermentation broth directly in the electrochemical reactor. The broth contained 
whole yeast cells, unspent salts, and biogenic impurities coming from cellular metabolism and 
lysis. The ECH was then allowed to proceed at room temperature and atmospheric pressure for 
1 hour by applying a potential of -1.5 V vs. Ag/AgCl on a 10 cm2 lead rod, resulting in 95% 
MA conversion with 81% selectivity to HDA. To assess the stability of the catalyst in the 
fermentation media (in the presence of all potential poisons), five successive one-hour 
electrocatalytic batch reactions were performed (Figure 6b). Notably, no signs of deactivation 
were observed and leaching of the catalyst into the solution was minimal at 6.5 ± 0.4 ppm as 
determined by elemental analysis.  
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To further increase the yield of HDA, the effects of Ph and applied voltage were 
investigated independently. A model solution of pure MA dissolved in a potassium 
sulfate/sulfuric acid electrolyte was used to accurately control ionic strength and to maintain a 
constant ionic conductivity. Acidic conditions favored the selective formation of HDA, 
especially for reaction times below 30 min (Supplementary Figure 1). Further 1H nuclear 
magnetic resonance (NMR) analysis of a HDA model solution after ECH revealed that the 
observed decrease in selectivity as the reaction proceeded was due to the formation of 
decomposition products through secondary reactions and not through the formation of 
additional hydrogenation products e.g. adipic acid. 
Conditions optimized with the model solutions were found to also enhance the 
hydrogenation of the fermentation broth (Figure 6c). Notably, when the Ph of the solution was 
fixed at 2.0, the selectivity towards HDA became 98 ± 4% at 96 ± 2% MA conversion. It is 
worth noting that the yield achieved for the unpurified broth was actually higher than for the 
model solution (94% vs. 77%). While catalyst poisoning is a common issue for most of the 
hydrogenation reactions catalyzed by precious metals (Schwartz et al., 2014a; Zhang et al., 
2008), it appears that the broth’s impurities were beneficial in the present work as it prevented 
the formation of decomposition products during the ECH. 
3.5 Polymerization of HDA 
In the pursuit of a fully integrated process, from glucose to a commercially viable product, 
HDA was separated from the fermentation broth by vacuum evaporation, activated carbon 
filtration, and crystallization. High purity (98%) of HDA at a yield of 67% was obtained and 
subjected to the final step of polymerization. The corresponding saturated nylon 6,6 was 
synthesized using adipic acid and HMDA in an attempt to compare the conventional 
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petrochemical-based nylon 6,6 and the bio-based UPA 6,6 polymers. The obtained UPA 6,6 
consisted of a transparent, partly crystalized material with comparable physical and chemical 
properties to petrochemical nylon (Table 3, Figure 7, Supplementary Table 2). Polymers 
based on blends of HDA and adipic acid were also achieved (Figure 7a) to enable different 
levels of 63ccession63. These HDA-containing nylon materials offer precious grafting sites to 
custom-tailor the existing nylon grades with desirable properties, for example crosslinkability, 
paintability, flame retardance, etc. 
 
 
Table 3: The properties of Nylon 6,6 and UPA 6,6. Mn indicates the number average 
molecular weight, PDI: polydispersity, Q*: primary diffraction peak, Gʹ: storage modulus, Gʺ: 
loss modulus, and G*c: crossover modulus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property Nylon 6,6 UPA 6,6 
Mn (Da) 17,800 12,200 
PDI 2.0 3.36 
Melting Temp (°C) 250 60 
Q* (Å-1) 4.4 4.7 
G’ (Mpa) - 18.9 
G’’ (Mpa) - 6.24 
G’’C (°C) - 60 
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Figure 6: Electrocatalytic hydrogenation of MA to HDA directly in the fermentation 
broth. The hydrogen necessary for the reaction is generated in situ (Had) at the surface of the 
Pb electrode. A) Electrocatalytic single-cell reactor for conversion of MA to HDA. Atoms in 
the molecules are color-coded: grey: carbon; white: hydrogen; red: oxygen; blue: nitrogen; 
green: carbon-carbon double bond. The reaction was performed under ambient temperature 
and pressure using a three-electrode electrochemical cell at -1.5 V vs. Ag/AgCl. B) Conversion 
of MA and average selectivity to the desired product showed no signs of catalyst deactivation 
when repeating the reaction five successive times (runs 1-5). C) MA and HDA conversion and 
selectivity for the ECH of the doped (Ph 2.0, -1.5 V) fermentation broth. 
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Figure 7: Polymer visualization. A) Polymer blends of adipic acid and HDA. Percentages 
are based on molar ratios of adipic acid and HDA reacted with a 1:1 mol ratio of HMDA. B) 
Nylon 6,6 and C) UPA 6,6, for which petroleum-based adipic acid was substituted with HDA; 
atoms in both molecular structures are color-coded for easier identification. Grey: carbon; 
white: hydrogen; red: oxygen; blue: nitrogen; green: carbon-carbon double bond 
 
 
A)
B) C)
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4. Discussion 
Development of diverse microbial cell factories as biorefineries has been thriving in the 
past ten years, with a steady growing number of bio-based chemicals reaching production at 
commercial scale (Choi et al., 2015; Straathof, 2014). The biosynthetic routes of many key 
monomers for the polymer industry, including diols, dicarboxylic acids, ω-amino acids, 
aromatics, diamines, and hydroxyl acids, have been established at various production levels 
via implementing metabolic engineering and synthetic biology strategies. These monomers 
were then chemically converted to polymers such as nylon, polyethylene terephthalate (PET), 
polyurethane, and polystyrene (Chung et al., 2015). Many companies (i.e. DSM, BASF, 
Cargill, DuPont, Verdezyne, Myriant, BioAmber, and Genomatica) are actively involved in 
the development of bio-based monomer production. Some successful cases include the 
production of succinic acid as a polyamide monomer, and 1,4-butanediol or 1,3-propanediol 
as polyester monomers (Choi et al., 2015).  
Cis, cis-Muconic acid is the unsaturated synthetic precursor of adipic acid and terephthalic 
acid, which are the corresponding monomers constituting Nylon and PET, with a total market 
value greater than $22 billion (Burk et al., 2011; Niu et al., 2002; Picataggio and Beardslee, 
2012). The traditional benzene-derived synthetic routes for adipic acid and terephthalic acid 
are environmentally unfriendly, warranting the need to develop a sustainable and green 
production platform. The design of biological production methods using fermentation as an 
alternative to petrochemistry addresses this need. For large-scale fermentation, yeast is the 
preferred microbial host in industry with unique economic advantages such as the greater ease 
in maintaining phage-free culture conditions and by selling biomass byproducts as animal 
feeds (In et al., 2005; Nielsen, 2015; Nielsen et al., 2013). Particularly for dicarboxylic acids, 
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yeast-based fermentation is preferred over E. coli-based platform due to yeast’s high tolerance 
to the gradually decreasing Ph occurring during the production of the desired organic acids. In 
addition, being able to produce and purify these products in their protonic forms (instead as 
carboxylates) is economically important considering the significant cost saving by avoiding 
the usage of alkali and acid titrants and the downstream disposal of salt byproducts (e.g. 
gypsum) (Abbott et al., 2009; Xiao et al., 2014). Here we achieved the highest production of 
MA in S. cerevisiae, representing a 4-fold improvement over the previous effort (Curran et al., 
2013). The success was attributed to two key innovations, including (1) the introduction of the 
mutant Aro1 to increase the synthetic flux towards DHS at the same time halting it from being 
further converted to shikimate, and (2) improving the activity of the oxygen-sensitive AroY by 
controlling the oxygen supplied during fermentation.  
Although the current titer of MA is still relatively low when compared to the E. coli 
platforms (Niu et al., 2002; Zhang et al., 2015), industry e.g., Amyris Biotechnologies (Horwitz 
et al., 2015) and Myriant (Rogers et al., 2013) has shown strong interest in the yeast production 
platform. Substantial, improvement should be expected in the next several years. Most 
recently, a yeast strain was engineered to produce p-coumaric acid using fed-batch 
fermentation at a titer of about 2 g/L (Rodriguez et al., 2015b). Considering that the 
biosynthesis of p-coumaric acid shares the same precursor with the MA pathway, this success 
evidences the room to improve MA production. Furthermore, the rate-limiting constraint posed 
by AroY can be approached by applying directed evolution strategies to relieve its oxygen 
sensitivity (Stapleton and Swartz, 2010). A high throughput strain optimization method 
established on MA sensors (Chugani et al., 1998; Ezezika et al., 2006) could be used to screen 
AroY variant library or identify beneficial genotypes on genome scale that could not be easily 
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predicted by rational design. Screening global genetic perturbation has proven to be an 
effective strategy for engineering complex phenotypes in yeast; to date, at least 4000 regulatory 
interactions have been identified to tightly control the primary metabolism in yeast (Herrgard 
et al., 2004).  
Following fermentation, metal-catalyzed hydrogenation represents one of the main 
strategies to diversify building block molecules. The resistance to impurities allowed us to 
significantly simplify the hydrogenation reaction by placing the fermentation broth directly in 
the electrochemical reactor. Under optimized conditions, the selectivity towards HDA reached 
98 ± 4% at 96 ± 2% MA conversion.  Moreover, the successful synthesis of UPA 6,6 with 
various ratios of HDA and adipic acid demonstrates the compatibility of the two monomers. 
The unsaturated polyamide presents the advantage of having an extra double bond in its 
backbone that can be used to incorporate additional functionality in Nylon 6,6, e.g. for tuned 
hydrophobicity and hydrophilicity. In addition to polyamides, HDA has been previously used 
as a precursor to generate dodecanedioic acid (Frost et al., 2010), a monomer of Nylon 6,12, 
and to produce polyester ethers with biomedical applications (Olson et al., 2006; Vardon et al., 
2015).  
This work presents one strategy to bridge the gap between biological and chemical catalysis 
in biorefineries. We demonstrated its potential by synthesizing a new family of unsaturated 
polyamides from sugar and anticipate that this strategy will facilitate the incorporation of 
fermentation and catalytic hydrogenation for a broad range of reactions. Future efforts will be 
taken towards (1) scale-up of the hybrid pipeline with a detailed technoeconomic analysis to 
assess the cost efficiency and (2) ultimate-level integration combining biocatalytic and 
chemocatalytic reactions into a one-pot process, which represents an attractive solution to 
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develop economically and ecologically advantageous chemical synthesis schemes in the 
context of the water, energy, and food nexus (Gröger and Hummel, 2014). 
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6. Supplementary Information 
 
6.1. Supplementary Methods  
6.1.1. Electrocatalytic hydrogenation 
The electrochemical studies were conducted in a three-electrode electrochemical cell using a 
BioLogic VSP-300 potentiostat. The Ag/AgCl in NaCl reference electrode and platinum 
counter electrode were purchased from BioLogic Science Instruments. The working electrode 
was purchased from Rotometals (Lead rod, 99.9%). Electrocatalytic hydrogenation 
experiments were performed in 11 Ml of reacting medium with a stir bar at 700 rpm. During 
the chronoamperometry experiments, 0.5 Ml samples of the reaction medium were taken at 5 
min, 15 min, 30 min, and 60 min for analysis.  
Samples were subsequently analyzed either by ultra-performance liquid chromatography 
(UPLC) or 1H NMR. For NMR analysis, the samples were dried at room temperature, 
reconstituted in deuterium oxide, and analyzed with a Bruker 600 MHz NMR spectrometer 
(AVIII600). UPLC analysis was performed with a Waters H-Class Acquity chromatograph 
equipped with a HSS C18 Column (1.8 µm, 2.1 x 100 mm) and photo-diode array detector. 
Samples were prepared by filtration with a 2 µm syringe filter. The mobile phase consisted of 
a 100% methanol solution (Solution A) and 1% acetic acid (Solution B) in nanopurewater. The 
method was as follows: 0.35 ml min-1 of 4% Solution A and 96% of Solution B for 4.5 min 
followed by ramping A to 50% (50% B) and maintained until min 6. The composition of the 
mobile phase was reverted to 4% Solution A and 96% Solution B and maintained for 8 
additional min. The column was maintained at 45 °C and the sample reservoir at 15 °C. ACS 
grade cis,cis-MA was used to synthesize cis,trans-MA by heating in water at 75 °C for 25 min. 
trans-HDA (Sigma, St Louis, MO) and cis,trans-MA were used for UPLC calibration and as 
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references. Retention times of cis, trans-MA and trans-HDA are 6.4 min and 4.0 min and were 
analyzed at 295 nm and 231 nm respectively. Conversions and selectivities, were calculated 
with the following equations:  
 
 
 
 
 
Voltage and Ph studies were performed on MA in K2SO4/H2SO4 electrolyte solutions in 
order to keep ionic strength and conductivity constant. A 0.1 M K2SO4 with 1.41 Mm MA 
solution was mixed in varying ratios with 0.1 M H2SO4 and 1.41 Mm MA. The solutions with 
the specified Ph were ECH in the 11 Ml small volume cell. In-between experiments, the 
electrodes were rinsed with DI water and the lead electrode was polished with a kimwipe.  
ECH of the fermentation medium was performed as follows. Directly after the fermentation, 
11 Ml of broth was put in a small volume cell. At the start of the ECH, the surface of a lead 
electrode was polished with a kimwipe and used as the electrocatalyst. In-between the 
successive batch reactions, the lead electrode was gently dipped in deionized water, dried, and 
put in another 11 Ml solution of the fermentation medium. In addition, the counter and 
reference electrodes were washed with deionized water in-between each run. To achieve a 94% 
yield of 3-hexenedioic acid (HDA) the Ph of the fermentation broth was decreased to 2.0 by 
dropwise adding 0.5 M H2SO4. Additionally, the concentration of MA was increased to 2.4 
Mm. 
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6.1.2. Separations 
Recovery of HDA was accomplished by concentrating ~2 L of cell-free fermentation broth 
containing the highest titer of HDA under basic conditions, followed by activated carbon 
filtration, and crystallization at reduced Ph and temperature. A yield of 67% and a high purity 
of 98% were obtained (Supplementary Figure 3). 
Specifically, after removing cells from 2 L fermentation broth, the Ph of the cell-free broth 
was brought from 3 to 8.5 with 10 M NaOH to increase the solubility of HDA. The basic 
solution was run through a 0.2-µm filter to remove any solid impurities remained in the broth. 
Following filtration, the broth was concentrated in a vacuum evaporation set up, from ~2 L to 
80 Ml and re-filtered through a 0.2-µm filter, separating the impurities that precipitated during 
concentration. The concentrate was then dripped through a 15-mm deep Norit CN1 activated 
carbon bed (preconditioned with 10 Mm NaOH), adsorbing soluble impurities including 
colorants and odor-causing compounds. The subsequent filtrate was acidified to Ph 1.5 using 
18.4 M sulfuric acid and crystalized at 4 °C overnight. Crystals of HDA were recovered using 
vacuum filtration with a Whatman 50 filter, washed with 4 °C 10 Mm sulfuric acid, and placed 
in a desiccator to dryness. 
6.1.3. Polymerization 
The polycondensation reaction between trans-3-HDA and HMDA was adapted from the 
synthesis of nylon 6,6. Specifically, trans-3-HDA (TCI America) was dissolved in methanol 
and mixed with a 1:1 mol ratio of HMDA dissolved in methanol. The resulting solution was 
heated in a round bottom flask at 60 °C. The liquid was decanted from the precipitated salt. 
The precipitated salt was subsequently washed with methanol, decanted, and left to dry in a 
fume hood. The solid was then mixed at a 0.86 mass ratio with deionized water. The resulting 
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solution was put in an aluminum weigh pan and heated at 7.5 °C min-1 to 250 °C in a tube 
furnace under flowing ultra-high purity nitrogen. The sample dwelled at the temperature for 
30 min before cooling. It was not uncommon during the synthesis of UPA 6,6 to produce a 
slightly yellow colored polymer. The same synthesis procedure was applied to adipic acid and 
HMDA to form nylon 6,6. 
 
6.2. Supplementary Tables  
 
Supplementary Table 1: Primers used for gene knockout in S. cerevisiae InvSc1. 
 
Fragment Primer 
aro1-Upstream F: caacatattctcgatgtgct R: taagataattgtatattacg 
aro1-Downstream  F: caataatatatctatccttt R: tacctgttcagtcgatacgt 
pdc1-Upstream F: tttcaatcattggagcaatc R: ataattagagattaaatcgc 
pdc1-Downstream F: tttgattgatttgactgtgt R: agtcagaagagcatacataa 
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Supplementary Table 2: Triple detection SEC results of triplicate injections of UPA 6,6. 
Average recovery of all injection was 101.05 ± 0.72 % 
 
Sample 
ID 
Injection Vpeak 
(Ml) 
Mn 
(Da) 
Mw 
(Da) 
Mz 
(Da) 
Mw/Mn 
(PDI) 
[η] 
(dl/g) 
Rh 
(nm) 
M-H ! M-H Log K 
UPA 
6,6 
1 14.831 11,516 40,156 237,526 3.487 0.3142 5.124 0.525 -2.823 
2 14.826 10,255 39,336 349,171 3.836 0.3131 5.057 0.519 -2.794 
3 14.819 14,941 41,165 175,890 2.755 0.3097 5.24 0.551 -2.961 
Average 14.825 12,237 40,219 254,196 3.359 0.3123 5.14 0.532 -2.859 
σ 0.0049 1,980 748 71,717 0.45 0.0019 0.08 0.014 0.073 
% RSD 0.03% 16.18% 1.86% 28.21% 13.40% 0.61% 1.47% 2.61% 2.55% 
Nylon 
6,6 
1 14.924 15,958 35,568 95,554 2.229 0.4538 5.831 0.573 -2.884 
2 14.968 19,547 37,217 95,573 1.904 0.4470 5.941 0.579 -3.006 
3 14.891 17,951 36,057 98,070 2.009 0.4592 5.900 0.580 -2.915 
Average 14.928 17,819 36,281 96,399 2.047 0.4533 5.890 0.583 -2.935 
σ 0.0315 1,468 692 1,182 0.135 0.0050 0.05 0.010 0.052 
% RSD 0.21% 8.24% 1.91% 1.23% 6.61% 1.10% 0.77% 1.73% 1.76% 
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6.3 Supplementary Figures  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: ECH of model solutions of MA with varying Ph. The Ph in the 
solution was changed by adding various ratios of K2SO4 and H2SO4 to maintain the ionic 
conductivity. An ECH of the solution was run at -1.5 V for 1 h with the Pb catalyst. A) MA 
conversion and B) HDA selectivity. 
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Supplementary Figure 2: Photographs and 1H NMR spectra, 600 MHz, D2O during the 
separation of HDA following fermentation. The fermentation broth containing HDA was 
concentrated through distillation at Ph 8.5 (A). After concentration, the solid products were 
removed with a 0.2-µm filter (B) and the following solution was purified with activated carbon 
(C). Following the purification, HDA was recovered by crystallization at Ph 1.5 and 4°C 
overnight (D). Purity was obtained through liquid chromatography with a photodiode array 
detector 
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Abstract 
Although Saccharomyces cerevisiae is the most highly domesticated yeast, strain dependency 
in biotechnological processes still remains as a common, yet poorly understood phenomenon. 
To investigate this, the entrance to the aromatic amino acid biosynthetic pathway was 
compared in four commonly used S. cerevisiae laboratory strains. The strains were engineered 
to accumulate shikimate by overexpressing a mutant version of the pentafunctional ARO1 
enzyme with disrupted activity in the shikimate kinase subunit. Carbon tracing and 13C 
metabolic flux analysis combined with quantitative PCR, revealed that precursor availability 
and shikimate production were dramatically different in the four equally engineered strains, 
which were found to be correlated with the strains’ capacity to deal with protein overexpression 
burden. By implementing a strain-dependent approach, the genetic platform was reformulated, 
leading to an increase in yield and titer in all strains. The highest producing strain, INVSc1-
SA3, produced 358 mg L-1 of shikimate with a yield of 17.9 mg g-1glucose. These results underline 
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the importance of strain selection in developing biological manufacturing processes, 
demonstrate the first case of high production of shikimate in yeast, and provide an appropriate 
platform for strain selection for future production of aromatic compounds. 
 
1. Introduction 
 
The metabolic pathways for the biosynthesis of aromatic compounds are present in many 
microorganisms and plants, and lead to the production of three key amino acids, i.e., 
tryptophan, phenylalanine, and tyrosine. In certain plants such as Papaver somniferum (opium 
poppy) and Catharanthus roseus, these amino acids become intermediates in the production 
of more complex molecules that range from pigments, tannins, and alkaloids (Bohlmann et al., 
1996; Facchini, 2001; Maeda and Dudareva, 2012). Given the versatile applications of these 
compounds and their great market opportunities (Evans, 2014), studying the relevant 
endogenous pathways has been central in microbial metabolic engineering efforts for the 
production of aromatic compounds. Some of the molecules that have reached considerable 
biotechnological production levels in Escherichia coli include shikimate (SA) (87 g/L) 
(Chandran et al., 2003), muconic acid (30 g/L) (Niu et al., 2002), and phenol (9.8 g/L) (Kim et 
al., 2014). 
The production of more specialized aromatics such as flavonoids and alkaloids requires the 
functional expression of membrane-bound plant cytochrome P450 enzymes, which is feasible 
in yeast, but remains as a challenge in E. coli (Leonard et al., 2007). For instance, naringenin 
and resveratrol can only be converted through tyrosine in E. coli, but can be synthesized from 
both tyrosine and phenylalanine in S. cerevisiae due to the functional expression of cytochrome 
P450 reductase (Koopman et al., 2012; Shin et al., 2012), and the most recent breakthrough, 
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the biosynthesis of tyrosine-derived opioids (Galanie et al., 2015; Minami et al., 2008; Thodey 
et al., 2014), demonstrates the great potential of using yeast as a host to produce plant 
secondary metabolites. However, due to intrinsically complicated genetic and metabolic 
regulations, the efforts in engineering the central carbon metabolism to increase the production 
of aromatics in yeast seem somewhat ineffective. The reported yields in S. cerevisiae are far 
from reaching the theoretical values (Curran et al., 2012; Hansen et al., 2009; Koopman et al., 
2012; Rodriguez et al., 2015), evidencing the demand for extensive strain development efforts.   
A key step in the development of microbial platforms for the production of valuable 
chemicals is the appropriate selection of the host strain. Although it may sound trivial, it 
becomes more and more evident that selecting strains even among those belonging to the same 
species is key to ensuring optimal titers, yields, and productivities. Different S. cerevisiae 
strains, varying slightly in genetic makeups, unexpectedly display disparate behaviors (Strucko 
et al., 2015). The differences can be attributed to the varying capabilities of maintaining 
episomal plasmids (Karim et al., 2013), expressing proteins (Caesar et al., 2007), hosting 
heterologous pathways (Du et al., 2012), and responding to signaling processes (Kummel et 
al., 2010). However, the underlying basis for these varying phenotypes remains unclear and 
may vary case by case when engineering metabolic pathways in yeasts.  
The purpose of this work was to analyze the metabolic differences among four commonly 
used S. cerevisiae strains (YSG50, BY4741, INVSc1, and BY4743) to understand the 
precursor dynamics that leads to high production of aromatic compounds. SA was chosen as 
the target compound since it is an early precursor for all the high-value aromatic compounds 
produced through this pathway, and itself is the starter compound of the commercial influenza 
antiviral Tamiflu® (Bochkov et al., 2012; McQuade and Blair, 2015). Although being equally 
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engineered, the four strains produced SA at dramatically different levels. 13C-metabolic flux 
analysis (13C-MFA) was implemented to systematically characterize the metabolic differences 
in the SA producing strains. The results demonstrated that the flux distribution in the central 
metabolism was very well conserved among all strains, but that the efficacy of producing SA 
was strongly dependent on the ability of each strain to auto-adjust the copy numbers of the 
episomal vectors. Studying the behavior of the engineered strains led to developing a new 
metabolic engineering rationale based on a low-copy plasmid, as a result enabling higher SA 
accumulation in all four strains. The work sheds light on increasing the titers of other aromatic 
amino acid-derived compounds in yeast.  
 
2. Materials and Methods 
 
2.1. Strains and media  
 
Two haploid and two diploid strains of S. cerevisiae were analyzed in this study (Table 1). 
The haploid strains include YSG50 (MATa ade2-1 ade3D22 ura3-1 his3-11,15 trp1-1 leu2-
3,112 can1-100) and BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0); the diploid strains 
include INVSc1 (MATa/a his3D1/his3D1 leu2/leu2 trp1-289/trp1-289 ura3-52/ura3-52 MAT), 
and BY4743 (MATa/a his3D1/his3D1 leu2D0/leu2D0 LYS2/lys2D0 met15D0/MET15 
ura3D0/ura3D0). The wild type strains were propagated in YPAD media (1% yeast extract, 
2% peptone, 0.01% adenine, and 2% dextrose). After plasmid transformation, yeast strains 
were cultured in Synthetic Complete media lacking uracil and histidine (0.5% ammonium 
sulfate, 0.16% yeast nitrogen without amino acid and ammonium sulfate, complete amino acid 
supplement mix lacking uracil and histidine, and 2% dextrose). The minimal growth medium 
composition used for labeling experiments was the same as reported previously with 20 g/L 
glucose as the sole carbon substrate (Feng and Zhao, 2013a; Feng and Zhao, 2013b). When 
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culturing yeast strains with 13C-labeled glucose, the regular glucose was replaced with 80% [1-
13C] glucose and 20% [U-13C] glucose (Cambridge Isotope Laboratories, Inc., Tewksbury, 
MA). All chemicals were purchased from Fisher Scientific (Pittsburgh, PA). E. coli BW25141 
was cultured in Luria Bertani (LB) medium supplemented with 100 µg Ml-1 ampicillin.  
2.2. Plasmid construction 
All plasmids constructed in this study (Table 1) were derived from the PRS shuttle vector 
series (New England BioLabs, Ipswich, MA). To assemble the genetic cassettes, the DNA 
Assembler technique (Shao et al., 2012; Shao and Zhao, 2013) was implemented. All primers 
in this work were synthesized by IDT (Coralville, IA). The aspartic acid at the position of 920 
in the wild type ARO1 was substituted to alanine by incorporating the mutation into PCR 
primers (fwd:gttacaaattagttgacctagcggagctgtttgagcaaca, rev: 
tgttgctcaaacagctccgctaggtcaactaatttgtaac) and the variant was cloned downstream of the S. 
cerevisiae GPD constitutive promoter and upstream of the PYK1 terminator. The expression 
cassette was assembled in the PRS426 backbone digested with XhoI, yielding the plasmid 
pRS426-aro1D920A (Supplementary Figure 1).  Plasmid pRS413-aro4K229L-tkl1 was 
constructed in the previous study (Suastegui et al., 2016) and used here to enhance the entrance 
of carbon into the SA pathway. Plasmid pRS413-aro1D920A-aro4K229L-tkl1 was constructed by 
assembling the XhoI digested pRS413-aro4K229L-tkl1 with the PCR-amplified aro1D920A 
cassette with the ends overlapping to the pRS413 backbone and TPI1 promoter. Similarly, to 
construct pRS426-aro1D920A-aro4K229L-tkl1, plasmid pRS426-aro1D920A was digested with 
BamHI and re-assembled by addition of the PCR cassette aro4K229L-tkl1 with the overlapping 
ends to the PYK terminator and the backbone of pRS426. Plasmid transformation was done by 
the lithium acetate technique (Kawai et al., 2010) 
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Table 1: Plasmids and strains constructed in this work. 
Plasmid Expression Cassette Features 
pRS413-
aro4K229L-TKL1  
TPI1p-scaro4K229L-TDH2t 
ADH1p-scTKL1-ADH1t 
Feedback insensitive DHAP synthase. 
Transketolase 1 to increase E4P pool. 
 
pRS426-
aro1D920A 
GPDp-scaro1D920A-PYK1t Mutant version of pentafunctional  
ScARO1 with disrupted activity of SA 
kinase subunit.  
pRS426-
aro1D920A – 
ecaroL 
GPDp-scaro1D920A-PYK1t 
TEFp-ecaroL-HXT7t 
E. coli aroL to complement the activity of 
mutant aro1D920A 
 
pRS413-
aro1D920A 
aro4K229L-TKL1 GPDp-scaro1D920A-PYK1t 
TPI1p-scARO4K229L-TDH2t 
ADH1p-ScTKL1-ADH1t  
Complete pathway in pRS413 backbone for 
accumulation of SA.  
  
pRS426-
aro1D920A 
aro4K229L-TKL1 
Complete pathway in pRS426 backbone for 
accumulation of SA.  
Strains Genotype / Plasmid  
YSG50 MATa; ade2-1; ade3 Δ22; ura3-1; his3-11,15; trp1-1; leu2-3,112; can1-100 
INVSc1 MATa/a;  his3 Δ 1/his3 Δ1; leu2/leu2; trp1-289/ trp1-289; ura3-52/ ura-52 
MAT 
BY4741 MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0 
BY4741 Δaro1 BY4741 aro1::KanMX 
BY4743 MATa/a; his3Δ1/his3Δ1; leu2Δ0/leu2Δ0; LYS2/lys2Δ0; met15Δ0/MET15; 
ura3Δ0/ura3Δ0 
SA0 pRS426 & pRS413 
SA1  pRS426-aro1D920A 
SA2 pRS426-aro1D920A & pRS413 aro4K229L-TKL1 
SA3 pRS426 & pRS413-aro1D920A-aro4K229L-TKL1 
SA4 pRS426-aro1D920A- aro4K229L-TKL1 & pRS413  
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2.3. Biomass and metabolite analysis  
Biomass growth in minimal media was monitored by optical density changes with an 
absorbance reader at 600 nm (OD600) (Biotek Synergy 2 Multi-Mode Microplate Reader). 
Samples were taken every 2 to 3 hours until the late exponential phase was reached. Cell-free 
samples were used to measure extracellular metabolites by Shimadzu HPLC (Columbia, MD) 
equipped with an Aminex HPX-87H column (Bio-Rad, Hercules, CA) and Shimadzu RID-
10A refractive index detector. The column was kept at 50°C, and 5 Mm sulfuric acid solution 
was used as the mobile phase with a constant flow rate of 0.6 Ml/min. Standard samples of 
ethanol, glucose, glycerol, and SA were purchased from ACROS Organics™ (Geel, Belgium). 
2.4. Isotopomer analysis of proteinogenic amino acids and SA  
The protocol for sample preparation and amino acid analysis was followed based on Feng et 
al. (Feng et al., 2012). During the late exponential phase, 1 Ml samples were collected from 
the cultures grown with the labeled glucose for proteinogenic amino acid profiling. The 
samples were centrifuged and the biomass was hydrolyzed with 6 M HCl at 100°C for 20 h, 
followed by drying and derivatization with 25 µL of tetra-hydrofuran and 25 µl of tert-
butyldimethylsilyl ether at 70°C for 1h. To analyze the labeled SA, 1 Ml of the supernatant 
from the culture samples was dried overnight followed by derivatization with 60 µl of N,O-
bis(trimethylsilyl)trifluoroacetamide at 70°C for 1 h. The derivatized samples were analyzed 
by gas chromatograph (GC2010, Shimadzu) equipped with a SH-Rxi-5Sil column (Shimadzu) 
and a mass spectrometer (QP2010, Shimadzu). Two types of charged fragments were detected 
by GC-MS for various amino acids (Supplementary Table 1): the [M-57]+ group (containing 
unfragmented amino acids), and the [M-159] + or the [M-85] + group (containing amino acids 
that had lost an α-carboxyl group). The whole derivatized SA fragment was detected from the 
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sample supernatant. The mass distribution vectors (MDVs) were represented by M0, M1, M2, 
etc., which were the corresponding fractions of non-labeled, singly labeled, doubly labeled 
amino acids. The effects of natural isotopes on isotopomer labeling patterns were corrected by 
the previously reported algorithms (Wahl et al., 2004). 
2.5. Metabolic Flux Analysis  
MDVs were used to calculate the summed fractional labeling (SFL) values which were directly 
used in the MFA (Biomet Toolbox 2.0 (Garcia-Albornoz et al., 2014), based on MATLAB 
(MathWorks, Inc. MA). The central carbon metabolic model for the MFA was developed based 
on the KEGG database (http://www.genome.jp/kegg/), and it included the glycolysis pathway, 
pentose phosphate pathway, anaplerotic pathways, the tricarboxylic acid (TCA) cycle, the SA 
synthesis pathway, and the transport reactions between different cell compartments 
(Supplementary Table 2). For our metabolic flux analysis, flux estimation was repeated at 
least 50 times starting with different initial values generated by a genetic algorithm for all the 
fluxes to find a likely global solution. A fit of the simulated and measured SFLs was 
determined to be a global solution only after the solution fit was obtained at least twice using 
this method (Supplementary Figure 2). 
2.6. Plasmid copy number assay 
The copy number of the two plasmids used in this work was quantified using quantitative PCR 
(Qpcr). Cell cultures were grown in minimal media for 24 hours and cell amounts equivalent 
to 2 OD600 units were collected for total DNA extraction as previously described (Moriya et 
al., 2006). The primers were designed using the online PrimeTime© tool for Qpcr assays 
through IDT. The primer pair p-ura3 (fwd: tagcagaatgggcagacattac; rev: ggcctctaggttcctttgttac) 
was used to quantify the plasmid pRS426; the primer pair p-his3 (fwd: gtccacacaggtatagggtttc; 
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rev: gtgatggtcgtctatgtgtaagt) was used to quantify the plasmid pRS413. Plasmid copy number 
was normalized to total DNA with alg9 as the reference gene (fwd: ccgttgccatgttgttgtatg; rev: 
gccaggaaattgtacgctaaac). A standard curve for each target was prepared using pure plasmid or 
genomic DNA samples. 
 
3. Results and Discussion 
 
3.1 Building the first yeast platform for SA production 
Unlike prokaryotes and higher eukaryotes, the five steps involved in SA biosynthesis in yeast 
are catalyzed by a single pentafunctional enzyme ARO1 (Braus, 1991) (Figure 1). Knocking 
out individual steps of this pathway without affecting the rest of the catalytic functions in yeast 
could be a cumbersome task. Hence, a single amino acid substitution in the active site of the 
SA kinase subunit (ARO1B) is preferred to halt the conversion of SA to shikimate-3-phosphate 
(S3P). Initially, an amino acid sequence alignment with SA kinases from several prokaryotic 
and eukaryotic organisms was performed. Despite the genetic variations within these species, 
it was observed that the catalytic sites of the shikimate kinases (D920-aro1 in S. cerevisiae) 
were 100% conserved (Figure 2). This residue was substituted by alanine, yielding the mutant 
enzyme ARO1D920A that was further cloned into plasmid pRS426 (pRS426-aro1D920A) and 
transformed into the four S. cerevisiae strains (YSG50, INVSc1, BY4741, and BY4743). 
However, no SA was detected in the fermentation media in any of the strains (Figure 3). It 
was not a surprise since the endogenous synthesis of aromatic amino acids could have (i) 
channeled the accumulated SA into the downstream reactions, and (ii) feedback inhibited the 
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first step of aromatic amino acid biosynthesis catalyzed by 3-dehydroxy-D-arabino-heptulose-
7-phosphate (DAHP) synthase. 
 
 
Figure 1: Pathway depicting engineering efforts for the accumulation of SA. The arrows 
in green represent the overexpressed enzymes for unlocking the production of SA. 
Metabolites: G6P, glucose-6-phosphate; G1P, glucose-1-phosphate; F6P, fructose-6-
phosphate; G3P, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; PEP, 
phosphoenolpyruvate; Pyr, pyruvate; AcCoA, acetyl-CoA; OAA, oxaloacetic acid; Ri5P, 
ribulose-5-phosphate; X5P, xylulose-5-phosphate; R5P, ribose-5-phosphate; S7P, 
sedoheptulose-7-phosphate; E4P, erythrose-4-phosphate; DAHP, 3-deoxy-D-
arabinoheptulosonate 7-phosphate; DHQ, dehydroquinoate; DHS, dehydroshikimate; S3P, 
shikimate-3-phosphate; EPSP, 5-enolpyruvyl-3-shikimate phosphate. Abbreviation of genes: 
ZWF1, glucose-6-phosphate 1-dehydrogenase; PYK1, pyruvate kinase; PCK, 
phosphoenolpyruvate carboxykinase; PYC, pyruvate carboxylase. Abbreviation of enzymes: 
TKL1, transketolase; ARO3/4, DAHP synthase isoenzymes; ARO4K229L, feedback insensitive 
DAHP synthase; ARO1, pentafunctional enzyme converting DAHP to EPSP; subunits – C: 
DHQ synthase, E: DHQ dehydratase, D: DHS dehydrogenase, B: SA kinase, A: ESPS 
synthase; ARO1D920A, mutant ARO1 with disrupted activity of shikimate kinase subunit; 
TRP2, anthranilate synthase; ARO2, chorismate synthase; TRP3, indole-3-glycerol-phosphate 
synthase; ARO7, chorismate mutase 
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Figure 2: Sequence alignment of shikimate kinases from different species. The aspartic 
acid residue (D920 in S. cerevisiae) is conserved in the five selected species, from which the 
corresponding residue has been reported to be the catalytic residue. UNIPROT 92ccession 
number: S. cerevisiae: aro1B subunit (P08566), Escherichia coli (P0A6D7), Pseudomonas 
syringae (Q87V14), Arabidopsis thaliana (Q8GY88), Helicobacter pylori (P56073), and 
Dickeya dadantii (E0SJR7). 
 
Scerevisiae  841 EVANPVRILERHCTGKTWPGWWDVLHSELGAKLDGAEPLECTSKKNSKKSVVIIGMRAAG 
Ecoli          3 ----------------------------------------------EKRNIFLVGPMGAG 
Psyringae      2 ------------------------------------------------RNLILVGPMGAG 
Athaliana     67 -------LLE---TGSLLHSPFDEEQQILKKKA------EEVKPYLNGRSMYLVGMMGSG 
Hpylori        2 ------------------------------------------------QHLVLIGFMGSG 
Ddadantii      3 ----------------------------------------------EKRNIFLVGPMGAG 
 
 
Scerevisiae  901 KTTISKWCASALGYKLVDLDELFEQQ-HNNQSVKQFVVENGWEKFREEETRIFKEVIQNY 
Ecoli         17 KSTIGRQLAQQLNMEFYDSDQEIEKR-T-GADVGWVFDLEGEEGFRDREEKVINELTE-- 
Psyringae     14 KSTIGRLLAKELRLPFKDSDKEIELR-T-GANIPWIFDKEGEPGFREREQAMIAELCEA- 
Athaliana    111 KTTVGKIMARSLGYTFFDCDTLIEQAMK-GTSVAEIFEHFGESVFREKETEALKKLSLM- 
Hpylori       14 KSSLAQELGLALKLEVLDTDMIISER-V-GLSVREIFEELGEDNFRMFEKNLIDELKTL- 
Ddadantii     17 KSTIGRQLAQQLNMEFFDSDQEIERR-T-GADVGWVFDVEGEEGFREREEKVINELTE-- 
 
 
Scerevisiae  960 GDDGYVFSTGGGIVESAESRKALKDFASSGGYVLHLHRDIEETIVFLQS--DPSRPAYVE 
Ecoli         73 -KQGIVLATGGGSVKSRETRNRL----SARGVVVYLETTIEKQLARTQR--DKKRPLLHV 
Psyringae     71 --DGVVLATGGGAVMRTENRQAL----RAGGRVVYLHASIEQQVGRTAR--DRNRPLLRT 
Athaliana    169 -YHQVVVSTGGGAVIRPINWK-Y----MHKGISIWLDVPLEALAHRIAAVGTGSRPLLHD 
Hpylori       71 -KTPHVISTGGGIVMHE----NL----KGLGTTFYLKMDFETLIKRLNQKEREKRPLLNN 
Ddadantii     73 -KQGIVLATGGGSVKSRETRNRL----SARGVVVYLETTIEKQLARTQR--DKKRPLLQV 
 
 
Scerevisiae 1018 --EIREV----------WNRREGWYKE------------------CSNFSFFAPHCSAEA 
Ecoli        126 ETPPREVLEA------LANERNPLYEE------------------IADVT---------- 
Psyringae    123 ADPARVLSEL-------LAIRDPLYRE------------------IADVV---------- 
Athaliana    223 DESGDTYTAALNRLSTIWDARGEAYTKASARVSLENITLKLGYRSVSDLT---------- 
Hpylori      122 LTQAKEL----------FEKRQALYEK------------------NASFI---------- 
Ddadantii    126 ETPPREVLEA------LAKERNPLYEE------------------IADVT----------!
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To characterize the activity of ARO1D920A, a complementation experiment was carried out. 
The plasmid pRS426-aro1D920A was transformed into the strain BY4741 Daro1 (GE Healthcare 
Bio-Sciences, USA) and plated onto medium lacking uracil and the three aromatic amino acids. 
Cell were incubated for two days and as expected no growth was observed, indicating that the 
novel mutant ARO1D920A is incapable of complementing growth in the Daro1 background 
(Figure 4a). To confirm that the growth defect is caused exclusively by the disrupted kinase 
subunit (ARO1B) in the novel mutant ARO1D920A, a new plasmid was constructed harboring 
the E. coli shikimate kinase gene aroL (pRS426-aro1D920A – ecaroL). The strain BY4741 
Daro1 was transformed with the latter plasmid and after two days of culturing in media lacking 
uracil and aromatic amino acids, colonies were observed (Figure 4b). Complementation of 
growth by the ecaroL, was a definitive indication that the novel enzyme ARO1D920A remains 
functional in all of its subunits except for the subunit ARO1B, which catalyzes the conversion 
of shikimic acid to shikimate-3-phosphate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
94 
 
 
 
 
 
 
 
Figure 3: Media optimization for the production of SA. To allow the accumulation of SA  
in all fours strains, it was necessary to incorporate the three aromatic amino acids into the 
growth media, through which the conversion of SA into downstream metabolites was at least 
partially reduced and hence the positive outcome of expressing the mutant ARO1D920A was 
observed. Samples were taken after 24 h of fermentation. The variation is represented as the 
standard deviation from three biological replicates. 
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The plasmid pRS413-aro4K229L-tkl1 was transformed into the strains (Group SA2) which 
carries the tyrosine-insensitive DAHP synthase to overcome the feedback inhibition, as well 
as the transketolase gene tkl1 to increase the flux of the precursor erythrose-4-phosphte (E4P) 
(Curran et al., 2012). These approaches have been successfully implemented in E. coli to 
produce SA and in S. cerevisiae for the production of dehydroshikimate-derived muconic acid 
(Chen et al., 2012; Cui et al., 2014; Curran et al., 2012; Niu et al., 2002). Nevertheless, SA was 
still not observable in any of the strains. We hypothesized that the genome-copy of aro1 was 
causing a rapid channeling of SA into the production of aromatic amino acids. Hence, to 
completely shut down the native pathways downstream of SA, tryptophan, phenylalanine, and 
tyrosine were added to the minimal medium at low concentrations of 50 mg L-1. The presence 
of these three amino acids blocked the endogenous flux into the downstream branches, and SA 
was finally observed (Figure 3). This result demonstrated that despite genotypic differences, 
all four S. cerevisiae strains had undergone strong regulatory controls on the aromatic amino 
acid biosynthesis. It is known that the presence of external aromatic amino acids inhibits the 
first committed step in the biosynthesis of aromatics (ARO3 and ARO4) and the downstream 
branch points (ARO7 and TRP2/3, Figure 1) (Braus, 1991). However, inhibition may also 
have occurred at the step converting SA to S3P (ARO1B), most likely by the reduced 
transcription rates of the wild type aro1, thus allowing SA to accumulate in the strains 
overexpressing the mutant ARO1D920A. To our knowledge, this is the first report of success in 
engineering yeasts to accumulate a significant amount of SA.  
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Figure 4: Characterization of the novel mutant enzyme ARO1D920A. A) The strain BY4741 
Daro1 harboring plasmid pRS426-aro1D920A cannot grow in medium lacking aromatic amino 
acids (AA). B) Complementation of growth was achieved by constructing the plasmids 
pRS426-aro1D920A – ecaroL, which harbors the E. coli shikimate kinase gene aroL. C-D) 
Control plates containing aromatic amino acids. 
  
97 
 
3.2. Comparison of fermentation profiles 
Although all strains were able to produce SA, the titers among the strains varied drastically; 
the lowest being 30 mg L-1 in strain YSG50 and the highest, 350 mg L-1 in strain INVSc1. 
Small batch fermentations in minimal media were carried out to investigate physiological 
characteristics. The consumption rates of glucose and the formation rates of SA, ethanol, and 
glycerol among the four strains during exponential phase were compared (Table 2, Figure 5). 
From the fermentation profiles it was easy to arrange the strains into two groups; the strain pair 
of BY4741 and BY4743, and the pair of YSG50 and INVSc1. Although all four strains had 
similar specific growth rates (0.13-0.17 h-1), the BY4741 and BY4743 strains did have about 
2-3 fold higher rates in terms of glucose consumption and ethanol production. The rate of 
glycerol production varied slightly, although it was not observable in strain YSG50. The 
production of SA revealed the highest difference among the strains. Apparently, no correlation 
between strain ploidy and SA production could be drawn since strains YSG50 and BY4743 
(haploid and diploid, respectively) showed the lowest productions, with yields around 0.83 and 
0.32 mmol Gdcw-1, respectively. The strain BY4741 had a mid SA production with a yield of 
2.38 mmol Gdcw-1, and finally, strain INVSc1 had the highest yield of 8.1 mmol Gdcw-1, 3.4-
fold higher than strain BY4741, 9.8-fold higher than strain YSG50, and 25-fold higher than 
BY4743. These results suggested that, despite all the strains being equally engineered, either 
the expression of the pathway enzymes, the entrance into the aromatic amino acid pathway or 
both were strain dependent. 
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Table 2: Physiological characterization of SA producing strains. µ (h-1), specific growth 
rate; r (mmol Gdcw-1 h-1), rate of consumption or production; Ymax (mmol Gdcw-1), molar 
yield based on consumed glucose; titer (mg L-1). 
 
Strain  Glucose Ethanol Glycerol SA 
µ   r r Ymax r Ymax r Ymax titer 
YSG50-
SA2 0.13 13.2 15.1 241.8 - - 0.17 0.83 30 
INVSc1-
SA2 0.17 13.8 12.8 206.9 1.49 28.6 1.53 8.1 350 
BY4741-
SA2 0.15 28.7 34.8 246.4 4.79 36.1 1.36 2.38 150 
BY4743-
SA2 0.16 33.4 40.1 310.6 1.18 18.6 0.15 0.32 40 
 
 
 
Figure 5: Fermentation profiles of strain groups SA2 
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3.3. Inspection of 13C isotopic “finger prints” of aromatic amino acids 
The most significant difference between strains in the group SA2 arose from comparing the 
13C isotopic “fingerprints” of the aromatic amino acids, namely phenylalanine and tyrosine 
Interestingly, the strains with the highest production of SA (INVSc1 and BY4741) showed the 
highest percentage of labeled phenylalanine and tyrosine (m1:m9), whereas the strains with 
the lowest production (YSG50 and BY4743) showed a lower labeling distribution (Figure 6). 
This was a clear indication that not only were the strains INVSc1 and BY4741 able to 
accumulate SA in higher titers, but they also had a higher pull of carbon from the downstream 
metabolic branch leading to the production of phenylalanine and tyrosine. It is crucial to 
mention that these observations were not due to different extracellular amino acid uptake, since 
measurement of the fermentation supernatant showed equal uptake rates (data not shown here). 
Analyzing the isotopic labeling patterns of leucine, another non-labeled amino acid added in 
the culture medium for all four strains also showed similar labeling patterns; the non-labeled 
leucine (m0) constituted more than 93% in all strains. This confirmed that the high producing 
SA strains had more active aromatic amino acid biosynthetic pathway. It is noteworthy that 
although the endogenous entrance of carbon into the aromatic pathway was supposedly 
blocked by the supplementation of aromatic amino acids, de novo production of tyrosine and 
phenylalanine was observed in all strains. Therefore, to maximize SA accumulation, future 
work should target the implementation of a more stringent blockage of the downstream 
branches. 
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Figure 6: Isotropic distribution of labeled and non-labeled amino acids. Strains INVSC1-
SA2 and BY4741-SA2 showed higher percentages of labeled A) phenylalanine and B) tyrosine 
compared to YSG50-SA2 and BY4743-SA2. This corroborated the higher fluxes into the 
biosynthesis of aromatic compounds in the strains with higher SA levels. C) Analysis of 
leucine, another non-labeled amino acid, showed equal distribution across all four strains.  
 
 
3.4. Comparison of flux distributions in key nodes 
To further investigate the metabolic differences in a quantitative manner, the isotopomer 
labeling patterns, i.e., mass distribution vectors, of proteinogenic amino acids were utilized to 
obtain the metabolic fluxes through the central carbon metabolism of the S. cerevisiae strains. 
Similar fluxes were found in the glycolytic pathway up to the formation of 
phosphoenolpyruvate (PEP), as well as in the oxidative pentose phosphate pathway (PPP) 
(Figure 7). The main variation resulted from the flux entrance into the SA synthesis pathway 
(v11). This reflected difference in the availability of the precursors PEP and E4P to enter the 
pathway. Less than 8% of the flux into PEP (v5), ranging from 143 to 172, was channeled into 
the formation of SA in all the strains. 
Therefore, a potential strategy to increase the availability of PEP is to lower the activity of 
the pyruvate kinase encoded by PYK1 (Figure 1). This strategy has been implemented in the 
bacterium Bacillus subtilis through (i) deleting PYK1, resulting in 8% increase of SA (Liu et 
al., 2014), and (ii) reducing the activity by means of a mutant PYK1 (Fry et al., 2000) or by 
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replacing its promoter to an inducible one which resulted in the least detrimental growth (Zhu 
et al., 2005). A similar approach could be implemented in S. cerevisiae, since complete 
removal of PYK1 would impede the cells from growing in fermentable sugars (Sprague, 1977). 
Besides the difference in the PEP supply, another major difference occurred in the reductive 
PPP, which is controlled by the Tkl1 and the transaldolase (Tal1) enzymes, catalyzing the 
transfer of C2 and C3 units from a ketose donor to an aldose acceptor. The enzyme Tkl1 has 
been shown to be indispensable in the production of aromatic amino acids; deletion of this 
enzyme in S. cerevisiae made the strain auxotrophic to aromatic amino acids (Schaaff-
Gerstenschlager et al., 1993). Furthermore, TKL1 has been overexpressed to increase the 
production of DHS-derived muconic acid in combination with the deletion of the gene ZWF1 
to force carbon to enter PPP at the non-oxidative node (Figure 1). However, only a small 
increase in muconic acid was observed (from ~ 30 mg L-1 to 40 mg L-1 ), which could be 
correlated with the preference of  TKL1 to catalyze the opposite reaction (Curran et al., 2012). 
Although this strategy has been successfully implemented in E. coli (Niu et al., 2002; Patnaik 
and Liao, 1994), a recent publication studying the production of muconic acid in a co-culture 
system showed that this approach overexpression resulted in a lower titer (Zhang et al., 2015). 
Expectedly, the flux through the reaction v10 evidently differed among the strains; the lowest 
value, 1.1, corresponded to the highest producer, while the lowest producer showed a flux 
value of 17.5. This confirmed that INVSc1 had a stronger pull of carbon into the aromatic 
amino acid pathway, whereas in YSG50 and BY4743 more carbon returned to glycolysis at 
the node of E4P. An important point to highlight is that between the two precursors for 
aromatic compounds, E4P was clearly the limiting one. For instance, in strain INVSc1, despite 
that about 90% of the flux of E4P ended up entering the SA pathway (v11/v9), it was only 
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equivalent to 8% of the calculated flux of PEP (v11/v5). Thus, engineering the node to increase 
the availability of E4P is key to maximizing the production of aromatic compounds. This could 
entail pulling more carbon into the non-oxidative PPP by means of a mutant TKL incapable of 
converting E4P back to F6P (Nilsson et al., 1997), or by implementing global transcriptional 
manipulations to increase the transcription rates of multiple genes in this node coupled with a 
fast-screening method (Iraqui et al., 1998; Kim et al., 2015; Lee and Hahn, 2013). 
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Figure 7: Major intracellular metabolic flux distributions in the engineered strains in 
group SA2 (Table 1). All fermentations were performed in batch mode supplemented with 20 
g L-1 of 80% [1-13C] glucose and 20% [U-13C] glucose. The fluxes are expressed as normalized 
values relative to specific glucose uptake rate (Table 2). These values represent a global 
solution obtained via isotopomer modeling of the 13C labeled proteinogenic amino acids. To 
emphasize the flux differences in the SA pathway, the thickness of the arrows of reactions v9 
to v11 was normalized by a value of 5; a value of 25 was used otherwise. P5P: pentose 
phosphate sugar.  
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 3.5. Pathway balancing for enhanced production of SA 
Carbon tracing and 13C-MFA corroborated that the four equally engineered strains had 
dramatically different flux distributions through the SA pathway stretching from the upstream 
precursor synthesis to the downstream aromatic amino acid production, which was likely 
caused by the differential expression of the three cloned enzymes. Initially, we hypothesized 
that the plasmid copy numbers could vary significantly from one strain to another, causing the 
major metabolic differences observed, despite all strains being equally engineered. Previous 
research has shown that specific genetic elements on the plasmid such as the selection marker, 
as well as the segregation element (centromere or 2µ) play an important role in the yeast’s 
fitness with some correlations to the strain’s ploidy (Karim et al., 2013). Since our platform 
consisted of plasmids harboring structural genes under the transcriptional control of strong 
constitutive promoters, we further reasoned that the engineered strains might have had very 
different capacities to deal with the energy burden posed by plasmid synthesis and enzyme 
overexpression. This effect was first recognized based on the observation that the optical 
densities at the late exponential phase of strain cultures in the group SA2 were reduced 
compared to the strains carrying the empty plasmids (SA0 strains, Figure 8a), but interestingly 
the growth reduction did not correlate with SA production level. This observation excluded 
SA toxicity as the major factor causing the growth reduction, suggesting that the actual copy 
numbers in the four strains might not reflect the behaviors of typical 2µ and centromere as the 
segregation elements.  
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Figure 8: Phenotypic comparison of S. cerevisiae engineered for the production of SA. A) 
Growth percentage of strains in the group SA2 versus strains carrying empty plasmids (group 
SA0, Table 1). B) Correlation between SA production and plasmid maintenance. The ratio 
between plasmid pRS426-aro1D920A and pRS413-aro4K229L-TKL1 was calculated and plotted 
on the x-axis. Samples were taken after 24 h of growth in minimal media. Variation is 
represented as the standard deviation from three biological replicates. 
 
Measurement of the plasmid copy numbers revealed interesting insights on the capacity of 
each strain to cope with the stress caused by excessive enzyme expression. It appeared that 
plasmid pRS426-aro1D920A had a significant impact on the cell’s fitness, and most importantly, 
on the production of SA. As shown in Figure 8b, the copy number ratio between the plasmid 
pRS426-aro1D920A and pRS413-aro4K229L-tkl1 was calculated and a clear negative correlation 
was identified. The strains with the highest production of SA (INVSc1 and BY4741) had a 
plasmid ratio closer to 1, whereas the poor-producing strains (YSG50 and BY4743) had a ratio 
between 3 and 7. It was also noticed that although the plasmid pRS426-aro1D920A had the 
2µ segregation element, the copy number was dramatically reduced to resemble a 
centromere-like plasmid. The absolute copy numbers of the plasmids were compared between 
the strain groups SA0 and SA2 (Figure 9). The reduction in plasmid copy number was evident 
in all strains in the group SA2; the most significant reduction occurred in the plasmid pRS426-
aro1D920A in the strain INVSc1-SA2, where the copy number was reduced 95% compared to 
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the empty plasmid. Contrary to our findings, Karim et al., (2013) showed that using histidine 
and uracil as selection markers result in similar growth rates and plasmid copy number when 
comparing strains BY4741 and BY4743. In our study, we did observe major discrepancies that 
can be attained to 1) co-expression of two distinct episomal plasmids and 2) constitutive 
overexpression of structural genes. Although the four, wildtype strains studied here have slight 
differences in their auxotrophic markers, no correlation with their capacity to accumulate 
shikimate can be observed. For instance, the only major auxotrophic difference between strains 
YSG50 and INVSc1 is the deletion of ade1 in the former, yet these strains have the most 
evident disparity in accumulation of shikimate. Similarly, supplementation of L-trp in the 
growth medium brings the strains INVSc1 and BY4743 to the same auxotrophic level, but their 
capacity to produce shikimic is considerably different. We hypothesized that overexpression 
of aro1D920A in the pRS426 background had a negative impact on SA production. Hence, only 
the strains capable of adjusting this plasmid to a very low copy number could produce higher 
amounts of SA. 
 
 
 
Figure 9: Absolute copy number of plasmid in strains SA0 and SA2. A) Comparison 
between plasmids pRS413 and pRS413-aro4K229L-tkl1. B) Copy number comparison between 
plasmids pRS426 and pRS426-aro1D920A. 
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To test this hypothesis, we constructed a new plasmid encoding the three genes on the 
pRS413 backbone (pRS413-aro1D920A-aro4K229L-tkl1). To maintain the same selective 
nutrients as used previously, this plasmid was transformed along with an empty pRS426 vector 
yielding the group SA3. As expected, all the strains in group SA3 showed increases in the SA 
titers. A 2-fold increase was observed for strains YSG50 and BY4741, and the most significant 
increase occurred in strain BY4743-SA3, where the SA titer was elevated 5.5-fold over the 
corresponding. The strain INVSc1-SA3 showed very similar titers when compared to INVSc1-
SA2 (358 and 350 mgL-1), indicating that such strains might have reached the maximum flux 
attainable into the aromatic amino acid pathway with the provided manipulations (Figure 10). 
In parallel, we reconstructed a new plasmid encoding all three genes on the pRS426 backbone 
(pRS426-aro1D920A-aro4K229L-tkl1), and co-transformed it with the empty pRS413 into all 
strains, yielding SA producing groups SA4 (Table 1). Very interestingly, a dramatic decrease 
in titers was observed in all strains in this group. In the case of INVSc1, BY4741, and BY4743, 
the production dropped 94%, 96%, and 83%, respectively, whereas the strain YSG50 showed 
no SA accumulation (Figure 10). This result suggested that overexpressing aro4K229L and tkl1 
excessively added a new layer of stress that negatively affected cellular metabolism. 
Contrary to our findings, Karim et al (2013) showed that using histidine and uracil as 
selection markers result in similar growth rates and plasmid copy number when comparing 
strains BY4741 and BY4743. In our study, we did observe major discrepancies that can be 
attained to 1) co-expression of two distinct episomal plasmids and 2) constitutive 
overexpression of structural genes. Although the four wildtype strains studied here have slight 
differences in their auxotrophic markers, no correlation with their capacity to accumulate 
shikimate can be observed. For instance, the only major auxotrophic difference between strains 
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YSG50 and INVSc1 is the deletion of ade1 in the former, yet these strains have the most 
evident disparity in accumulation of shikimate. Similarly, supplementation of L-trp in the 
growth medium brings the strains INVSc1 and BY4743 to the same auxotrophic level, but their 
capacity to produce shikimic is considerably different.  
 
 
 
Figure 10: Accumulation of SA in the strains of groups SA2, SA3, and SA4. All strains 
showed an increased production of SA when the genes were encoded in the plasmid pRS413 
(group SA3). Conversely, incorporating all three genes into the backbone of pRS426 (group 
SA4) resulted in extremely low production of SA.  
 
Balancing gene expression for efficient production of chemicals is a common task carried 
out in metabolic engineering research (Du et al., 2012; Kim et al., 2013). The results presented 
here reaffirm that pathway balancing is an obligated step for the construction of efficient 
microbial factories. Moreover, the pipeline for optimization should also consider the selection 
of the host strain and tailoring the plasmid selection according to the host. Recently, it has been 
recognized that yeast strains can auto-adjust plasmid copy number in accordance to the burden 
of excessive enzyme expression (Carquet et al., 2015). Our study showed that four 
independent, yet commonly used S. cerevisiae strains had disparate responses to simple 
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metabolic manipulations, which was correlated to their ability to balance the introduced 
plasmids. A careful inspection of the behavior of each strain brought valuable insights into 
how to properly engineer the carbon entrance into the aromatic amino acid pathway.  
 
5. Conclusion 
 
Altogether, we were able to observe high-level accumulation of SA in three of the four 
strains engineered in this work. Having four S. cerevisiae strains with different capacity to 
produce SA, allowed us to implement a strain-dependency approach to discern the appropriate 
way to engineer our pathway of interest. The higher production of strains in the group SA3 
was a result of rationally engineering the entrance of carbon into the aromatic amino acid 
biosynthetic pathway. This work emphasizes the significance of strain and plasmid selection 
in metabolic engineering efforts and provides insights to optimize the production of aromatic 
compounds in yeast. 
  
110 
 
6. Bibliography 
 
Bochkov, D., Sysolyatin, S., Kalashnikov, A., Surmacheva, I., 2012. Shikimic acid: review 
of its analytical, isolation, and purification techniques from plant and microbial 
sources. J Chem Biol. 5, 5-17.  
Bohlmann, J., Lins, T., Martin, W., Eilert, U., 1996. Anthranilate synthase from Ruta 
graveolens. Duplicated AS alpha genes encode tryptophan-sensitive and tryptophan-
insensitive isoenzymes specific to amino acid and alkaloid biosynthesis. Plant 
Physiol. 111, 507-14.  
Braus, G. H., 1991. Aromatic amino acid biosynthesis in the yeast Saccharomyces 
cerevisiae: a model system for the regulation of a eukaryotic biosynthetic pathway. 
Microbiol Rev. 55, 349-70.  
Caesar, R., Palmfeldt, J., Gustafsson, J. S., Pettersson, E., Hashemi, S. H., Blomberg, A., 
2007. Comparative proteomics of industrial lager yeast reveals differential expression 
of the cerevisiae and non- cerevisiae parts of their genomes. Proteomics. 7, 4135-
4147.  
Carquet, M., Pompon, D., Truan, G., 2015. Transcription interference and ORF nature 
strongly affect promoter strength in a reconstituted metabolic pathway. Front Bioeng 
Biotechnol. 3, 21.  
Chandran, S. S., Yi, J., Draths, K. M., von Daeniken, R., Weber, W., Frost, J. W., 2003. 
Phosphoenolpyruvate availability and the biosynthesis of shikimic acid. Biotechnol 
Prog. 19, 808-14.  
Chen, K., Dou, J., Tang, S., Yang, Y., Wang, H., Fang, H., Zhou, C., 2012. Deletion of the 
aroK gene is essential for high shikimic acid accumulation through the shikimate 
pathway in E. coli. Bioresour Technol. 119, 141-147.  
Cui, Y. Y., Ling, C., Zhang, Y. Y., Huang, J., Liu, J. Z., 2014. Production of shikimic acid 
from Escherichia coli through chemically inducible chromosomal evolution and 
cofactor metabolic engineering. Microb Cell Fact. 13, 21.  
Curran, K. A., Leavitt, J. M., Karim, A. S., Alper, H. S., 2012. Metabolic engineering of 
muconic acid production in Saccharomyces cerevisiae. Metab Eng. 15, 55-66.  
Du, J., Yuan, Y., Si, T., Lian, J., Zhao, H., 2012. Customized optimization of metabolic 
pathways by combinatorial transcriptional engineering. Nucleic Acids Res. 40, e142.  
  
111 
Evans, J., Commercial Amino Acids. Vol. BIO007K. BCC Research Wellesley MA USA, 
2014, pp. 214.  
Facchini, P. J., 2001. Alkaloid biosynthesis in plants: biochemistry, cell biology, molecular 
regulation, and metabolic engineering applications. Annu Rev Plant Physiol Plant 
Mol Biol. 52, 29-66.  
Feng, X., Zhao, H., 2013a. Investigating glucose and xylose metabolism in Saccharomyces 
cerevisiae and Scheffersomyces stipitis via 13C metabolic flux analysis. AIChE J. 59, 
3195-3202.  
Feng, X., Zhao, H., 2013b. Investigating xylose metabolism in recombinant Saccharomyces 
cerevisiae via 13C metabolic flux analysis. Microb Cell Fact. 12, 114.  
Feng, X., Zhuang, W. Q., Colletti, P., Tang, Y. J., 2012. Metabolic pathway determination 
and flux analysis in nonmodel microorganisms through 13C-isotope labeling. Methods 
Mol Biol. 881, 309-30.  
Fry, B., Zhu, T., Domach, M. M., Koepsel, R. R., Phalakornkule, C., Ataai, M. M., 2000. 
Characterization of growth and acid formation in a Bacillus subtilis pyruvate kinase 
mutant. Appl Environ Microbiol. 66, 4045-9.  
Galanie, S., Thodey, K., Trenchard, I. J., Filsinger Interrante, M., Smolke, C. D., 2015. 
Complete biosynthesis of opioids in yeast. Science. 349, 1095-100.  
Garcia-Albornoz, M., Thankaswamy-Kosalai, S., Nilsson, A., Varemo, L., Nookaew, I., 
Nielsen, J., 2014. BioMet Toolbox 2.0: genome-wide analysis of metabolism and 
omics data. Nucleic Acids Res. 42, W175-81.  
Hansen, E. H., Moller, B. L., Kock, G. R., Bunner, C. M., Kristensen, C., Jensen, O. R., 
Okkels, F. T., Olsen, C. E., Motawia, M. S., Hansen, J., 2009. De novo biosynthesis 
of vanillin in fission yeast (Schizosaccharomyces pombe) and baker's yeast 
(Saccharomyces cerevisiae). Appl Environ Microbiol. 75, 2765.  
Iraqui, I., Vissers, S., Cartiaux, M., Urrestarazu, A., 1998. Characterisation of 
Saccharomyces cerevisiae ARO8 and ARO9 genes encoding aromatic 
aminotransferases I and II reveals a new aminotransferase subfamily. Mol Genet 
Genomics. 257, 238-48.  
Karim, A. S., Curran, K. A., Alper, H. S., 2013. Characterization of plasmid burden and copy 
number in Saccharomyces cerevisiae for optimization of metabolic engineering 
applications. FEMS Yeast Res. 13, 107-116.  
  
112 
Kawai, S., Hashimoto, W., Murata, K., 2010. Transformation of Saccharomyces cerevisiae 
and other fungi: methods and possible underlying mechanism. Bioeng Bugs. 1, 395-
403.  
Kim, B., Du, J., Eriksen, D. T., Zhao, H., 2013. Combinatorial design of a highly efficient 
xylose-utilizing pathway in Saccharomyces cerevisiae for the production of cellulosic 
biofuels. Appl Environ Microbiol. 79, 931-41.  
Kim, B., Park, H., Na, D., Lee, S. Y., 2014. Metabolic engineering of Escherichia coli for the 
production of phenol from glucose. Biotechnol J. 9, 621-9.  
Kim, S. R., Xu, H., Lesmana, A., Kuzmanovic, U., Au, M., Florencia, C., Oh, E. J., Zhang, 
G., Kim, K. H., Jin, Y. S., 2015. Deletion of PHO13, encoding haloacid dehalogenase 
type IIA phosphatase, results in upregulation of the pentose phosphate pathway in 
Saccharomyces cerevisiae. Appl Environ Microbiol. 81, 1601-9.  
Koopman, F., Beekwilder, J., Crimi, B., Van Houwelingen, A., Hall Robert, D., Bosch, D., 
Van Maris Antonius, J., Pronk Jack, T., Daran, J.-M., 2012. De novo production of 
the flavonoid naringenin in engineered Saccharomyces cerevisiae. Microb Cell Fact. 
11, 155.  
Kummel, A., Ewald, J. C., Fendt, S. M., Jol, S. J., Picotti, P., Aebersold, R., Sauer, U., 
Zamboni, N., Heinemann, M., 2010. Differential glucose repression in common yeast 
strains in response to HXK2 deletion. FEMS Yeast Res. 10, 322-32.  
Lee, K., Hahn, J. S., 2013. Interplay of Aro80 and GATA activators in regulation of genes 
for catabolism of aromatic amino acids in Saccharomyces cerevisiae. Mol Microbiol. 
88, 1120-34.  
Leonard, E., Lim, K. H., Saw, P. N., Koffas, M. A., 2007. Engineering central metabolic 
pathways for high-level flavonoid production in Escherichia coli. Appl Environ 
Microbiol. 73, 3877-86.  
Liu, D. F., Ai, G. M., Zheng, Q. X., Liu, C., Jiang, C. Y., Liu, L. X., Zhang, B., Liu, Y. M., 
Yang, C., Liu, S. J., 2014. Metabolic flux responses to genetic modification for 
shikimic acid production by Bacillus subtilis strains. Microb Cell Fact. 13, 40.  
Maeda, H., Dudareva, N., 2012. The shikimate pathway and aromatic amino acid 
biosynthesis in plants. Annu Rev Plant Biol. 63, 73-105.  
McQuade, B., Blair, M., 2015. Influenza treatment with oseltamivir outside of labeled 
recommendations. Am J Health Syst Pharm. 72, 112-6.  
  
113 
Minami, H., Kim, J. S., Ikezawa, N., Takemura, T., Katayama, T., Kumagai, H., Sato, F., 
2008. Microbial production of plant benzylisoquinoline alkaloids. Proc Natl Acad Sci 
U S A. 105, 7393-8.  
Moriya, H., Shimizu-Yoshida, Y., Kitano, H., 2006. In vivo robustness analysis of cell 
division cycle genes in Saccharomyces cerevisiae. PLoS Genet. 2, e111.  
Nilsson, U., Meshalkina, L., Lindqvist, Y., Schneider, G., 1997. Examination of substrate 
binding in thiamin diphosphate-dependent transketolase by protein crystallography 
and site-directed mutagenesis. J Biol Chem. 272, 1864-9.  
Niu, W., Draths, K. M., Frost, J. W., 2002. Benzene-free synthesis of adipic acid. Biotechnol 
Prog. 18, 201-11.  
Patnaik, R., Liao, J. C., 1994. Engineering of Escherichia coli central metabolism for 
aromatic metabolite production with near theoretical yield. Appl Environ Microbiol. 
60, 3903-8.  
Rodriguez, A., Kildegaard, K. R., Li, M., Borodina, I., Nielsen, J., 2015. Establishment of a 
yeast platform strain for production of p-coumaric acid through metabolic 
engineering of aromatic amino acid biosynthesis. Metab Eng. 31, 181-188.  
Schaaff-Gerstenschlager, I., Mannhaupt, G., Vetter, I., Zimmermann, F. K., Feldmann, H., 
1993. TKL2, a second transketolase gene of Saccharomyces cerevisiae. Cloning, 
sequence and deletion analysis of the gene. Eur J Biochem. 217, 487-92.  
Shao, Z., Luo, Y., Zhao, H., 2012. DNA assembler method for construction of zeaxanthin-
producing strains of Saccharomyces cerevisiae. Methods Mol Biol. 898, 251-62.  
Shao, Z., Zhao, H., 2013. Construction and engineering of large biochemical pathways via 
DNA assembler. Methods Mol Biol. 1073, 85-106.  
Shin, S. Y., Jung, S. M., Kim, M. D., Han, N. S., Seo, J. H., 2012. Production of resveratrol 
from tyrosine in metabolically engineered Saccharomyces cerevisiae. Enzyme 
Microb Technol. 51, 211-6.  
Sprague, G. F., Jr., 1977. Isolation and characterization of a Saccharomyces cerevisiae 
mutant deficient in pyruvate kinase activity. J Bacteriol. 130, 232-41.  
Strucko, T., Magdenoska, O., Mortensen, U. H., 2015. Benchmarking two commonly used 
Saccharomyces cerevisiae strains for heterologous vanillin-β-glucoside production. 
Metab Engin Commun. 2, 99-108.  
  
114 
Suastegui, M., Matthiesen, J. E., Carraher, J. M., Hernandez, N., Rodriguez Quiroz, N., 
Okerlund, A., Cochran, E. W., Shao, Z., Tessonnier, J. P., 2016. Combining 
Metabolic Engineering and Electrocatalysis: Application to the Production of 
Polyamides from Sugar. Angew Chem Int Ed Engl. 55, 2368-73.  
Thodey, K., Galanie, S., Smolke, C. D., 2014. A microbial biomanufacturing platform for 
natural and semisynthetic opioids. Nat Chem Biol. 10, 837-44.  
Wahl, S. A., Dauner, M., Wiechert, W., 2004. New tools for mass isotopomer data evaluation 
in (13)C flux analysis: mass isotope correction, data consistency checking, and 
precursor relationships. Biotechnol Bioeng. 85, 259-68.  
Zhang, H., Pereira, B., Li, Z., Stephanopoulos, G., 2015. Engineering Escherichia coli 
coculture systems for the production of biochemical products. Proc Natl Acad Sci U S 
A. 112, 8266-71.  
Zhu, T., Pan, Z., Domagalski, N., Koepsel, R., Ataai, M. M., Domach, M. M., 2005. 
Engineering of Bacillus subtilis for enhanced total synthesis of folic acid. Appl 
Environ Microbiol. 71, 7122-9. 
 
  
  
115 
 
6. Supplementary Information 
 
 6.1 Supplementary Tables 
 
Supplementary Table 1: Isotopic labeling patterns of SA2 strains. 
  YSG50 INVSc1 BY4741 BY4743 
Amino 
acid 
Labeling 
pattern M-57 M-159 M-57 M-159 M-57 M-159 M-57 M-159 
          
Ala m0 0.51 0.49 0.49 0.47 0.48 0.46 0.51 0.49 
 m1 0.32 0.34 0.34 0.35 0.35 0.35 0.32 0.34 
 m2 0.03 0.17 0.03 0.18 0.02 0.19 0.03 0.17 
 m3 0.14  0.14  0.15  0.14  
          
Gly* m0 0.85 0.84 0.79 0.83 0.79 0.82 0.85 0.87 
 m1 0.03 0.16 0.06 0.17 0.05 0.18 0.02 0.13 
 m2 0.12  0.15  0.16  0.12  
          
Val m0 0.32 0.31 0.27 0.28 0.26 0.26 0.32 0.31 
 m1 0.29 0.28 0.31 0.30 0.29 0.27 0.29 0.28 
 m2 0.19 0.25 0.21 0.25 0.21 0.31 0.19 0.25 
 m3 0.12 0.13 0.12 0.13 0.15 0.13 0.12 0.13 
 m4 0.05 0.03 0.07 0.03 0.06 0.04 0.05 0.03 
 m5 0.03  0.02  0.03  0.03  
          
Leu m0 0.94 0.95 0.96 0.94 0.94 0.95 0.93 0.95 
 m1 0.06 0.04 0.04 0.05 0.06 0.04 0.06 0.03 
 m2 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 
 m3:6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
          
Ile m0 0.45 0.27 0.43 0.24 0.41 0.24 0.46 0.29 
 m1 0.21 0.26 0.18 0.26 0.22 0.27 0.20 0.26 
 m2 0.17 0.26 0.19 0.28 0.18 0.26 0.19 0.25 
 m3 0.11 0.15 0.11 0.16 0.09 0.17 0.08 0.14 
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 m4 0.04 0.05 0.05 0.05 0.07 0.06 0.05 0.05 
 m5 0.02 0.01 0.03 0.01 0.03 0.01 0.02 0.01 
 m6 0.00  0.00  0.01  0.00  
          
Pro m0 0.31 0.32 0.24 0.27 0.24 0.29 0.31 0.32 
 m1 0.24 0.29 0.29 0.31 0.27 0.29 0.24 0.29 
 m2 0.25 0.24 0.28 0.27 0.28 0.27 0.25 0.24 
 m3 0.15 0.12 0.13 0.12 0.15 0.12 0.15 0.12 
 m4 0.04 0.03 0.06 0.03 0.05 0.03 0.04 0.03 
 m5 0.01  0.01  0.01  0.01  
          
Ser m0 0.49 0.55 0.55 0.54 0.45 0.47 0.52 0.51 
 m1 0.32 0.32 0.29 0.34 0.37 0.39 0.31 0.34 
 m2 0.06 0.13 0.06 0.12 0.01 0.14 0.06 0.14 
 m3 0.13  0.11  0.17  0.12  
          
Thr m0 0.42 0.39 0.41 0.41 0.41 0.43 0.48 0.47 
 m1 0.32 0.39 0.37 0.37 0.36 0.35 0.31 0.33 
 m2 0.12 0.23 0.07 0.19 0.08 0.18 0.06 0.15 
 m3 0.11 0.00 0.11 0.03 0.11 0.04 0.11 0.05 
 m4 0.03  0.05  0.03  0.04  
          
Phe m0 0.81 0.80 0.64 0.61 0.65 0.63 0.80 0.79 
 m1 0.09 0.11 0.11 0.14 0.12 0.14 0.11 0.11 
 m2 0.04 0.04 0.06 0.10 0.08 0.10 0.03 0.04 
 m3 0.02 0.02 0.07 0.06 0.06 0.05 0.02 0.03 
 m4 0.02 0.01 0.04 0.03 0.04 0.03 0.01 0.01 
 m5 0.01 0.01 0.04 0.03 0.03 0.03 0.01 0.01 
 m6 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 
 m7 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 
 m8:9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
          
Asp m0 0.43 0.45 0.40 0.41 0.40 0.43 0.42 0.43 
 m1 0.30 0.34 0.33 0.33 0.37 0.36 0.36 0.33 
 m2 0.12 0.17 0.12 0.21 0.06 0.16 0.09 0.19 
 m3 0.13 0.04 0.12 0.05 0.12 0.06 0.10 0.05 
 m4 0.02  0.03  0.04  0.03  
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Glu m0 0.27 0.29 0.23 0.23 0.20 0.23 0.31 0.32 
 m1 0.29 0.26 0.28 0.33 0.30 0.31 0.22 0.26 
 m2 0.20 0.28 0.27 0.29 0.28 0.29 0.23 0.28 
 m3 0.18 0.15 0.15 0.12 0.16 0.12 0.20 0.11 
 m4 0.06 0.03 0.05 0.03 0.05 0.04 0.05 0.03 
 m5 0.00  0.01  0.01  0.00  
          
          
Lys m0 0.24 0.25 0.17 0.17 0.17 0.17 0.24 0.25 
 m1 0.18 0.23 0.20 0.21 0.21 0.22 0.18 0.23 
 m2 0.27 0.23 0.24 0.30 0.26 0.31 0.27 0.23 
 m3 0.19 0.20 0.23 0.21 0.22 0.20 0.19 0.20 
 m4 0.09 0.07 0.12 0.08 0.08 0.08 0.09 0.07 
 m5 0.04 0.02 0.03 0.02 0.05 0.01 0.04 0.02 
 m6 0.00 - 0.01 - 0.01 - 0.00 - 
          
Tyr m0 0.66 0.57 0.52 0.52 0.48 0.44 0.66 0.57 
 m1 0.10 0.19 0.17 0.17 0.16 0.18 0.10 0.19 
 m2 0.09 0.11 0.09 0.13 0.11 0.15 0.09 0.11 
 m3 0.05 0.04 0.07 0.07 0.10 0.09 0.05 0.04 
 m4 0.05 0.04 0.05 0.04 0.06 0.06 0.05 0.04 
 m5 0.03 0.02 0.05 0.04 0.04 0.03 0.03 0.02 
 m6 0.02 0.01 0.02 0.02 0.03 0.03 0.02 0.01 
 m7 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 m8 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 
 m9 0.00 - 0.00 - 0.00 - 0.00 - 
          
Met m0 0.27 0.33 0.26 0.28 0.82 0.88 0.27 0.33 
 m1 0.34 0.34 0.30 0.36 0.15 0.09 0.34 0.34 
 m2 0.19 0.22 0.23 0.23 0.02 0.00 0.19 0.22 
 m3 0.11 0.08 0.12 0.11 0.00 0.02 0.11 0.08 
 m4 0.09 0.02 0.07 0.02 0.01 0.00 0.09 0.02 
 m5 0.01 - 0.02 - 0.00 - 0.01 - 
          
SA m0 - - 0.2193 - 0.2255 - 0.2408 - 
 m1 - - 0.2932 - 0.3219 - 0.3317 - 
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 m2 - - 0.1675 - 0.124 - 0.1341 - 
 m3 - - 0.153 - 0.1508 - 0.1417 - 
 m4 - - 0.0824 - 0.1074 - 0.078 - 
 m5 - - 0.0846 - 0.0705 - 0.0738 - 
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Supplementary Table 2: Reaction model for MFA. 
 
Reaction numeration Atom transition Stoichiometry chemistry 
Glycolysis pathway   
v1 abcdef <-> abcdef GLC <-> G6P 
v2 abcdef <-> abcdef G6P <-> F6P 
v3 abcdef <-> cba + def F6P <-> DHAP + G3P 
v4 abc <-> abc DHAP <-> G3P 
v5 abc <-> abc G3P <-> PEP 
v6 abc <-> abc PEP <-> PYRCYT 
Pentose phosphate pathway 
v7 abcdef <-> a + bcdef G6P <-> CO2 + P5P 
v8 abcde + fghij <-> fgabcde + hij P5P + P5P <-> S7P + G3P 
v9 abcdefg + hij <-> abchij + defg S7P + G3P <-> F6P + E4P 
v10 abcde + fghi <-> abfghi + cde P5P + E4P <-> F6P + G3P 
Shikimate synthesis 
v11 abc + defg <-> abcdefg PEP + E4P <-> SA 
v12 abc + defghij <-> abcefghij + d PEP + SA <-> PHE + CO2 
Ethanol, acetate, and glycerol formation 
v13 abc <-> bc + a PYRCYT <-> ACA + CO2 
v14 ab <-> ab ACA <-> ETH 
v15 ab <-> ab ACA <-> ACE 
v16 abc <-> abc G3P <-> GLYC 
Formation of AcCoA in the cytosol 
v17 ab <-> ab ACE <-> ACCOACYT 
Anaplerotic reaction (cytosolic) 
v18  abc + d <-> abcd PYRCYT + CO2 <-> OAACYT 
TCA-cycle 
v19 abc <-> bc + a PYRMIT <-> ACCOAMIT + CO2 
v20 abcd + ef <-> dcbafe OAAMIT + ACCOAMIT <-> ICIT 
v21 abcdef <-> abcef + d ICIT <-> AKG + CO2 
v22 abcde <-> bcde + a AKG <-> FUM + CO2 
v23 abcd + efgh <-> abcd + hgfe FUM + FUM <-> OAAMIT + OAAMIT 
Transports 
v24 abcd <-> abcd OAAMIT <-> OAACY 
v25 ab <-> ab ACCOACYT <-> ACCOAMIT 
v26 abc <-> abc PYRCYT <-> PYRMIT 
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Threonine / Serine / Glycine metabolism 
v27 abc <-> abc G3P <-> SER 
v28 abc <-> ab + c SER <-> GLY + C1 
v29 abcd <-> abcd OAACYT <-> THR 
v30 abcd <-> ab + cd THR <-> GLY + ACA 
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6.2 Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1: Plasmids constructed in this work. 
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Supplementary Figure. 2: Fitting between measured and simulated summed fractional 
labeling (SFL) of strains in group SA2 (Table 1). 
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CHAPTER 5 
 
MULTILEVEL ENGINEERING OF THE UPSTREAM AROMATIC AMINO ACID 
BIOSYNTHESIS MODULE IN S. CEREVISIAE FOR HIGH PRODUCTION OF 
POLYMER AND DRUG AROMATIC PRECURSORS 
 
Authors: Miguel Suástegui1,3, Chiam Yu Ng2,3, Anupam Chowdhury2,3, Wan Sun3,4, Emma 
House3, Costas D. Maranas2,3, Zengyi Shao*,1,3,4,5 
 
1Department of Chemical and Biological Engineering, Iowa State University, 618 Bissell 
Road, Ames, Iowa 50011, United States 
2Department of Chemical Engineering, Pennsylvania State University, University Park, 
Pennsylvania 16802, United States 
 
Abstract 
A multilevel approach was implemented in Saccharomyces cerevisiae to optimize the 
precursor module of the aromatic amino acid biosynthesis pathway, which is a rich resource 
for synthesizing a great variety of chemicals ranging from polymer precursor, to nutraceuticals 
and pain-relief drugs. To facilitate the discovery of novel targets to enhance the pathway flux, 
we incorporated the computational tool YEASTRACT for predicting novel transcriptional 
repressors and OptForce strain-design for identifying non-intuitive pathway interventions. The 
multilevel approach consisted of (i) relieving the pathway from strong transcriptional 
repression, (ii) removing competing pathways to ensure high carbon capture, and (iii) rewiring 
precursor pathways to increase the carbon funneling to the desired target. The combination of 
these interventions led to the establishment of a S. cerevisiae strain with shikimic acid (SA) 
titer reaching as high as 2.48 g L-1, 7-fold higher than the base strain. Further expansion of the 
platform led to the production of muconic acid (MA) and its intermediate protocatechuic acid 
together close to 1.6 g L-1. Both SA and MA production platforms demonstrated increases in 
titer and yield around 300% from the previously reported, highest-producing S. cerevisiae 
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strains. Further examination elucidated the diverged impacts of disrupting the oxidative branch 
(ZWF1) of the pentose phosphate pathway on the titers of desired products belonging to 
different portions of the pathway. The investigation of other non-intuitive interventions like 
the deletion of the Pho13p enzyme also revealed the important role of the transaldolase in 
determining the fate of the carbon flux in the pathways of study. This integrative approach 
identified novel determinants at both transcriptional and metabolic levels that constrain the 
flux entering the aromatic amino acid pathway and provided a readily usable platform for 
engineering the downstream modules in the future towards production of important plant-
sourced aromatic secondary metabolites. 
 
1. Introduction 
Engineering microbial factories for the production of valuable chemicals often requires the 
optimization of long metabolic pathways. Splitting the pathways into modules can allow for 
faster optimization, leading to higher overall yields and titers. Grouping genetic elements 
permits a more precise analysis of bottlenecks, rate-limiting steps, and metabolic imbalances 
(Biggs et al., 2014). Moreover, studying metabolic pathways as independent modules 
facilitates the analysis of transcriptional regulators that may act on the genes within distinct 
modules, hence enabling a multilevel approach encompassing engineering at both 
transcriptional and metabolic levels. 
Modular approaches for engineering microbes have been implemented in a variety of cases. 
In Escherichia coli, for example, implementing a modular design strategy led to significant 
increases in the production of total fatty acids (Xu et al., 2013).  In Saccharomyces cerevisiae, 
the most recent example was observed for the de novo production of benzylisoquinoline 
alkaloids (BIAs), which required the coordinated overexpression of more than 20 endogenous 
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and heterologous genes (Galanie et al., 2015). Partitioning the pathway into several modules 
allowed efficient optimization of precursor and cofactor availability, and reduction of pathway 
bottlenecks. In fact, the aromatic amino acid pathway from which BIAs are originated is a 
source of a great variety of chemicals that range from polymer precursors to nutraceuticals and 
pain-relief drugs (Suástegui and Shao, 2016). Previous metabolic engineering efforts in S. 
cerevisiae have enabled the production of chemicals derived from this pathway including, but 
not limited to, shikimic acid (SA) (Suástegui et al., 2016a), muconic acid (MA) (Curran et al., 
2012; Suástegui et al., 2016b), vanillin (Brochado et al., 2010), L-tyrosine (L-tyr) (Gold et al., 
2015), coumaric acid (Rodriguez et al., 2015), and secondary metabolites from the flavonoid 
and stilbenoid families, as well as BIAs (Galanie et al., 2015; Jiang et al., 2005; Koopman et 
al., 2012; Li et al., 2015; Trantas et al., 2009; Yan et al., 2005). 
One major metabolic engineering strategy employed to unlock the production of derivatives 
spun off the aromatic amino acid biosynthetic pathway is the overexpression of the feedback 
insensitive enzymes 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase, 
Aro3/4p, and chorismate mutase, Aro7p, catalyzing the first committed step in the pathway, 
and the branching point towards the production of L-tyr and phenylalanine (L-phe), 
respectively (Brown and Dawes, 1990; Luttik et al., 2008). As shown in Figure 1, other 
strategies include rewiring the pentose phosphate pathway (PPP) for increasing the pool of 
erythrose-4-phosphate (E4P), and the overexpression of mutant versions of the pentafunctional 
protein Aro1 to halt the activity at specific subunits for accumulating the desired intermediates 
(Suástegui and Shao, 2016). Despite the implementation of these strategies, the carbon yields 
in S. cerevisiae still remain low, suggesting the existence of unknown determinants 
constraining the carbon flux entering the pathway. Therefore, a more comprehensive 
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investigation needs to be prosecuted to determine novel transcriptional and metabolic targets, 
which will benefit the design of microbial cell factories for producing many high-value 
compounds from such a resourceful pathway.  
Herein, we have focused the attention on engineering the precursor module of the aromatic 
amino acid pathway using SA as a reporter product. The target module is composed of the 
genes in the glycolytic pathway (up to the production of phosphoenolpyruvate, PEP), the PPP 
(leading to the production of erythrose-4-phosphate, E4P), and the genes in the SA pathway 
including ARO2, ARO3, ARO4, and the pentafunctional ARO1 (Figure 1). Besides 
implementing a comprehensive engineering strategy at the metabolic level (i.e. deletion or 
overexpression of structural genes), we identified that the protein Ric1, involved in regulating 
the efficient localization of trans-Golgi network proteins (Bensen et al., 2001), can act as a 
transcriptional repressor of multiple genes in the aromatic amino acid pathway. Furthermore, 
the incorporation of in silico modeling and pathway analysis led to the discovery of a novel 
genetic target. Overexpression of ribose-5-phosphate ketol-isomerase, RKI1, in addition to 
other tested interventions, facilitated PPP flux redirection into the aromatic amino acid 
pathway through E4P. The combination of these novel, multilevel interventions led to the high 
production of SA, MA, and its intermediate. Such a multilevel intervention strategy thoroughly 
removes the constraints in the upstream precursor module of the aromatic amino acid pathway, 
maximize the carbon flux flowing to the downstream, and therefore pave the way for 
synthesizing high-value molecules from the downstream branches. 
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Figure 1: Modular visualization of the aromatic amino acid biosynthetic pathway. The 
multilevel strategy consisted of removing pathway repressors (level 1), removing pathway 
competition (level 2), and increasing precursor funneling (level 3). Color codes: green, 
gene overexpressions; red, gene knockouts. Metabolite abbreviations: PEP, 
phosphoenolpyruvate; E4P, erythrose-4-phosphate; DAHP, 3-deoxy-D-arabino-
heptulosonate-7-phosphate; DHS, 3-dehydroshikimic acid; SA, shikimic acid; EPSP, 5-
enolpyruvyl-3-shikimate phosphate; CA, chorismic acid. Gene abbreviations: TKL1, 
transketolase; RKI1, ribose-5-phosphate ketol-isomerase; ZWF1, glucose-6-phosphate 
dehydrogenase; PFK1, phosphofructokinase; ARO1, pentafunctional aromatic enzyme; 
aro1D920A, mutant version of ARO1 with disrupted shikimate kinase activity; ARO2, 
chorismate synthase, PDC, pyruvate decarboxylase; PGK1, 3-phophoglycerate kinase; 
TDHI1, glyceraldehyde-3-phosphate dehydrogenase.  
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2. Materials and Methods 
 
2.1. Strains and media  
The strain S. cerevisiae BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) was used as the 
microbial platform for the production of SA and MA, as well as for the assembly of plasmids 
using the DNA Assembler technique (Shao et al., 2012; Shao and Zhao, 2013; Shao and Zhao, 
2014). The yeast cultures were maintained in YPD medium (1% yeast extract, 2% peptone, 
and 2% dextrose). Antibiotic G418 was supplemented at a concentration of 200 µg Ml-1 for the 
growth of the deletion strains carrying the KanMX marker from the MATa Yeast Knockout 
Collection (GE Dharmacon, USA). Synthetic complete (SC) media lacking single or multiple 
nutrients (0.5% ammonium sulfate, 0.16% yeast nitrogen without amino acid and ammonium 
sulfate, complete amino acid supplement mix, and 2% dextrose) were used to culture the cells 
after plasmid transformation. The addition of the three aromatic amino acids L-tyr, L-trp 
(tryptophan), and L-phe was required at a level of 50 mg L-1 each, for strains carrying the ARO1 
deletion. For SA or MA production, minimal medium supplemented with 2% dextrose was 
used, as previously reported (Feng and Zhao, 2013a; Feng and Zhao, 2013b; Suástegui et al., 
2016a). The E. coli strain BW25141 was used for plasmid propagation. The bacterial 
transformation was done by the TSS method (Chung et al., 1989) and cultured in Luria-Bertani 
(LB) broth supplemented with 100 µg Ml-1 ampicillin.   
2.2. Plasmid construction 
The plasmids constructed in this work were assembled via DNA assembler (> 4 fragments) 
(Shao et al., 2012; Shao and Zhao, 2013; Shao and Zhao, 2014) or Gibson assembly (2-3 
fragments) (Gibson et al., 2009). The Pcrct plasmids containing the CRISPR/Cas9 system for 
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gene editing were constructed via Golden Gate assembly (Engler et al., 2009; Engler et al., 
2008) following the previously reported design (Bao et al., 2014). A list of the plasmids used 
in this work is displayed in Table 1. Transformation of plasmids into yeast was performed 
following the “quick and dirty” protocol (Amberg et al., 2006). All yeast genetic fragments 
(promoters, genes, and terminators) were amplified by PCR using the genomic DNA of strain 
BY4741. For gene knockouts using plasmid Pcrct, gBlocks® containing the donor DNA and 
the guide RNA were synthesized by IDT DNA (Coralville, IA).  
 
Table 1: List of plasmids used in this study. 
 
Production 
plasmids Genetic elements Reference 
pRS413   
pRS413-lowAA pRS413-ARO1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL1 This study 
pRS413-midAA pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL1 
(Suastegui 
et al., 
2016a) 
pRS413-highAA pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL1 /  PGK1-RKI1 
This study 
 pRS413-midAA_1 pRS413-GPD1-aro1D1409A,D920A / TP1-aro4K229L /ADH1-TKL1 
pRS413-
highAA_1 
pRS413-GPD1-aro1D1409A,D920A / TP1-aro4K229L /ADH1-TKL1 
/ PGK1-RKI1 
pRS425-MA pRS425- PYK1-AROZ / GPD1 – HQD2 / TEF1 – AROY 
(Suastegui 
et al., 
2016b) 
 
CRISPR plasmids 
pCRCT (Bao et al., 
2014) 
pCRCT_aro1 This study 
pCRCT_pho13 This study 
pCRCT_zwf1 This study 
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2.3. Gene deletion using CRISPR/Cas9 
The engineered strains with single or multiple gene deletions are listed in Table 2. Deletion of 
the genes ARO1, PHO13, and ZWF1 was performed using the plasmid Pcrct containing the 
CRISPR/Cas9 system (Bao et al., 2014). The CRISPR RNA (crRNA) cassettes for gene 
deletion were composed of 100 bp of the donor fragment lacking 8-bp to induce a frame shift 
and a 20-bp guide sequence (Supplementary Table 1). The guide sequences were designed 
based on the CHOPCHOP web tool (Montague et al., 2014). After plasmid transformation (1 
µg), the yeast cells were grown for two days in liquid SC-Uracil medium. After this period, 
200 µL of culture was transferred to fresh liquid medium and incubated for two more days. 
Finally, 100 µL of 104–fold diluted cells were plated on selective medium. Individual colonies 
were picked and inoculated in YPD plus 5-fluoroorotic acid and grown for 2 days to ensure 
plasmid loss. Genomic DNA was extracted by two cycles of freeze/boil and the supernatant 
was used as a template for diagnostic PCR. The PCR product was recovered from agarose gel 
and sent for Sanger sequencing at the DNA facility at Iowa State University. 
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Table 2. Knockout S. cerevisiae strains. 
Strain Description Genotype Source 
 BY4741   
AA_001 BY4741 ric1Δ ric1Δ::KanMX GE Dharmacon 
AA_002 BY4741 aro1Δ aro1Δ::KanMX GE Dharmacon 
AA_003 BY4741 ric1Δ aro1Δ ric1Δ::KanMX , aro1Δ This study 
AA_004 BY4741 zwf1Δ zwf1Δ::KanMX GE Dharmacon 
AA_005 BY4741 pho13Δ aro1Δ ric1Δ ric1Δ::KanMX, aro1Δ, pho13Δ This study 
AA_006 BY4741 zwf1Δ aro1Δ ric1Δ ric1Δ::KanMX, aro1Δ, zwf1Δ This study 
 
2.4. Analysis of transcriptional repressors 
The genes ARO1, ARO2, ARO3, and ARO4 were chosen for analysis of TFs using the 
YEASTRACT website (Teixeira et al., 2014). The search for TFs by target gene was performed 
in the Regulatory Associations tool by filtering the regulation type to only those acting as 
repressors (referred as ‘inhibitors’ on the website) with ‘evidence of DNA binding plus 
expression’. This resulted in a list of 66 TFs, from which only 21 were selected for further 
analysis based on evidence of knockout viability and availability in the MATa yeast library 
(Table 3).  
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Table 3: List of the transcription factors studied in this work. Description collected from 
the yeast genome online database (http://www.yeastgenome.org/) 
 
Gene Systematic 
name 
Description 
STP1 YDR463W Transcriptional activator of amino acid permease genes 
YAP1 YML007W Basic leucine zipper transcription factor; required for oxidative stress tolerance 
AGP1 YCL025C Low-affinity amino acid permease with broad substrate range 
ZAP1 YJL056C Zinc-regulated transcription factor 
CBF1 YJR060W Centromere Binding Factor  
TGL3 YMR313C Triacylglycerol Lipase  
GAL4 YPL248C DNA-binding transcription factor required for activating GAL genes 
RPN4 YDL020C Transcription factor that stimulates expression of proteasome genes 
NRG1 YDR043C Transcriptional repressor; recruits the Cyc8p-Tup1p complex to promoters 
OAF1 YAL051W Oleate-Activated transcription factor 
AAD3 YCR107W Putative aryl-alcohol dehydrogenase 
MIG3 YER028C Transcriptional regulator with a major role in catabolite repression and ethanol 
YAP5 YIR018W Basic leucine zipper iron-sensing transcription factor; involved in diauxic shift 
CST6 YIL036W 
 
Basic leucine zipper transcription factor involved in stress-responsive regulatory 
network 
ESC2 YDR363W Establishment of silent chromatin 
YRM1 YOR172W Zinc finger transcription factor involved in multidrug resistance 
ARR1 YPR199C 
 
Transcriptional activator required for transcription of genes involved in resistance 
to arsenic compounds. 
IXR1 YKL032C Transcriptional repressor that regulates hypoxic genes during normoxia 
DAL80 YKR034W Negative regulator of genes in multiple nitrogen degradation pathways 
SPT10 YJL127C Histone H3 acetylase with a role in transcriptional regulation 
RIC1 YLR039C Protein involved in retrograde transport to the cis-Golgi network 
  
133 
Table 3 continued 
PHO2 YDL106C Homeobox transcription factor; regulatory targets include genes involved in 
phosphate metabolism 
PHO3 YBR092C Constitutively expressed acid phosphatase similar to Pho5p 
PHO4 YFR034C 
 
Basic helix-loop-helix transcription factor, activates transcription cooperatively 
with Pho2p in response to phosphate limitation 
PHO5 YBR093C 
 
Repressible acid phosphatases that also mediates extracellular nucleotide-derived 
phosphate hydrolysis 
PHO8 YDR481C Repressible vacuolar alkaline phosphatase; regulated by levels of Pi 
PHO13 YDL236W Conserved phosphatase acting as a metabolite repair enzyme 
PHO80 YOL001W Regulates the response to phosphate limitation and stress-dependent calcium 
signaling  
PHO84 YML123C 
 
High-affinity Pi transporter; also low-affinity manganese transporter 
PHO88 YBR106W Probable membrane protein; involved in phosphate transport 
PHO90 YJL198W Low-affinity phosphate transporter 
PHO92 YDR374C Posttranscriptional regulator of phosphate metabolism 
 
2.5. Computational modeling 
The optimization-based OptForce algorithm (Ranganathan et al., 2010) was implemented 
to identify target reaction-level interventions leading to the overproduction of SA and MA 
individually. In particular, the objective of the computational study was to identify key motifs 
in the intervention strategies that were conserved, and those that differed due to cofactor or 
energy equivalent requirements, when attempting to overproduce two metabolites in the same 
branch of metabolism (i.e. aromatic amino acid pathway). The genome-scale metabolic model 
iAZ900  (Zomorrodi and Maranas, 2010) was used to simulate the metabolic flux profiles in 
S. cerevisiae for both target molecules. For the case of SA production, the base model was 
modified by adding the SA exchange and transport reactions. Likewise, for simulation of MA 
production, the MA production pathway was included in the model by adding DHS 
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dehydratase (SKHL), PCA decarboxylase (PCC) and catechol 1,2-dioxygenase (CATO) 
reactions, along with the corresponding exchange and transport reactions (Supplementary 
Table 2). All simulations were performed in the aerobic minimal media with glucose as the 
sole carbon substrate mimicking the experimental fermentation conditions. Details of 
simulation conditions and regulation are described in the Supplementary Information. The 
CPLEX optimization software was used to solve the mixed integer optimization programming 
problems to optimality, and was accessed through the General Algebraic Modeling System 
optimization package. Note that the reaction-level intervention strategy suggested by OptForce 
was converted to gene-level suggestion using the gene-protein-reaction relationship 
information mined from iAZ900 model, as well as from the most recent curation of S. 
cerevisiae metabolism reported in literature (Chowdhury et al., 2015). 
 
2.6. Fermentation and strain characterization 
Single colonies were picked from transformation plates and inoculated into 3 mL of SC-
Histidine or SC-Histidine-Leucine for seed culturing of the SA and MA production strains, 
respectively. After overnight growth, 30 µL of the saturated cultured was transferred into 3 mL 
of minimal medium lacking the corresponding amino acids. 1 mL of samples were collected 
after 72 h and centrifuged at 5,000 rpm for 5 min; the supernatant was stored at -20 °C for 
chromatographic analysis.  
SA and DHS were analyzed by High Performance Liquid Chromatography (HPLC) 
(Waters, Milford, MA) with an Aminex HPX-87H column (300×7.8 mm) (Bio-Rad, Hercules, 
CA) as previously reported (Gao et al., 2016). An ACQUITY Ultra Performance Liquid 
Chromatography (UPLC) with a BEH-C18 column (Waters) as the stationary phase was used 
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to analyze MA and PCA. The mobile phase program was implemented as described previously 
(Suástegui et al., 2016b). Standard curves of PCA (MP Biomedicals, Santa Clara, CA), SA, 
DHS, and MA (Sigma-Aldrich, St. Louis) with authentic compounds were generated for 
metabolite quantification. 
 
3. Results 
 
3.1. Identification of a novel transcriptional regulator 
SA was selected as the reporter molecule to track the entrance of carbon into the precursor 
module. Initially, to study the transcriptional regulation upon this module, we focused the 
attention to the ARO1 promoter as it controls the expression of the pentafunctional gene ARO1, 
the main core of the module. Table 1 shows the plasmid design based on the previously 
reported platform in S. cerevisiae for production of SA (Suástegui et al., 2016a). The promoter 
controlling the expression of the mutant gene aro1D920A was switched from the strong 
constitutive GPD1 promoter (glycerol-3-phosphate dehydrogenase, strain SA2) to the native 
ARO1 promoter, yielding plasmid pRS413-lowAA (strain SA1, Table 4 and Figure 2a). The 
production after 3 days of fermentation reached 176.27 ± 0.50 mg L-1 of SA (Figure 2b), a 
reduction of almost 46% compared to strain SA2. This indicated that, indeed, the two 
promoters had different strengths, presumably due to distinct responses to transcriptional 
regulatory elements. Hence we proceeded to investigate which specific transcription factors 
(TFs) could be involved in the regulation of the upstream precursor module of the aromatic 
amino acid biosynthesis, including ARO1, ARO2, ARO3, and ARO4 (Figure 1), as a direct 
approach to discerning the cause of the repressive regulation of carbon flux into the pathway.  
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A list of TFs with reported evidence of acting as repressors under different environmental 
conditions was retrieved from the Yeast Search for Transcriptional Regulators and Consensus 
Tracking (YEASTRACT) website (Teixeira et al., 2014). YEASTRACT is a repository of over 
200,000 regulatory associations between transcription factors and target genes in S. cerevisiae, 
developed based on more than 1300 references. The list contained 66 unique TFs from which 
21 were selected for further analysis according to the criteria described in the Materials and 
Methods section (Table 3). 
 
Table 4: Shikimic acid producing strains. 
 
Strain Genotype Plasmid Parent 
SA1 BY4741 pRS413-ARO1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL BY4741 
SA2 BY4741 pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL BY4741 
SA3 ric1Δ::KanMX pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL AA_001 
SA4 aro1Δ::KanMX pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL AA_002 
SA5 ric1Δ::KanMX , aro1Δ pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL AA_003 
SA6 zwf1Δ::KanMX pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL AA_004 
SA7 ric1Δ::KanMX, aro1Δ, pho13Δ pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL  AA_005 
SA8 ric1Δ::KanMX, aro1Δ 
pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL / 
PGK1-TAL  AA_003 
SA9 ric1Δ::KanMX , aro1Δ 
pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL 
PGK1-RKI1 AA_003 
SA10 ric1Δ::KanMX, aro1Δ, pho13Δ 
pRS413-GPD1-aro1D920A /  TP1-aro4K229L  / ADH1-TKL 
PGK1-RKI1 AA_005 
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3.2. Removal of competing pathways  
The precursor module in the aromatic amino acid pathway can be exploited for the 
production of molecules such as drug precursors (e.g. SA), polymer precursors (e.g. MA), and 
flavoring agents (e.g. vanillin). It is evident that to divert more flux towards the target 
molecules, deletion of the competing pathways (i.e. the biosynthesis of L-tyr, L-trp, and L-
phe) is required. In fact, OptForce also suggested the down-regulation of shikimate kinase 
(SHKK) or 3-phosphoshikimate 1-carboxyvinyltransferase (PSCVT) to restrict flux drainage 
towards biomass precursors and competitive products during SA overproduction (Figure 3). 
This intervention can be achieved by knocking out the gene ARO1, which catalyzes the five 
intermediate steps in the SA pathway, in combination with overexpression of ARO1 variant 
that maintains the catalytic functions of the first three conversions from DAHP to SA. The 
strain BY4741 Daro1 overexpressing aro1D920A, TKL1, and aro4K229L (Strain SA4), reached a 
titer of 606.0 ± 4.8 mg L-1 SA (Figure 4). By combining the deletions of RIC1 and ARO1 
(Strain SA5), the production increased to 800.3 ± 26.8 mg L-1 SA, which represented a 4.5-
fold increase compared to the initial strain SA1 (Figure 4).  
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Figure 2: Engineering the production of SA at the transcriptional level. A) Minimal 
genetic cassettes for production of SA. The transcription of the mutant aro1D920A was 
controlled by the native ARO1p or the constitutive GPD1p. B) Production of SA from strains 
with different promoters for expression of aro1D920A. C) Fermentation results from TF KO 
strains. “SA2” represents the control strain. The variation is represented by the standard 
deviation from three biological replicates. Statistical different groups are depicted by * and **.  
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3.3. Upstream manipulations for increased precursor availability 
 
3.3.1. Clarification of the role of oxidative PPP 
The next level of engineering was directed towards enabling higher availability of the precursor 
E4P.  Previously, we have identified that between the two precursors PEP and E4P, the latter 
is the rate limiting one constraining the entrance flux into aromatic amino acid biosynthesis 
pathway in S. cerevisiae (Suástegui et al., 2016a). We began with the deletion of the gene 
ZWF1 encoding glucose-6-phosphate dehydrogenase (G6PDH2), a strategy that has been 
previously implemented for producing MA and L-tyr. The combination of this deletion with 
the overexpression of transketolase (TKL1), has been demonstrated to force the carbon flux to 
enter through the non-oxidative branch of the pentose phosphate pathway thereby enhancing 
the pool of E4P (Curran et al., 2012; Gold et al., 2015).   
Deletion of ZWF1 (strain SA6) caused a reduction in SA production to 213.8 ± 6.75 mg L-1, 
but the total titer of 3-dehydroshikimic acid (DHS) and SA (676.81 mg L-1) increased ~2.1-
fold when compared to strain SA2 (Figure 4). The reaction catalyzed by G6PDH2 is the main 
source for generating reducing power in the form of NADPH, which in turn serves as the 
cofactor for the SA dehydrogenase subunit of Aro1 protein. A reduction in the NADPH pool 
directly translated into a lower catalytic conversion of the SA dehydrogenase, resulting in a  
higher accumulation of DHS (Zhang et al., 2015). Very interestingly, this result was consistent 
with our computational study. In contrary to the prediction of Genetic Design by Local Search 
(GDLS) (Gold et al., 2015), OptForce did not suggest the knockout of ZWF1 because SA 
production requires the cofactor NADPH. Knocking out ZWF1 in silico reduced the theoretical 
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maximum yield of SA by 4.8% (from 64.0 mmol g DW-1 h-1 to 60.9 mmol g DW-1 h-1) because 
metabolic flux has to be drained towards competitive metabolic pathways such acetaldehyde 
dehydrogenase to supply the required NADPH.   
 
 
 
 
Figure. 3: Metabolic interventions predicted using OptForce. A) Simplified map of the 
central carbon metabolism depicting the upstream pathway (glycolysis and PPP) leading 
towards the aromatic amino acid pathway. B) The minimum guaranteed yield achievable by 
downregulation (¯), deletion (D), or overexpression (­) of the selected novel genes. C) The 
intervention strategies predicted by OptForce for the overproduction of SA. The 
overexpression of the genes RKI1, TKL1, aro1D920A (DHQS), in combination with the deletion 
of ARO1 (SHKK), led to a minimum guaranteed SA yield equivalent to 89.41% of the 
maximum theoretical yield. Green, red, and blue arrows (and circles) represent overexpression, 
downregulation and knockout of genes, respectively 
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Deletion of ZWF1 (strain SA6) appeared to have a similar effect to that of deleting ARO1 
(strain SA4), with accumulation of DHS and a slight reduction (11%) of the overall titer (MA 
plus DHS). Despite the fact that the deletion of ZWF1 increases the supply of precursor E4P 
with a concomitant increase in flux into the SA pathway (observed by comparing strains SA2 
vs. SA6), the resulting loss of NADPH cofactor regeneration limits the production of SA and 
the subsequent metabolites downstream of SA. On a side note, replenishment of cytosolic 
NADPH by other reactions (e.g. aldehyde dehydrogenase ALD6) could potentially reactivate 
the conversion of DHS to SA, but could cause a loss of carbon towards the formation of 
undesirable byproduct acetate.  Based on this study, we clarified that the deletion of ZWF1 
should not be included as a strategy to improve the carbon flux into aromatic amino acid 
pathway if the target products are downstream of DHS unless NADPH can be efficiently 
replenished  
3.3.2. Clarification of the role of transaldolase 
Previous studies have shown that deletion of the haloacid dehalogenase encoded by PHO13 
can increase the transcription rates of the genes in the PPP (Kim et al., 2015). We hypothesized 
that such manipulation could increase the pool of E4P that enters the aromatic amino acid 
biosynthesis pathway. Accordingly, we deleted PHO13 as a new alternative to rewiring the 
PPP to enhance the production of pathway precursor. However, the strain SA7 (Dpho13) 
accumulated 731 ± 44 mg L-1 of SA, which represented an 11% reduction compared to strain 
SA5 (Dric1 Daro1) (Figure 4). 
Re-inspecting the mechanism of gene up-regulation in a Dpho13 strain (Kim et al., 2015) 
led to the hypothesis that the decrease in SA production could be due to the reverse of carbon 
flux into glycolysis rather than into the aromatic amino acid pathway. In a Dpho13 background, 
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transaldolase (TAL1) has a 3.5-fold increase in expression (Kim et al., 2015). However, the 
kinetic parameters (Km) of this transaldolase suggest that the favored direction of the reaction 
is towards consuming E4P (Tsolas and Horecker, 1973), which is the opposite of what is 
desired. In fact, the xylose utilization rate in S. cerevisiae strains can be enhanced by 
overexpressing TAL1 (Vilela Lde et al., 2015), indicating that the transaldolase is pivotal in 
connecting the flux from PPP to glycolysis. To prove this, we overexpressed TAL1 in strain 
SA5 (resulting in strain SA8), leading to a SA titer of 709.4 ± 45 mg L-1 (Figure 4); no 
statistical difference was observed when compared to strain SA7 (Student’s t-test, p > 0.05). 
These results supported our hypothesis that the drop in SA production in strain SA7 was a 
result of carbon being drained to glycolysis presumably due to the increased expression of 
TAL1 when PHO13 was deleted. 
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Figure. 4: Fermentation results from strains engineered to produce SA. Strain were grown 
in minimal media lacking histidine and supplemented with uracil and the three aromatic amino 
acids. Samples were collected at 72 h for HPLC analysis. The accumulation of DHS was only 
included for strain SA4 and SA6 since it was accumulated at a decent amount in these two 
strains. The variation is represented by the standard deviation from three biological replicates. 
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3.3.3. Discovery of novel metabolic interventions by OptForce 
The OptForce algorithm intends to scope out non-intuitive interventions generally 
overlooked in manual investigation. For SA hyper-accumulation, OptForce first suggested two 
interventions consistent with what has been successfully implemented for producing aromatic 
amino acid pathway derivatives in the previous studies. These include, up-regulation of 
transketolase (TKL1) and 3-dehydroquinate synthase (DHQS, by replacing native ARO1 with 
ARO1D920A). In addition, pyruvate kinase (PYK) down-regulation by 2.9-fold was identified as 
one of the single interventions that could improve SA production. Down-regulation of PYK 
allows for the accumulation of precursor PEP (Supplementary Table 2). Note that while this 
intervention appeared to be detrimental towards up-regulating the aromatic amino acid 
pathway as observed previously (Gold et al., 2015), we believe that it was because this 
intervention was combined with the deletion of ZWF1, causing an NADPH deficiency in the 
organism as explained in Section 2.3.1.  
OptForce has also suggested the rewiring of the PPP including up-regulation of 
transketolase (Supplementary Table 2), consistent with the manipulations introduced in the 
base strain (SA1) and previously reported (Curran et al., 2012; Suástegui et al., 2016b). In this 
work, however, the primary focus was on identifying interventions that, to the best of our 
knowledge, have not been previously linked to the production of aromatic amino acid pathway 
derivatives. In this regard, manipulations of four individual metabolic targets in the central 
carbon metabolism were identified, including: downregulation of the reactions 3-
phophoglycerate kinase (PGK1) and glyceraldehyde-3-phosphate dehydrogenase (TDH1), 
knockout of phosphofructokinase 1 (PFK1), and overexpression of ribose-5-phosphate ketol-
isomerase (RKI1) (Figure 3a, b, Supplementary Table 2). Overall, the intention of all these 
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interventions was to divert carbon flux from glycolysis towards the biosynthesis of the 
precursor E4P. Although all four interventions individually demonstrated an increase in the 
production of SA compared to the wild-type scenario based on in silico analysis, 
overexpression of RKI1 seemed to be most feasible. Considering the type of fermentation 
regime studied here (aerobic and glucose-rich), deletion or knockdown of the genes PGK1, 
TDH1, and PFK1, could drastically reduce cell growth given their key roles in glycolysis. 
Hence, only the overexpression of RKI1 was selected as the new intervention to be tested.  
Ribose-5-phosphate ketol-isomerase catalyzes the interconversion of ribose-5-phosphate 
and ribulose-5-phosphate in the PPP (Figure 3a). According to OptForce, its overexpression 
could generate a higher flux into the aromatic amino acid pathway by maintaining a higher 
carbon pull into the non-oxidative PPP, i.e., by directing the flux towards the formation of E4P 
and preventing it from recirculating back into glycolysis (Figure 3a). The in silico 
overexpression of RKI1 resulted in the highest increase in SA compared to the other individual 
manipulations, achieving 83.45% of the theoretical yield. Furthermore, its combination with 
TKL1 overexpression, DHQS upregulation (enabled by aro1D920A overexpression), and SHKK 
knockout (enabled by aro1 deletion) increased the yield to 0.55 g SA g-1glucose, representing 
89.41% of the maximum theoretical yield based on in silico prediction (Figure 3c).  
Experimentally, the overexpression of RKI1 in strain SA5 (yielding strain SA9) resulted in 
a titer of 1,026.6 ± 51 mg L-1 SA (Figure 4). This strain constituted the highest-producing strain 
in this work with a yield of 51 mg g-1glucose, an increase of 4.82-fold compared to the initial 
strain. In a final attempt to increase the flux into the SA titers, we deleted PHO13 on strain 
SA9 (yielding strain SA10). Although this strain improved the production by 11% compared 
to strain SA8, there was a decrease of about 23% compared to strain SA9 (Figure 4). This 
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indicates that overexpression of RKI1 resulted in a consistent, beneficial manipulation for 
improving the flux in the aromatic amino acid pathway, but the higher transcription rate of 
TAL1 resulting from PHO13 deletion channeled the flux back into glycolysis, leading to a 
lower titer. 
To further study the upper production limit of strain SA9, we performed fermentation in the 
media with increasing concentrations of carbon source. As demonstrated in Figure 5, elevating 
the sugar concentrations resulted in higher titers of SA. The first enhancement was observed 
from doubling the glucose concentration from 2% to 4%, in which the SA titer increased to 1.9 
± 0.1 g L-1 while maintaining a yield above 54 mg g-1glucose. The highest SA titer was achieved 
at 2.4 ± 0.051 g L-1, with DHS accumulation at 193.2 ± 5.1 mg L-1, in media containing 4% 
sucrose. The overall titer reached the highest production in S. cerevisiae among all aromatic 
amino acid pathway derivatives reported to date, although the glucose yield was compromised, 
dropping 42% compared to the fermentation in 2% glucose. 
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Figure 5: Variation of sugar concentration for SA fermentation. Strain SA9 was selected 
as the highest SA producer and tested for high glucose fermentations. Increasing the sugar 
concentration to 4% glucose and 4% sucrose increased the production of SA to 1.9 g L-1 and 
2.4 g L-1, respectively. 
 
 
 
3.4.  Case study: Muconic acid 
To show the applicability of the manipulations that yielded the SA producing platform 
strain, we introduced the genetic elements to switch the production towards MA (Table 5). It 
is important to mention that unlike SA, MA is not an endogenous product in S. cerevisiae, 
hence the introduction of three heterologous genes from diverse microorganisms was required. 
According to previous studies, and also observed in this work, the gene AroY from the 
bacterium Klebsiella pneumoniae is the rate-limiting step in the pathway (Curran et al., 2012; 
Suástegui et al., 2016b). This gene encodes for protocatechuic acid (PCA) decarboxylase, and 
due to its oxygen sensitivity, it prevents an efficient conversion of PCA into catechol. 
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Therefore, to fully capture the effects of the metabolic manipulations, the comparison of titers 
will include the sum of PCA and MA from here on. 
 
Table 5: Muconic acid producing strains.	
	
Strain Genotype Plasmid Parent 
MA1 BY4741 pRS413- GPD1-aro1D1409A,D920A /  TP1-aro4K229L  / 
ADH1-TKL 
BY4741 
pRS425- PYK1-AROZ / GPD1 – HQD2 / TEF1 – 
AROY 
MA2 BY4741 pRS413-GPD1-aro1D1409A,D920A / TP1-aro4K229L 
/ADH1-TKL / PGK1-RKI1 
BY4741 
pRS425- PYK1-AROZ / GPD1 – HQD2 / TEF1 – 
AROY 
MA3 BY4741 aro1Δ 
ric1Δ 
pRS413-GPD1-aro1D1409A,D920A / TP1-aro4K229L 
/ADH1-TKL / PGK1-RKI1 
AA_003 
pRS425- PYK1-AROZ / GPD1 – HQD2 / TEF1 – 
AROY 
MA4 BY4741 aro1Δ 
ric1Δ zwf1Δ 
pRS413-GPD1-aro1D1409A,D920A / TP1-aro4K229L 
/ADH1-TKL / PGK1-RKI1 
AA_006 
pRS425- PYK1-AROZ / GPD1 – HQD2 / TEF1 – 
AROY 
 
Initially, the single-copy plasmid for DHS accumulation (pRS413-midAA_1) was co-
transformed with the multiple-copy plasmid pRS425-MA to channel DHS into the production 
of MA. Compared to the platform strains for the production of SA, the MA strains harbored 
the mutant aro1D1409A-D920A to ensure complete blockage of the SA dehydrogenase subunit for 
accumulating DHS for MA synthesis (Suástegui et al., 2016b). This yielded the reference strain 
MA1, capable of accumulating 247.24 mg L-1 of MA and PCA. Overexpression of RKI1, 
yielding strain MA 2, increased the titer by 47%, achieving 363.97 mg L-1 (Figure 6). Deletion 
of RIC1 and ARO1 (strain MA3) increased the overall titer by another 3-fold, reaching 1105 
mg L-1 (873 mg L-1 PCA plus 232 mg L-1 MA), a similar titer observed from strain SA9, 
indicating that the set of metabolic engineering strategies for the SA platform are translatable 
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to other products from the same module. The strategies implemented here were consistent with 
OptForce predictions, wherein different combinations of interventions involving transketolase 
(TKL1/TKL2), ribose-5-phosphate isomerase (RKI1), and 3-dehydroquinate synthase (ARO1 
mutant) led to the highest yield of MA (Supplementary Table 2).  
In strain SA6 (Figure 4), DHS was accumulated due to an imbalance in reducing power caused 
by ZWF1 deletion. Here for MA production, this manipulation was presumed to be beneficial 
since DHS is the precursor of MA pathway (also suggested by the OptForce analysis, Figure 
6 and Supplementary Table 2). Surprisingly, deletion of ZWF1 (strain MA4) did not increase 
the production of PCA and MA in experiment; rather, it decreased the overall titer by 31%. 
This could be a result of removing the primary source of NADPH, in combination with a higher 
metabolic burden imposed on the MA producing strain, which carries the three-gene 
heterologous pathway in a multiple-copy plasmid along with multiple gene deletions. Despite 
that, it is noteworthy that OptForce was capable of distinguishing the redox requirements of 
SA and MA synthesis by suggesting ZWF1 knockout for only MA production.  
In order to test the upper limit of MA production, the glucose concentration was doubled, 
which led to an overall titer of 1598 mg L-1, composed of 1267.1 ± 125.3 mg L-1 PCA and 
330.9 mg L-1 ± 34.9 MA. Although this is the highest overall titer achieved, the yield was 
compromised, dropping from 55.3 to 40 mg g-1glucose (Figure 7). The MA to PCA ratio was 
conserved at 0.26 when growing the strain in both 2% and 4% glucose.  
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Figure 6: Metabolic interventions for the overproduction of MA identified through 
OptForce analysis. Green, red, and orange arrows (and circles) represent overexpression, 
downregulation and knockout of genes, respectively. A combination of ZWF1 knockout, 
TKL1, RKI1 and DHQS overexpression led to 0.441 g MA g-1 glucose, which is equivalent to 
91.21% of theoretical maximum yield.  
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Figure 7: Fermentation results from strains engineered to produce MA. Strain were grown 
in minimal media lacking histidine and leucine and supplemented with uracil and the three 
aromatic amino acids. Samples were collected at 72 h for HPLC analysis. The variation is 
represented by the standard deviation from three biological replicates. The asterisk (*) 
indicates MA3 was grown in 4% glucose. 
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4. Discussion 
Knowledge about the mechanism of transcriptional repression of a metabolic pathway can 
substantially facilitate the engineering efforts to construct microbial hosts with high production 
titers and yields. Thus far, only few reports have studied transcriptional regulation mechanisms 
in the aromatic amino acid pathway in the yeast S. cerevisiae. For example, it is known that 
the global TF Gcn4p can bind to the promoter sequences of several genes in the pathway in 
response to the levels of aromatic amino acids present in the culture media (Hinnebusch, 1988; 
Hinnebusch and Natarajan, 2002). Also, another TF Aro80p can activate the transcription of 
the genes ARO9 and ARO10 to initiate catabolism of the aromatic amino acids in the presence  
of a poor nitrogen source (Lee and Hahn, 2013). However, compared to other metabolic 
pathways in yeast, e.g., glycolysis/glycogenesis and fatty acid metabolism, the knowledge of 
the aromatic amino acid pathway transcriptional repression remains understudied. As a result, 
only low production titers from this pathway have been achieved (Suástegui and Shao, 2016). 
Therefore, we decided to investigate, for the first time, which transcription factors could affect 
the carbon flux entrance, focusing our attention to the precursor module of the pathway.    
Herein, we employed the web tool YEASTRACT (Teixeira et al., 2014) to create a 
functional link between TFs, and their effects on the production of aromatic amino acid 
pathway precursors. Combining it with a minimal, plasmid-based, SA-production platform 
corroborated the prediction capability of this database. By screening a small set of 21 TFs for 
knockout analysis, we already identified one regulator encoded by RIC1, which appears to 
negatively interact with the aromatic genes (ARO2-4). The increases in titers caused by the 
deletion of RIC1 were consistent throughout the constructed strains for both SA and MA 
production. This demonstrated the applicability of this tool to discover non-intuitive targets by 
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significantly narrowing the landscape of possible genetic interventions with the built-in 
ranking algorithms in YEASTRACT. Deletion of RIC1 constituted the first level in enhancing 
the production of aromatic amino acid pathway-derived compounds. As such, it contributed to 
relieving the pathway from strong transcriptional repression, which, along with removal of 
feedback inhibition (i.e. expression of the mutant aro4K229L), is key to unlocking higher carbon 
flux into the aromatic amino acid pathway. 
According to the YEASTRACT analysis, there is evidence that the protein encoded by RIC1 
can also interact with the promoters of the genes PHO3, PHO11, and PHO12. Recently, a gene 
from the same family of phosphate metabolism regulators, PHO13, was found to act as a global 
regulator of the PPP (Kim et al., 2015). Deletion of this gene increased the transcription rate 
of several genes in the PPP, a characteristic that is beneficial for the assimilation of xylose. We 
initially hypothesized that such elevated transcription rates would also benefit the production 
of aromatic amino acid pathway derivatives. However, deletion of PHO13 (strain SA7) 
decreased the SA titer, a phenotype that was also observed when the gene TAL1 was 
overexpressed (strain SA8). This close relationship between the phosphate regulating family 
(PHO) and the biosynthesis of amino acid pathway derivatives led us to study the deletion of 
ten PHO genes and their effects on the production (Supplementary Table 2). The plasmid 
pRS413-midAA was transformed into all the PHO deletion strains and tested for the 
production of SA. Increase was not observed when comparing the titers to strains SA2. The 
lowest titer was 115 mg L-1 in strain BY4741 Dpho90 and the highest, 303.6 mg L-1, was 
achieved in strain BY4741 Dpho88 (Figure 8). The products of both genes are involved in the 
transport of phosphate; hence the lower titers could be due to alterations in phosphate 
availability (Ghillebert et al., 2011; Yompakdee et al., 1996). Although these results indicate 
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that the carbon entry into the aromatic pathway is highly dependent on the PPP, and this 
pathway appears to be regulated by phosphate metabolism (PHO genes) (Kim et al., 2015), 
more in-depth studies are required to establish a link between these important metabolic 
modules. 
As a second level of engineering, we deleted the gene ARO1 to ensure full carbon capture 
for the products of interest (i.e. SA and MA). We observed that this intervention increased the 
titers higher than 50%; however, this was at the expense of adding slightly higher amounts of 
the three aromatic amino acids (50 mg L-1 of each amino acid).  
The third level of engineering revolved around manipulating the structural genes to improve 
the precursor availability. This included the deletion of ZWF1, which, unlike the results from 
other reported work (Curran et al., 2012), did not benefit the production of either MA or SA 
(Figure 4 and Figure 7). Deletion of this important gene in charge of supplying the cell with 
reducing power apparently affected the cells’ fitness. Strains carrying this deletion required 2 
to 3 more days to observe colonies on the selective plate, making this modification much less 
appealing for the construction of microbial cells for industrial-scale production. On the other 
hand, deleting ZWF1 could be beneficial for the production of downstream metabolites by 
linking the NADPH deficiency to an enzyme such as prephenate dehydrogenase that 
regenerates NADPH (Gold et al., 2015). To achieve this, however, the available pool of 
NADPH should be able to sustain the reaction conversion of DHS to SA that requires NADPH 
as a cofactor at the first place. Overexpressing a heterologous NADPH recycling 
transhydrogenase could potentially help overcome this metabolic hurdle (Fiaux et al., 2003).   
Within the same level of engineering, and as a result of implementing non-intuitive design 
predicted by the OptForce framework, we overexpressed the gene RKI1 encoding the essential 
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enzyme ribose-5-phosphate isomerase. To our knowledge, this is the first time this gene has 
been overexpressed to enhance the flux into the aromatic amino acid pathway. Overexpressing 
RKI1 led to the highest SA producing S. cerevisiae strain (SA9, Figure 4), due to an enhanced 
pull of carbon coming from the oxidative PPP and recycling of the product of the transketolase 
reaction (i.e. xylulose 5-phosphate, X5P) that is responsible for pulling flux from glycolysis 
back to PPP (Figure 3a). In combination with our previous manipulations, this overexpression 
enabled a titer of over 1 g L-1 and a yield of 51.3 mg g-1glucose, which is currently the highest 
recorded titer of all the compounds deriving from the aromatic amino acid pathway in S. 
cerevisiae. This final intervention further confirms that a higher pull into the PPP is required 
to enhance the pool of E4P. 
Finally, it is important to remark that the new manipulations implemented here were easily 
transferred to extend the applicability of this platform to the production of MA. The MA-
producing strain MA3 reached a total accumulation pool of MA and PCA that was 300% higher 
than that of the previously highest-producing strain reported under equivalent fermentation 
condition (Suástegui et al., 2016b). This evidences that the novel interventions implemented 
here significantly contributed towards redirecting carbon into the aromatic amino acid 
pathway. Given the economic relevance of this compound for the polymer industry, future 
work to improve strain MA3 should focus on improving the conversion of PCA to MA, which 
still remains as the bottleneck step. For example, a recently developed fast-screening platform 
for MA (Skjoedt et al., 2016) could be applied for directed evolution of the enzyme PCA 
decarboxylase to address its oxygen sensitivity. Finally, chromosomal integration of the 
production pathway could help eliminate the drawback arising from plasmid instability.  
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Overall, this work underlines the advantages of integrating multi-level information garnered 
from computational tools for unlocking the full capabilities of microorganisms. We have 
demonstrated that OptForce could suggest novel fruitful interventions that are consistent over 
multiple target products in the same metabolic branch as long as they obey the same constraints 
of energy and redox balance. We expect that the engineering framework implemented here 
will translate to the production of downstream metabolites of the SA pathway that have special 
nutraceutical and pharmaceutical values, such as the tyrosine-derived alkaloids, flavonoids, 
and stilbenoids with attention then switched to the heterologous expression of downstream 
proteins from plants. A new analysis of TFs targeting the genes located downstream of SA in 
combination with a minimal genetic platform that is modularly optimized should allow 
enhanced yields and titers of the highly valuable plant-sourced secondary aromatic 
metabolites.  
 
5. Conclusion 
Partitioning the long aromatic amino acid pathway in a modular fashion facilitated a 
multilevel approach for achieving high yields and titers. In this work, we demonstrate novel 
metabolic engineering strategies to enhance the production of aromatic amino acid pathway 
precursors. Among them, deletion of RIC1 (based on the TF study) and overexpression of RKI1 
(based on the OptForce analysis) are two novel interventions that are crucial to enable the 
production of aromatic amino acid pathway precursors at titers higher than 1 g L-1, with the 
highest reported yields thus far in simple batch fermentation. This is a significant milestone 
considering the previous titers of the vast majority of the compounds derived from this 
resourceful pathway in the batch fermentation were constrained at low levels (Suástegui and 
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Shao, 2016). Future work will focus on transferring this engineering framework towards the 
production of the higher-value chemicals downstream of the precursor module.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Fermentation results from PHO KO strains 
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7. Supplementary Information 
 
7.1. Supplementary Methods 
7.1.1. Identification of pathway interventions using OptForce  
In all simulations, the maximum glucose and oxygen uptake rates were set to 100 mmol g 
DW-1 h-1 and 200 mmol g DW-1 h-1, respectively. The regulation on the tricarboxylic acid cycle 
(TCA) cycle activity under aerobic glucose conditions (i.e. the Crabtree effect) was originally 
imposed in the iAZ900 model by limiting the oxygen uptake rate (Zomorrodi and Maranas, 
2010). This is replaced in this simulation by directly imposing an upper bound on the 
mitochondrial cytochrome c oxidase (CYOOm) reaction flux to 20 mmol g DW-1 h-1. This 
modification, while simultaneously preserving the phenotypes observed due to the Crabtree 
effect in the model, did not restrict additional oxygen to be consumed in the MA pathway. 
Under minimal media condition, the maximum yields were 2.89 h-1 for biomass, 64 mmol g 
DW-1 h-1 for SA, and 62.13 mmol g DW-1 h-1 for MA.  
In brief, the procedure for identifying the reaction-level interventions is described as 
follows.  See detailed description of the procedure in our previous work (Ranganathan et al., 
2010).  
Step 1: MFA data for wild type S. cerevisiae (Jacqueline Shanks, Iowa State University, 
personal communication) was used to constrain the flux ranges for reactions in the central 
metabolism. Flux variability analysis (FVA) is performed to identify the wild type strain flux 
ranges ([#$%&',), #$%&',*]). 
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Step 2: The flux ranges for overproducing strain ( #$,-,), #$,-,* ) are identified by 
performing FVA on the metabolic network that is subjected to the desired overproduction 
target (90% of #./012 or #-/012) and at least 10% of theoretical biomass yield (#3450166012 ).  
Step 3: By superimposing the flux ranges for the wild type and the overproducing strain, 
the set of reactions that must be up-regulated (MUSTU), down-regulated (MUSTL) and 
knockout (MUSTX) are then determined.  Second order MUST sets (i.e. MUSTUU, MUSTUL 
and MUSTLL) were also identified according to previous work (Ranganathan et al., 2010).  
Step 4: The minimal set of interventions (FORCE sets) that guarantees the yield of the 
target product under worst-case scenario was then selected from the MUST sets. To this end, 
a bi-level mixed-integer optimization problem was formulated such that the objectives of the 
outer and the inner problem are the maximization and the minimization of the target product 
yield, respectively (Chowdhury et al., 2015). The lower bound of the biomass formation is set 
to 10% of #3450166012  to ensure viability. The flux range for each reaction excluding biomass 
formation and nutrients uptake is restricted to [min #$%&',), #$,-,) , max	 #$%&',*,#$,-,* ]. Note 
that the minimum guaranteed production flux and yield for each of the mutants were calculated 
under the same condition as Step 4.  All optimization problems were solved in GAMS 24.4.1 
with CPLEX Solver v.12.6.1. 
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7.2. Supplementary Tables 
Supplementary Table 1: List gRNA used for gene knockouts via the CRISPR system. The 
strikethrough represents the 8 bp deletion which includes the protospacer adjacent motif 
(PAM) in bold. 
 
Target gene gRNA Donor DNA 
ARO1  gttatggtagcgatcggtggtgg tagaagattatcttttagtggaaggatgtactcgtgatacggttatggtagcga
tcggtggtggtgttattggtgacatgattgggttcgttgcatctacatttatga 
PHO13 gtatgggtatttggagaaagcgg gactttctgaaattgcagcctggcaaagataaggtatgggtatttggagaaa
gcggtattggtgaagaattgaaactaatggggtacgaatctctaggaggtg
ccgat 
ZWF1 gtccaaattgtccatggaggagg tgatccatctaccaagatcttcggttatgcccggtccaaattgtccatggagg
aggacctgaagtcccgtgtcctaccccacttgaaaaaacctcacggtgaag
ccga 
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Supplementary Table 2: Metabolic interventions predicted by OptForce for (a) shikimic 
acid (SA) and (b) muconic acid (MA) overproduction. The theoretical maximum and 
minimum guaranteed fluxes are calculated under the condition specified in Supplementary 
Methods. Although multiple isozymes may be associated with each reaction only the major 
genes described in this study are shown in the gene-level interventions. Reaction abbreviations 
and the chemical equations written in the net flux direction are as followed:  
 
 
(i) DHQS, 3-dehydroquinate synthase (2dda7p => 3dhq + pi); 
(ii) G6PDH2, glucose-6-phosphate dehydrogenase (g6p + nadp => 6pgl + h + nadph); 
(iii) GAPD, glyceraldehyde-3-phosphate dehydrogenase (g3p + nad + pi <=> 13dpg + h + 
nadh); 
(iv) PFK, phosphofructokinase (atp + f6p => adp + fdp + h); 
(v) PGK, phosphoglycerate kinase (3pg + atp <=> 13dpg + adp); 
(vi) PYK, pyruvate kinase (adp + h + pep => atp + pyr); 
(vii) RPI, ribose-5-phosphate isomerase (ru5p <=> r5p); 
(viii) SHKK, shikimate kinase (atp + skm => adp + h + skm5p); 
(ix) SKHL, 3-dehydroshikimate dehydratase (3dhsk <=> h2o + pca); 
(x) TKT1, transketolase 1 (r5p + xu5p <=> g3p + s7p); 
(xi) TKT2, transketolase 2 (f6p + g3p <=> e4p + xu5p). 
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Supplementary Table 2 continued 
 
Metabolic 
interventions 
(Reaction level) 
Metabolic 
interventions 
(Gene level) 
Minimum 
guaranteed flux 
(mmol gDW-1 h-1) 
Yield  
(gproduct g-1glucose) 
% 
Theoretical 
maximum 
(a) Shikimic acid 
↓PGK ↓PGK1 51.59 0.499 80.61% 
↓GAPD ↓TDH1 51.59 0.499 80.61% 
ΔPFK ΔPFK1 51.85 0.501 81.02% 
↑RPI ↑RKI1 53.41 0.516 83.45% 
↑TKT1 ↑TKL1 54.71 0.526 85.48% 
↓PYK ↓CDC19 55.06 0.529 86.03% 
↑TKT2 ↑TKL1 55.52 0.537 86.75% 
↑TKT1  ↑TKT2 ↑TKL1 56.19 0.543 87.80% 
↑TKT1  ↑TKT2 ↑RPI ↑TKL1 ↑RKI1 56.19 0.543 87.80% 
↑TKT1 ↑TKT2 
↓SHKK ↑TKL1 ↓ARO1 56.49 0.546 88.27% 
↑TKT1 ↑TKT2 
↑DHQS 
↑TKL1 
↑ARO1D920A 
57.13 0.552 89.27% 
↑TKT1 ↑TKT2  
↑DHQS ↓SHKK 
↑RPI 
↑TKL1 
↑ARO1D920A 
↓ARO1 ↑RKI1 
57.22 0.553 89.41% 
(b) Muconic acid  
ΔG6PDH2 ΔZWF1 19.88 0.155 32.00% 
↑RPI ↑RKI1 25.07 0.195 40.35% 
↑TKT1 ↑TKL1 31.35 0.244 50.46% 
↑TKT1 ΔG6PDH2  ↑TKL1 ΔZWF1 51.44 0.4 82.79% 
↑TKT2 ↑TKL1 51.63 0.401 83.10% 
↑TKT1 ↑RPI 
ΔG6PDH2 
↑TKL1 ↑RKI1 
ΔZWF1 52.73 0.41 84.87% 
↑TKT2 ↑TKT1 ↑TKL1 53.24 0.414 85.69% 
↑TKT1 ↑RPI 
ΔG6PDH2 ↑SKHL 
↑TKL1 ↑RKI1 
ΔZWF1 ↑AROZ 55.92 0.435 90.00% 
↑TKT2 ↑TKT1 
↑SKHL ↑TKL1 ↑AROZ 55.92 0.435 90.00% 
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Supplementary Table 2 continued 
    
↑TKT1 ↑DHQS ↑RPI ↑TKL1 ↑ARO1D920A ↑RKI1 
56.67 0.441 91.21% 
↑TKT1  ↑TKT2 
↑DHQS ↑RPI 
↑TKL1 
↑ARO1D920A ↑RKI1 
56.67 0.441 91.21% 
↑TKT1  ↑TKT2 
↑DHQS ↑RPI 
ΔG6PDH2 
↑TKL1 
↑ARO1D920A ↑RKI1 
ΔZWF1 
56.67 0.441 91.21% 
↑TKT1  ↑DHQS 
↑RPI ΔG6PDH2 
↑TKL1 
↑ARO1D920A ↑RKI1 
ΔZWF1 
56.67 0.441 91.21% 
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CHAPTER 6 
 
NEW STRATEGIES, NEW PRODUCTS AND NEW SPECIES 
 
 
1. Introduction 
As studied in the previous chapters, the carbon entrance into the aromatic amino acid pathway 
depends on the availability of two main precursors. A fine balance between erythrose-4-
phosphate (E4P) and phosphoenolpyruvate (PEP) is expected to aid the production of 
metabolites deriving from the aromatic pathway. E4P is a product from the pentose phosphate 
pathway and various successful engineering strategies have been devised to enhance its 
accumulation (Suástegui and Shao, 2016). In contrast, strategies to increase the availability of 
phosphoenolpyruvate, the second precursor into the pathway, have not been established thus 
far in Saccharomyces cerevisiae. In prokaryotic microorganisms like Escherichia coli, a few 
manipulations have linked a higher production of shikimic acid pathway derivatives with a 
higher availability of PEP. For instance, the phosphotransferase system (PTS) in charge of 
transporting glucose into the cytoplasm can be knocked out, which reduces the utilization of 
PEP as the phosphate donor. Another successful strategy consists of recirculating pyruvate to 
PEP by means of overexpressing the phosphoenolpyruvate synthase, ppsA (Patnaik and Liao, 
1994).  
Intrinsic differences between prokaryotes and eukaryotes prevent the direct transfer of 
metabolic engineering strategies. For example, the transportation of glucose in S. cerevisiae 
does not depend on the PTS system. Furthermore, the presence of organelles results in the 
compartmentalization of metabolites, which reduces the availability of the desired precursors 
in the cytoplasm and dilutes the possibility of reaching higher product titers. PEP is a 
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cytoplasmic metabolite, meaning it could be readily available for condensation with E4P for 
the production of aromatic compounds. However, our metabolic flux analyses showed that the 
rates of PEP conversion to pyruvate are at least one order of magnitude higher than the E4P 
flux in the pentose phosphate pathway (Suástegui et al., 2016a). This is expected because 
pyruvate has considerably more metabolic fates in the cell, hence it is in higher demand for 
production of essential metabolites in aerobic respiration, fatty acid production, and production 
of other amino acids.  
Therefore, this section is dedicated toward finding novel alternatives to rewire the 
availability of PEP to allow increases in aromatic titers while maintaining a good metabolic 
balance for efficient biomass formation. Moreover, the production of molecules from the 
downstream module is presented and the non-conventional yeast is studied for the production 
of coumaric acid.  
 
2. New Strategies for Enhancing the Production of Aromatic Amino Acid Derivatives 
Slowing down the conversion of PEP to pyruvate is desired to reduce the competition between 
the aromatic amino acid production and other essential pathways. The most straightforward 
manipulations revolve around deleting or downregulating reactions that consume PEP or 
pyruvate. However, a detrimental effect is expected as it is likely that S. cerevisiae will lose its 
capability of growing in fermentable sugars. Some examples for this rationale include deleting 
the pyruvate kinase gene pyk1 (CDC19), which converts PEP to pyruvate, and deleting genes 
from the pyruvate decarboxylase family PDC to reduce the loss of carbon to ethanol and 
acetate (Suástegui et al., 2016b). However, neither of these techniques have resulted in positive 
outcomes which evidence that more dynamic strategies need to be implemented that 1) 
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consider the compartmentalization of metabolites, 2) overcome strong regulatory mechanisms, 
and 3) do not rely on knockout of essential genes. 
 
2.1. Direct recirculation of pyruvate to PEP  
There are several potential alternatives consisting mainly in gene overexpressions to recirculate 
pyruvate back to PEP. In Chapter 2, a strategy consisting on overexpressing the endogenous 
S. cerevisiae genes namely, pyruvate carboxylase PYC1 and phosphoenolpyruvate 
carboxykinase PCK1. This rationale was established with the goal of enforcing the conversion 
of pyruvate to oxaloacetate (OAA), which would then be converted to PEP. This strategy, 
however, did not consider key regulatory points that control the degradation of gluconeogenic 
proteins (PCK1p), and also did not account for the transport of pyruvate to other organelles 
such as the mitochondria. Hence, a new strategy for pyruvate recirculation will explore the 
overexpression of heterologous genes, namely ppsA from E. coli, and the pyruvate, 
orthophosphate dikinase (PPDK) from the plant Arabidopsis thaliana. One of the advantages 
of overexpressing heterologous genes is that posttranslational modifications that inactivate 
proteins (phosphorylation, ubiquitylation) can be avoided.  
To ensure a higher pyruvate availability in the cytosol to serve as the substrate for the 
recirculation enzymes mentioned above, the main carriers that transport pyruvate into the 
mitochondria need to be knocked out. This strategy has been previously established in S. 
cerevisiae to increase the cytosolic pools of pyruvate to elevate the production polyketides 
(Cardenas and Da Silva, 2016). In this study, two mitochondrial, outer membrane transporters 
(POR1 and POR2) and two mitochondrial pyruvate inner membrane carriers (MPC1 and 
MPC2) were deleted. Single-gene knockouts revealed that POR2 and MPC2 were good 
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candidates to increase the pool of pyruvate in cytoplasm resulting in at least a 3-fold 
improvement in triacetic acid lactone (TAL) production. The combination of these further 
increased the titers of TAL from ~ 300 mg L-1 to almost 1.0 g L-1.  
By combining the overexpression of the pyruvate recirculation genes in strains with the 
deletion of pyruvate mitochondrial transporters enhances in the availability of PEP to be 
channeled into the aromatic amino acid pathway are expected.  
 
2.2 Enforcing gluconeogenesis for PEP accumulation 
Gluconeogenesis is a metabolic pathway whose activation, in S. cerevisiae and other 
organisms, is triggered by a diauxic shift. This is, as glucose is depleted, the glycolytic genes 
undergo downregulation, while the gluconeogenic ones become activated with the goal of 
regenerating glucose from intracellular metabolites. Because the gluconeogenic pathway is 
highly ATP-consuming, very strict regulations at all metabolic levels protect the cell from 
unnecessary energy expenditures in the presence of high concentrations of glucose.  
Evidence of the diauxic shift (initiation of gluconeogenesis) and its impact on the 
production of aromatic amino acid derivatives can be observed from the fermentation profiles 
of shikimic acid (See supplementary information in Chapter 4). At 48 h of fermentation, the 
glucose levels have been completely depleted, and it is at this point when the accumulation of 
shikimic acid significantly increases. At 72 h the maximum titer is usually achieved, indicating 
that during this time the levels of PEP increase, hence allowing the DAHP synthase to carry 
out the first committed step in the shikimic acid pathway more efficiently.  
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Figure 1: New strategies for improving the production of aromatic amino acid 
derivatives. The engineering rationale is based on the recirculation of pyruvate to PEP by a 
direct catalytic step requiring the overexpression of heterologous genes such as Ec_ppsA, or 
At_PDK. Another strategy includes the overexpression of endogenous gluconeogenic genes to 
accumulate PEP through the PC-PCK cycle or by MDH genes. This strategy also considers 
the deletion of transporter proteins to prevent the loss of carbon into mitochondria.  
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Therefore, a new metabolic engineering strategy will be implemented with the goal of 
enforcing the activation of gluconeogenic genes even in the presence of high glucose 
concentrations.  
In S. cerevisiae, gluconeogenesis starts from the conversion of cytosolic malate to pyruvate 
through an NADH+ dependent malic acid enzyme (pyruvic-malic enzyme, MAE1p) or through 
the conversion of malate to OAA through the cytosolic malic acid dehydrogenase enzyme 
(MDH2p) (Figure 1). OAA is further converted to PEP through the PCK1 enzyme. Seven 
more steps proceed this reaction to obtain glucose-6-phosphate, however, because the target 
metabolite for the production of aromatic is PEP, the attention will be focused on the steps that 
convert malate to PEP. Similar to pyruvate, malate can also be transported into the 
mitochondria through the action of the specific carrier OAC1. This is an inner membrane 
transporter that imports the cytosolic OAA produced from pyruvate by the enzyme pyruvate 
carboxylase (Palmieri et al., 1999). Therefore, the deletion of this gene could be a potential 
strategy to increase high malate pools for the initiation of gluconeogenesis (Figure 1).   
Several regulatory mechanisms affect the gluconeogenic pathway at the transcriptional, 
post-transcriptional, and post-translational levels. For instance, it is known that strength of the 
PCK1 promoter is detectable only during the stationary phase of cell growth (Reider Apel et 
al., 2017). This is caused by the action of several carbon-responsive elements such as Mig1p, 
which can repress the transcription of gluconeogenic transcriptional activators through binding 
to specific promoter regions (Schuller, 2003). Moreover, the mRNA of key gluconeogenic 
genes are destabilized by the action of the Reg1p protein which is associated with the Mig1p 
glucose repression pathway (Yin et al., 2000). These drawbacks can be easily overcome by 
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overexpressing the two genes of interest, namely MDH2 and PCK1, with strong constitutive 
promoters which are not subjected to glucose repression. However, given the potential impact 
on cellular metabolism, it would be preferable to span a panel of promoters with different 
strengths to ensure an appropriate expression balance.    
Post-translational modifications (PTMs) serve as regulatory commands to control the 
stability, localization, and activity of proteins in the cell. One or more amino acid residues in 
a protein can be modified by the addition of a chemical group (e.g. phosphorylation) to induce 
a specific switch-like state of activation of deactivation. Two of the most common post-
translational modifications in eukaryotic systems are phosphorylation and ubiquitylation. The 
former is usually associated with enzymatic activity, whereas the latter serves as a tag for 
protein degradation. PTMs are commonly orchestrated by a network of genes and its study has 
been determinant in understating major hierarchical regulatory mechanisms of key metabolic 
pathways. Hence, it is not unexpected that PTMs play a crucial role in the regulation of highly 
energy-demanding pathways such as gluconeogenesis and the biosynthesis of aromatic amino 
acid. Several studies have revealed that, indeed, the gluconeogenic genes undergo major PTMs 
as an additional control level to regulate their cellular activity and abundance. For example, 
the cytosolic MDH protein (MDH2p), contains two phosphorylation residues at the proline 1 
(P1) residue and at the threonine 6 (T6) residue. Through biochemical characterizations, it has 
been demonstrated that substituting P1 to serine (P1S), or removing the first 12 residues of the 
protein can reduce its degradation when cells are shifted from non-fermentable carbon sources 
(acetate) to growth on glucose (Hung et al., 2004; Minard and McAlister-Henn, 1992). 
Through global proteomic studies, four lysine residues (K42, K180, K254, and K259) 
subjected to ubiquitylation have also been identified in MDH2p (Swaney et al., 2013). Whether 
  
176 
ubiquitylation of these residues is a product of cross-talk between the phosphorylated residues 
(i.e. phosphodegrons that induce ubiquitylation) remains unknown, however, it would be 
interesting to study these interactions to discern whether a higher activity of this enzyme can 
be achieved in the presence of glucose. Therefore, different mutant versions of the gene MDH2 
will be constructed and incorporated into the new genetic platform to study the recirculation 
of malate to OAA. 
To finalize the partial reconstruction of gluconeogenesis, the phosphoenolpyruvate 
carboxykinase gene, PCK1, will also be overexpressed, in order to ensure the conversion of 
OAA to PEP. Thus far there is no evidence of PCK1p undergoing PTMs such as 
phosphorylation or ubiquitylation. However, high sequence similarity with the protein ARO4p 
(50 % identity in the first 12 amino acids), which is known to undergo phosphorylation was 
observed. Therefore, new mutant versions of PCK1p with amino acid substitutions to avoid 
phosphorylation will be constructed and overexpressed to complete the production of PEP in 
the presence of glucose.  
 
 
 
Figure 2: Sequence alignment of the first 24 amino acid residues of the S. cerevisiae 
PCK1p and ARO4p proteins. The serine residues in blue in ARO4p represent the recognized 
phosphorylation sites (Albuquerque et al., 2008). The sequence similarity of these proteins 
indicates that the Serine residues in PCK1 could be substituted to avoid phosphorylation.  
 
 
 
 
PCK1    1 MSPSKMNATVGSTSEVEQKIRQELA-------------------LSDEVTTIRRNAPAAV 
ARO4    1 MSESPMFAANGMP-KVNQGAEEDVRILGYDPLASPALLQVQIPATPTSLETAKRGRREAI	
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3. Materials and Methods   
3.1. Strains and plasmid construction 
The strains constructed are listed in Table 1. Briefly, we used the haploid strain of S. cerevisiae 
BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and the oac1Δ BY4741 knockout strain to 
study the enforcement of gluconeogenesis through the overexpression of MDH1 and the 
phosphorylation-free MDH1P1S variant. In this study, we also constructed a strain carrying a 
single cassette integration of the minimal SA pathway, described in Chapter 5. 
The plasmid-free strains were propagated in YPAD media (1% yeast extract, 2% peptone, 
0.01% adenine, and 2% dextrose). The plasmid harboring the SA pathway (SA_high, chapter 
5) and the plasmid harboring the MDH2 variants were co-transformed into the corresponding 
S. cerevisiae strains following the quick and dirty protocol (Amberg et.al., 2016). After 
plasmid transformation, yeast strains were plated in Synthetic Complete solid media lacking 
histidine and leucine and supplemented, to a final concentration 50 mg L-1, with each of the 
three aromatic amino acids. All plasmids constructed in this study (Table 1) were derived from 
the pRS shuttle vector series (New England BioLabs, Ipswich, MA). To assemble the genetic 
cassettes, the DNA Assembler technique (Shao et al., 2012; Shao and Zhao, 2013) was 
implemented. 
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Table 1: The constructed plasmid and strains. 
Strain Plasmid Expression cassette 
BY4741 
Control 
pRS415 Empty 
pRS413-SA_high GPD1-aro1D1409A,D920A/TP1-aro4K229L /ADH1-TKL1 / PGK1-RKI1 
BY4741 
G1 
pRS415-MDH2 TEF1p-MDH2-HXT7t 
pRS413- SA_high GPD1-aro1D1409A,D920A/TP1-aro4K229L /ADH1-TKL1 / PGK1-RKI1 
BY4741 
G2 
pRS415-
MDH2P1S 
TEF1p-MDH2(P1S)-HXT7t 
pRS413- SA_high GPD1-aro1D1409A,D920A/TP1-aro4K229L /ADH1-TKL1 / PGK1-RKI1 
BY4741Δoac1 
G3 
pRS415-MDH2 TEF1p-MDH2-HXT7t 
pRS413- SA_high GPD1-aro1D1409A,D920A/TP1-aro4K229L /ADH1-TKL1 / PGK1-RKI1 
BY4741Δoac1 
G4 
pRS415-MDH2 
P1S 
TEF1p-MDH2(P1S)-HXT7t 
pRS413- SA_high GPD1-aro1D1409A,D920A/TP1-aro4K229L /ADH1-TKL1 / PGK1-RKI1 
BY4741::SA 
G5 pRS415-MDH2 TEF1p-MDH2 P1S -HXT7t 
BY4741::SA 
G6 
pRS415-MDH2 
P1S 
TEF1p-MDH2 P1S -HXT7t 
 
3.2. Fermentation conditions  
Single yeast colonies were picked from the transformation plates and inoculated into 3 mL of 
SC-His-Leu media for analysis of SA production. After overnight growth, 30 µl of culture was 
transferred into 3 ml of SC-His-Leu (2% glucose) and after 72 h of fermentation, 1 ml samples 
were collected, centrifuged at 5000 rpm for 5 min, and the supernatant was stored at -20  
until chromatographic analysis.  
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3.3. Biomass and metabolite analysis  
Biomass growth in media was monitored by optical density changes with an absorbance reader 
at 600 nm (OD600) (Biotek synergy 2 Multi-Mode microplate Reader). Analysis of SA was 
done by high liquid pressure liquid chromatography (HPLC) using an Agilent 1200 Series 
equipment (Agilent Technologies, USA) coupled to UV detector at 210 nm with an Aminex 
HPX-87H column (300×7.8 mm) (BioRad, Hercules, CA). The mobile phase was 0.5 mmol L-
1 H2SO4 with the flow rate of 0.3 mL min-1. 
 
4. Results and discussion 
Malate dehydrogenase (MDH2p) is the initial enzyme in the gluconeogenic pathway that 
catalyzes the reversible oxidation of malate to oxaloacetate in the cytosol. We hypothesized 
that overexpressing the MDH2 could enhance the pools of PEP leading to higher accumulation 
of SA. Unexpectedly, the production of SA slightly decreased when the MDH2p was 
overexpressed in the control BY4741 strain. A possible cause for this reduction could be that 
MDH2p favors the reverse reaction, which is the conversion of OAA to malate. In fact, 
previous reports show that increasing the concentration of this enzyme can lead to elevated 
titers of malate acid in S. cerevisiae (Zelle et al., 2008). To increase the availability and activity 
of MDH2p in the cytoplasm, we overexpressed a mutant version of this protein carrying a 
serine substitution in the proline 1 residue (Strain G2, Table 1). This mutation intended to 
remove the phosphorylation site in MDH2 which leads to protein degradation. As expected, 
this mutation reduced the degradation of MDH2 which led to increased activity and reduced 
SA production. The titers dropped 45% compared to the control strain. This indicated that 
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indeed, MDH2 favors the production of malate over OAA. We further studied the deletion of 
the OAA mitochondrial carrier OAC1 to increase the levels of OAA in the cytoplasm. 
However, the production of SA decreased in this knockout strain, carrying either version of 
MDH2p, to less the 200 mg L-1 (Figure 3) with no correlation with a decrease in biomass 
production (Figure 3). Further studies should focus on overexpressing an NADPH malic 
enzyme to recover malate and convert it to pyruvate with the completion of the shunt by 
overexpressing a phosphoenolpyruvate synthase (e.g. E. coli ppsA). Another possibility could 
be overexpressing new enzymatic versions of MDH2p with known irreversible activity. One 
such example is the malate:quinone oxidoreductase from E. coli (Ec_mqo, Figure 1).   
This rational can also be complemented by linking the metabolic engineering strategies with 
a biochemical driving force (Shen et al., 2011). Common driving forces are related energy 
exchange metabolites like ATP pools or other cofactors such as NADH and NADPH. In this 
light, the activity of the enzyme of study (present in the pathway of interest) can be elevated if 
its reaction can provide or complement a cofactor deficiency created by the deletion of selected 
genes. To enhance the production of aromatic compounds, such driving force can be created 
by deleting the ZWF1 gene in the oxidative pentose phosphate pathway. This would require a 
new source for replenishment of cytosolic NADPH levels that can be attained by 
overexpressing dehydrogenase enzymes that depend on the NADP+ cofactor. Overexpression 
of heterologous MDH2p enzymes that prefer NADP+ as the cofactor could help establishing 
the metabolic driving force. One potential gene for this strategy is the NADPH-dependent 
MDH enzyme involved in pyruvate metabolism and carbon fixation pathways in several 
organisms such as Zea mays (Metzler et al., 1989), A. thaliana and Methanobacterium 
thermoautotrophicum (Thompson et al., 1998).  
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Figure 3. Fermentation results from strains engineered to produce SA. Samples were 
collected at 72 h. The variation indicates the standard deviation from three biological 
replicates. 
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5. New Products and New Species 
 
5.1. Engineering the downstream module of the aromatic pathway in Saccharomyces 
cerevisiae and Pichia stipitis 
As reviewed in Chapter 2, the aromatic amino acid pathway is a precursor to a vast diversity 
of high-value secondary metabolites. The efforts described in the subsequent chapters and in 
the previous section to increase the carbon entrance into the aromatic amino acid pathway have 
led to constructing high-producing strains for MA and SA accumulation. It is expected that the 
genetic platforms, as well as the metabolic engineering strategies demonstrated in previous 
sections, translate seamlessly for the downstream compounds. Moreover, the highest producers 
obtained thus far will serve as the starting point for the construction of new strains  
The downstream module of the aromatic amino acid biosynthetic pathway encompasses two 
main branches: 1) the L-phe and L-tyr branch and 2) the L-trp branch. Most of the engineering 
work to produce downstream metabolites has focused on the L-tyr branch because it is the 
precursor to two big families of secondary metabolites, i.e., flavonoids and stilbenoids, and 
benzylisoquinoline alkaloids. L-tyr can be converted to coumaric acid for production of 
nutraceuticals like naringenin and resveratrol. On the other hand, L-tyr can undergo 
deamination and hydroxylation to produce L-DOPA, which is the main precursor to the 
production of major pain-management drugs.  
Although S. cerevisiae is the model yeast for unicellular eukaryotes, other yeasts possess 
diverse physiological features that make them more attractive for metabolic engineering 
applications. Such features include higher lipid accumulation such as Yarrowia lipolytica 
(Nicaud, 2012), higher assimilation rates of pentose sugars such as Pichia stipitis (Gao et al., 
2016), or a Crab-negative physiology, which entails higher biomass formation in the presence 
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of elevated glucose, rather than the production of ethanol. In previous work, we have 
demonstrated that P. stipits is an excellent host for production of aromatic compounds due to 
its greater activity in the pentose phosphate pathway (Gao et al., 2016). Ultimately, the goal is 
to engineer this strain to exploit its potential in the production of valuable aromatics, 
specifically, those deriving from gene L-tyr.  
 
5.2. Production of coumaric acid  
The production of coumaric acid was established by overexpressing the gene encoding the 
tyrosine ammonia lyase (TAL) from Flavobacterium johnsoniae in an episomal vector. The 
product of this gene has been previously characterized and compared to other enzymes from 
the same class and has been demonstrated to possess the highest catalytic activity to convert 
tyrosine to coumaric acid (Jendresen et al., 2015).  
A codon-optimized version of the TAL gene was synthesized for expression in S. cerevisiae 
and Pichia stipitis. The gene was cloned into the pRS414 vector under the expression of the 
strong promoter TEF1 and transformed into S. cerevisiae. For the production of coumaric acid 
in P. stipitis, the gene was cloned into an episomal vector for selection in tryptophan currently 
developed by our group. Transformation of the plasmids was done following the lithium 
acetate protocol and plated on SC-Ura plates. The selected colonies were grown in liquid 
selective media and supplemented with L-tyrosine to serve as the substrate for the tyrosine 
ammonia lyase enzyme. S. cerevisiae was able to produce 26.1 mg L-1 of coumaric acid while 
P. stipitis produced 13.3 mg L-1 (Figure 4). Both species produced coumaric acid at very 
similar yields, indicating that both enzymes have very similar activities. This is an indication 
that P. stipitis can be readily engineered to produce aromatic secondary metabolites.  
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Figure 4: Chromatogram of a S. cerevisiae and P. stipitis engineered for the production 
of coumaric acid.  
 
5.3. Engineering the downstream module of the aromatic amino acid pathway 
The S. cerevisiae strain SA9 from the previous chapter, which was found to have the highest 
accumulation of shikimic acid (SA) will be used as platform strain for the production of 
coumaric acid. To further unlock the carbon flux into the downstream module, the E. coli gene 
aroL will be overexpressed. This gene codes for a shikimate kinase enzyme, which has been 
demonstrated to be a bottleneck step in S. cerevisiae. It is important to mention that the strain 
SA9 contains the Daro1 which could be complemented with the aroL gene. However, we will 
also study the expression of this gene in a strain without the aforementioned deletion.  
Feedback inhibition occurs also in the downstream aromatic module at the level of the 
chorismate mutase enzyme Aro7p. This enzyme undergoes inhibition by high levels of L-tyr 
p-Coumaric Acid
3.5 mM Tyrosine
3 day fermentation 
26.1 +- 3.56 mg/L
p-Coumaric Acid
1.5 mM Tyrosine
3 day fermentation 
13.3 ± 1.44 mg/L
S. cerevisiae + pRS414-Tp1p-FjTAL 
P. stipitis + pRS416-Eno1p-FjTAL 
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in order to keep a strict balance between the L-tyr/L-phe branch and the L-trp branch.  Hence, 
we will overexpress a mutant version of this enzyme with the glycine residue 141 substituted 
to serine. This point mutation has been demonstrated previously to remove the feedback 
inhibition caused by L-tyr (Rodriguez et al., 2015). To avoid the loss of carbon through 
pathway competition, we will study the deletion of two genes, namely ARO10 and PDC5 
which are known to initiate the degradation of the aromatic amino acids to use as the nitrogen 
source. 
 
6. Future perspectives 
 
6.1. Exploration of downstream transcriptional regulators 
Following the studies described previously to find transcriptional repressors of the upstream 
module, new explorations can be performed to find new candidate factors that affect the 
downstream module of the aromatic amino acid pathway. This would entail analyzing the 
promoter sequences of the genes chorismate mutase (ARO7), prephenate dehydrogenase 
(PHA2), prephenate dehydrogenase (TYR1), and the two aromatic aminotransferases 
(ARO8/9).  
This study can be approached in a combinatorial way and relying on a fast screening method 
to increase the overall efficiency. Initially, the knockout strains obtained from the 
YEASTRACT database can be pooled into a single dense yeast culture. Secondly, a minimal 
genetic platform composed of the structural genes and a gene for fast screening will be 
constructed in a plasmid containing the CRISPR system for gene integration, ensuring only a 
single transformation event per strain. After transformation, the pooled cells will be plated on 
selective media. The cells with a positive result according to the colorimetric biosensor will be 
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picked and back-sequenced to determine the locus of the gene knockout. This strategy is 
depicted in Figure 5. 
 
 
 
Figure 5: Depiction of proposed strategy for engineering the downstream aromatic amino 
acid branch. 
 
6.2. CRISPR-dCas9-based metabolic valves to control the carbon flux into the 
aromatic pathway 
In Chapter 5 OptForce analyses indicated a series of potential metabolic interventions that can 
be implemented to enhance the carbon flux into the aromatic amino acid pathway. Besides the 
overexpression of RKI1, the simulations suggested the deletion or downregulation of important 
genes in the glycolytic pathway (Figure 3, Chapter 5). The predicted gene targets included 
knocking out the phosphofructokinase gene (PFK1), and downregulating the genes 
phosphoglycerate kinase (PGK) and glylceraldehyde-3-phosphate dehydrogenase (TDH). 
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However, it is imperative to consider that the activity of these genes is crucial for utilization 
of fermentable sugars, such as glucose. Deleting these genes could result in very low biomass 
titers which would ultimately decrease the production of the desired compounds. Hence, new 
alternatives ought to be explored that aim to modulate gene expression rather than a strict 
knockout, and one such alternative could be achieved through the implementation of CRISPR-
Cas technology. 
The prokaryotic adaptive immune system, composed of Clustered Regularly Interspaced 
Short Palindromic Repeats and CRISPR-associated genes (CRISPR-Cas), is an immune 
system against bacteriophage infections. This widespread mechanism enables microbes to 
precisely recognize specific sequences of the invader DNA, and acquire immunity against 
future attacks (Makarova et al., 2011). From an evolutionary perspective, studying the structure 
and mechanisms of CRISPR-Cas systems has opened new avenues for understanding the 
interactions between prokaryotes and viral populations and how these have shaped many 
microbial ecosystems (Andersson and Banfield, 2008; Bondy-Denomy and Davidson, 2014). 
Furthermore, given the ability of the Cas proteins to cleave DNA with a high sequence 
specificity, CRISPR-Cas has been repurposed as a robust tool for gene editing. In fact, 
researchers have taken advantage of the fewer requirements of type II CRISPR systems and 
have exploited them for many elegant genome editing applications. In bacterial and eukaryotic 
cells, applying this powerful platform can be as simple as the insertion or deletion of genes. 
Other more sophisticated cases can be achieved by employing and engineered Cas9 lacking its 
nuclease activity (dCas9), but maintaining its DNA binding ability. This has opened the door 
for implementing genome-wide interference studies in several species (Hawkins et al., 2015; 
Kiani et al., 2015; Larson et al., 2013; Lv et al., 2015).  
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For instance, this technology can be implemented to control, in a combinatorial way, the 
transcription of more the one gene more metabolic engineering applications. To complement 
the predictions established by OptForce in the previous Chapter, such engineering platform 
would consist of a library of multi-loci gRNAs for precise binding of dCAS9 with modulated 
strength to the target genes of interest. The second component is an optimized dCAS9 
engineered for different applications, including but not limited to: (i) gene silencing by 
promoter blockage, (ii) gene activation when linked to a transcriptional activator, or (iii) gene 
modification when linked to a transferase-like catalyst. This platform would enable the 
modulation of gene expression within its native genome context, bypassing the need to utilize 
heterologous or synthetic promoters. Rather than limiting the system to an “on” or “off” state 
(i.e., transcription vs. no transcription), it can provide a platform in which genes can be studied 
in a wide range of transcriptional strengths. By linking the gene of interest to a reporter, the 
screening process can be simplified, although this is not a requirement, e.g., when the gene of 
interest provides an evident visual phenotype, or when a high throughput screening method is 
in hand. 
This CRISPR-based tool can be exploited to study phenotypes resulting from manipulating 
the transcriptional strength of more than one gene simultaneously, for example, to 
downregulate the genes in glycolysis to enhance the production of aromatic compounds (TDH, 
PGK1, PFK1). This property enables the creation of genetic landscapes that otherwise would 
not be possible by single gene deletion or overexpression. The “fluidity” property of the 
transcriptional strength, or partial loss/gain of function, provided by CAMEO-dCas9 is of 
special interest when the deletion of the genes of study is lethal. This platform allows for a 
fine-tuning of gene expression. Figure 6 describes the construction and application of this 
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platform to target more than one gene simultaneously. The construction of the library of 
multiplex gRNAs can be performed by rapid in vivo assembly methods such as DNA assembler 
(Shao et al., 2009).  
 
 
Figure 6: Schematic representation of a CRISPR-Cas9 based platform for dynamic 
regulation of genes. The genes of interest are linked to a reporter gene for ease of screening; 
this can be bypassed when high-throughput methods are available for the desired phenotype. 
The combinatorial, in vivo-constructed gRNA library, is then introduced into the host cell. 
Selection of desired cell lines or strains is followed by sequencing of the gRNA construct that 
confers the phenotype of interest. The system is not limited to the number of genes of interest 
or type of dCas9; gene activation (Maeder et al., 2013) and modification, rather than 
repression, can be achieved by fusing dCas9 to other catalytically active units. 
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7. Conclusions 
Engineering the aromatic amino acid pathway in S. cerevisiae has proven to be a challenging 
endeavor. Nevertheless, successes in the production of important molecules like shikimic acid 
and muconic acid has been achieved through the implementation of several state of the art 
tools and technologies. As a matter of fact, by developing innovative engineering strategies, 
this work has built upon previous literature to construct strains with the highest reported yields 
and titers in molecules deriving from the pathway of interest. This work contains a compilation 
of studies that contribute towards understanding the metabolism of aromatic compounds in S. 
cerevisiae and establishes new engineering strategies that can be further implemented for the 
construction of new strains to manipulate new pathways.  
To establish successful metabolic engineering strategies to exploit the production of 
aromatic derivatives, it was imperative to comprehend the two main core metabolic pathways 
that provide the precursor substrates. The pentose phosphate pathway (PPP) serves an 
important function in the cell as it constitutes the main source of reducing power in the form 
of NADPH units. The gene ZWF1, a major component of the oxidative portion of PPP, 
catalyzes the dehydrogenation of glucose-6-phosphate utilizing NADP+ as a cofactor. 
Although several reports indicate that deleting this gene could enforce the carbon entrance 
through the non-oxidative PPP to allow a direct increase in E4P pools, major rearrangements 
occur in the cell to find new NADPH sources. This lowers the cells’ fitness and may not be an 
effective strategy for the establishment of industrial microbial factories. 
More dynamic approaches need to be developed to allow engineering the partition of the 
flux between two of the most important pathways in S. cerevisiae, namely, glycolysis and the 
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pentose phosphate pathway for the accumulation of aromatic amino acid compounds. With 
new advancements in gene editing technology, it is not unlikely that new strategies to explore 
large phenotypic landscapes will be constructed to rationally engineer the metabolism for the 
production any desired compound. Current in silico methods to predict gene deletion and 
overexpression may be greatly complemented by synthetic biology approaches that allow fast 
validations of the computational predictions. However, it remains unknown whether S. 
cerevisiae is the best microorganism to allow the industrial production of aromatic amino acid 
derivatives. As presented in this chapter and in previous publications, the unconventional yeast 
P. stipitis is a great candidate for the biosynthesis of compounds from this family, however, 
the tools available to engineer this yeast need to be further optimized to allow the establishment 
of high-producing strains. In the meantime, S. cerevisiae still remains as an organism that can 
be used as an exploratory model for metabolic engineering studies. It is expected that the 
engineering rationale should be translatable among close-related species, however, intrinsic 
differences such as regulatory networks at all levels of metabolism may remain as an additional 
challenge to overcome. 
The following list of statements summarize the conclusions obtained from this work: 
• The production of the target metabolite may not be fully accomplished through a 
biological route. In this case, a chemical step for diversification may be required. It 
is recommended to simultaneously evaluate the parameters of the main catalytic 
steps to enable seamless process integrations and to avoid expensive separation 
steps. 
• Although S. cerevisiae is the most studied yeast, several unknown factors can result 
in drastic production differences when engineering different wildtype strains from 
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the same species. Such strain-dependent phenomenon can be taken advantage of to 
develop new metabolic engineering rationales. 
• Multilevel metabolic engineering strategies following an orderly algorithm should 
allow high production titers of the target compound. 
• Understanding the transcriptional regulation that affects specific pathways is 
determinant in unlocking higher production titers. Promoter sequence analysis of 
closely related genes can represent a starting point to obtain important insights into 
the regulation of a specific pathway. 
• Single-gene perturbations may not be enough to understand the metabolic 
landscape within the cell, hence new approaches need to be devised targeting global 
perturbations. 
• In silico models that predict gene perturbations and carbon flux distributions require 
fast synthetic biology strategies for validation and high-throughput detection 
methods. 
• Regulations at all metabolic levels (transcriptional, post-transcriptional, post-
translational, and allosteric) should be expected and explored to engineer central 
and energy-demanding pathways. 
• The construction of microbial factories must not be limited to common model 
microorganisms. Non-conventional yeasts, with exemplary physiological features, 
may represent more feasible alternatives to achieve higher yields and titers.  
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1. Introduction 
In this thesis, the metabolic engineering were largely based on in silico modeling of carbon 
fluxes and strongly complemented with efficient synthetic biology techniques for fast assembly 
of DNA platforms. Assembly methods such as Gibson Assembly, Golden Gate Assembly, and 
DNA Assembler were implemented throughout this work. Hence, this appendix is dedicated 
to summarizing these outstanding technologies and expands on their applications to engineer 
microbial factories. Overall, this appendix may serve as reference for the establishment of 
assembly and optimization of genetic platforms for engineering microorganisms to produce 
compounds that go beyond the aromatic amino acid pathway.   
The technology described in this appendix encompasses trending methods for pathway 
engineering and optimization. Although efficient metabolite production in microbes does not 
rely solely on the introduction of heterologous pathways, it represents a big part of the 
engineering foundation to obtain industrial-level microbial factories. Nonetheless, to increase 
the pace of these advancements, several key aspects have to be enabled. One of them is to 
develop truly combinatorial assembly methods, i.e., methods that allow mixing and matching 
genetic parts in a few steps while relying on inexpensive chemicals. Developing fast screening 
techniques is also indispensable for the efficient selection of mutants with desired phenotypes. 
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And finally, it is important to develop assembly techniques capable of being adopted by a 
programing language for implementation in liquid-handlers or microfluidic devices. By 
transferring as most wet-lab work to a machine as possible, we are reducing potential errors, 
time, and money expenditures. But most importantly, we are ensuring that other researchers 
can easily adopt such technologies, which opens the door for fast advancements in the already 
palpable aims to substitute petroleum-derived chemicals with its biological counterparts.  
Pathway assembly represents one of the key aspects in the engineering of microbes for the 
production of valuable chemicals. With the aid of synthetic biology, recombinant DNA 
technology, and bioinformatics (Kahl and Endy, 2013; Priscilla and Ron, 2009), nowadays it 
is possible to assemble finely tuned pathways capable of producing a wide variety of natural 
and non-natural products (Lee et al., 2008; Rabinovitch-Deere et al., 2013) . The concept of 
pathway assembly has exponentially evolved with the development of tools that range from 
efficient and cheap DNA synthesis (Kahl and Endy, 2013; Robert, 2009) to microfluidics. At 
the present time, what used to be a time-consuming endeavor is now limited by one’s 
imagination.  
There is a commonly accepted "algorithm" for designing heterologous biosynthetic 
pathways (Figure 1). When a target molecule is identified, the first step is to check whether 
there are natural pathways responsible for its biosynthesis. If the enzymes have not been 
previously characterized, homolog search (Boratyn Grzegorz et al., 2012) is usually performed 
to help discern the enzymes that could best carry the desired reactions. In this step, 
phylogenesis (Jing et al., 2011) of the source organisms and the desired production host is 
taken into consideration. The functional expression of “difficult enzymes” is more likely to 
happen if two hosts have a closer evolutional relationship. With this, a group of candidate 
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enzymes can be selected to perform the desired set of reactions towards the molecule of 
interest. In case that a target molecule does not have precedence in nature, a biosynthetic 
pathway needs to be designed de novo. Generally, this process starts with searching for a 
pathway that synthesizes a product or an intermediate similar to the target compound in 
structure (Bloch and Schmidt-Dannert, 2014; Clementina et al., 2011; Ren et al., 2010). Next, 
how to design feasible routes to complete the remaining conversions is usually challenging and 
mostly important. Enzyme promiscuity sometimes allows for a direct fusion of two 
independent pathways; if not, protein engineering needs to be applied, rendering novel 
activities to the existing biocatalysts to complete the desired conversions (Lane and Seelig, 
2014; Li and Cirino, 2014; Pandya et al., 2014).  
The next important step is to select the organism in which the pathway will be implemented. 
This represents a pivotal point in the design of the pathway. Considerations such as codon-
optimization, transcriptional and translational regulation will have to be taken into 
consideration. The battle horses for heterologous pathway expression are usually the bacterium 
Escherichia coli and the yeast Saccharomyces cerevisiae, due to their well-understood 
metabolism and physiology when compared to other organisms. Great efforts have been put 
into understanding the mechanisms of gene expression and regulation in these organisms, 
allowing the development of powerful tools that permit quick manipulations in these hosts 
(Redden et al., 2014). Nevertheless, issues like low tolerance to exogenous metabolites have 
become a drawback in the implementation of metabolic pathways in such model 
microorganisms. This is mostly common in the heterologous production of biofuels and 
chemicals (Royce et al., 2013). Developing strains with higher tolerance to these metabolites 
are a strong area of research. The advent of technologies like genome sequencing and genome 
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editing have allowed the manipulation of non-conventional microorganisms with outstanding 
features that make them perfect candidates for the production of toxic compounds (Xiao et al., 
2014).  
Once the host organism has been selected, computational program such as Vector NTI (Lu 
and Moriyama, 2004), j5 (Hillson et al., 2012), and Gene Designer (Villalobos et al., 2006) 
can be implemented for convenient visualization of DNA parts. The next step consists of 
assemble the DNA pieces either in vitro or in vivo. Numerous techniques have been developed 
to carry out this task, all with the same objective: to maximize the assembly efficiency. The 
assembly efficiency will consist in, among other things, the time required to finalize pathway 
assembly with minimum errors.  
To finalize the pipeline, the pathway is introduced into the host organism and tested for the 
desired metabolite using, most commonly, chromatographic tools. After the initial 
characterization, the pathway may be modified in order to alter, for example, regulatory 
elements or the initially selected structural genes. Combinatorial design has become a new 
trend in pathway optimization, allowing the generation of large libraries of pathways with 
varying features. Elegant techniques have emerged from the need of generating strains with 
elevated titers in the case of biofuels; however, these techniques can also be applied to engineer 
the production of non-natural compounds (Cobb et al., 2014; Du et al., 2012).  
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Figure 1: Common rationale for pathway design. 
 
2. Assembly methods 
This section describes the most commonly used DNA assembly methods. Table 1 summarizes 
these techniques depicting the key features and the largest construct that was obtained as 
reported in the corresponding reference.  
 
2.1. In vitro assembly based on homologous recombination 
Unlike the conventional restriction enzyme- and ligase-dependent DNA cloning method, 
assembly based on homologous recombination does not require specific restriction sites. This 
enables the assembly of multiple fragments in a single step. By harnessing the power of 
homologous recombination, constructs can be assembled in vitro from a mixture of DNA 
fragments with overlapping regions. The assembled plasmids are then introduced into bacteria 
for enrichment, which finalizes the regeneration of the construct to double-stranded, intact 
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molecules. Among this category, SLIC, Gibson isothermal assembly, UNS, and PaperClip are 
typical and commonly used approaches  
2.1.1. SLIC 
Li et al. developed a sequence- and ligation-independent cloning (SLIC) method in 2007 (Li 
and Elledge, 2007). SLIC employs the exonuclease activity of T4 DNA polymerase to chew 
back the ends of an insert and a vector to reveal 5’ single-stranded overhangs. Two single-
stranded stretches will subsequently anneal based on homology to form a circular molecule. 
Addition of bacterial recombinase, RecA, could facilitate the annealing efficiency. Following 
electroporation to E. coli, the gaps in the recombinant molecule can be repaired by the 
endogenous homology recombination enzymes such as resolvases, nucleases, and 
polymerases. To stimulate an efficient recombination in vitro, 30-40 bp homology overlapping 
regions and a molar ratio of 2-4:1 between an insert and a vector are recommended. 
To prove the efficiency of SLIC, as many as ten fragments with 40-bp overlapping regions 
were assembled to generate a circular plasmid carrying a kanamycin-resistant gene. Among 
the fragments, nine were PCR-generated DNA molecules with sizes ranging from 275 bp to 
980 bp and the other one was a 3.1-kb linearized plasmid. It was observed that almost 20% of 
the colonies obtained after transformation had correct restriction digestion pattern (Li and 
Elledge, 2007). 
.
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Table 1: Summary of pathway assembly methods. 
 
Methods Main characteristics 
Size of the 
largest pathway 
reported (kb)* 
Uniqueness Reference 
SLIC 
In vitro homology-
based assembly with 
sticky ends 
10.2  (Li and Elledge, 2007) 
Gibson Isothermal Assembly 583 Commercial kit available (Gibson et al., 2009) 
BioBrick/BglBrick ~7 Commercial kit available (Anderson et al., 2010) 
        UNS-guided Assembly 64 
Algorithm available; Can be 
used for assembly of 
sequences with high 
similarity 
(Guye et al., 2013) 
SLiCE 24 Facilitated by bacterial cell extracts (Zhang et al., 2012) 
USER 3.2  (Bitinaite et al., 2007) 
PIPE 7.0 (Stevenson et al., 2013) 
LCR 20 (de Kok et al., 2014) 
CPEC 8.4 (Quan and Tian, 2009) 
PaperClip 
In vitro homology 
recombination-based 
assembly 
6.0 
 
(Trubitsyna et al., 2014) 
TAR 
In vivo homology 
recombination-based 
assembly 
250 Use S. cerevisiae as an 
assembly platform 
(Natalay and Vladimir, 
2006) 
DNA Assembler 52 (Shao et al., 2013) 
Genome Assembly (1.08 Mb genome) (Annaluru et al., 2014) 
MAGIC 3.9 Assembly accomplished through bacterial mating (Li and Elledge, 2005) 
Golden Gate 
In vitro Type II 
restriction enzyme 
digestion; 
Particularly useful for 
assembly of highly 
repeated fragments 
33  (Weber et al., 2011a) 
MASTER 36.4 (Chen et al., 2013) 
        GoldenBraid Assembly 14.3 
(Sarrion-Perdigones et 
al., 2011) 
Pairwise selection assembly 91 (Blake et al., 2010) 
OGAB 13 Use B. subtilis as an assembly platform (Tsuge et al., 2003) 
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2.1.2. Gibson Isothermal Assembly 
Gibson isothermal assembly is one of the most widely used DNA assembly methods due to its 
ease-of-use, flexibility, and capacity for constructing large vectors (Figure 2). It simplifies the 
recombination of overlapping DNA molecules in a single step while maintaining high 
efficiency. Very similar to SLIC, the assembly process begins with an enzyme cocktail 
(including an exonuclease, a DNA polymerase, and a DNA ligase) mixed with a set of 
overlapping DNA fragments. The function of the exonuclease is to remove nucleotides from 
the 5’ ends of double-stranded DNA molecules, thus exposing complementary single-stranded 
3’ overhangs for homologous annealing. The DNA polymerase fills in the remaining gaps after 
annealing, and the DNA ligase seals the nicks in the assembled DNA construct. After a short 
incubation period, double-stranded fully sealed DNA molecules are obtained. Gibson 
Assembly® Master Mix is commercially available, making this technique amenable to high-
throughput assembly automation.  
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Figure 2. Gibson Isothermal Assembly in vitro: Exonuclease is employed to generate ssDNA 
overhangs. Polymerase and ligase are used to repair annealed fragments and fill gaps 
……
exonuclease treatment
……
……
annealing
……
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2.1.3. UNS 
On the basis of Gibson Assembly, Unique Nucleotide Sequence (UNS) assembly introduces a 
computational algorithm to design short unique overlaps (40 bp) between adjacent DNA 
fragments. This allows to drive an ordered assembly with high efficiency, especially when 
repeated sequences are involved (Torella et al., 2014). The algorithm is built upon the 
following premises: UNSs are balanced on GC content, have no secondary hairpin structure, 
avoid promiscuous hybridization, and evade homology to start codons, promoter-like 
sequences, and commonly used restriction sites. Although the principle guiding UNS assembly 
is identical to Gibson Assembly and very similar to SLIC, it uniquely offers standard 
overlapping parts that can be easily repurposed among synthetic pathways and circuits. 
Therefore, this technology promotes a philosophy of standardization and insulation as 
emphasized in synthetic biology. To append the UNSs to the DNA fragments to be assembled, 
they can be cloned from preassembled vectors, from PCR amplification with primers 
containing the UNSs, or simply by direct synthesis of the cassettes with the corresponding 
UNSs. 
2.1.4. PaperClip 
PaperClip is a DNA assembly method based on bridging oligos attached to the ends of the 
fragments to be assembled. This flexible technique allows the assembly of DNA fragments 
without the need of restriction digestion, or specific primers to add end-homology. The 
attached oligos (clips) drive an orderly assembly process, enabling combinatorial assembly of 
fragments (Trubitsyna et al., 2014). 
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Four single stranded oligos are required for every part to be assembled. These oligos contain 
homology with the assembled part as well as 3-bp sticky ends to allow the formation of a full 
clip. Pairs of upstream oligos and downstream oligos of each DNA part are first annealed 
separately to form the upstream and downstream half-Clip. Then the downstream half-Clip of 
one DNA molecule and the upstream half-Clip of its adjacent downstream molecule, sharing 
the designed complementary tri-nucleotide sequence, are ligated to form an intact clip. The 
assembly reaction containing a destination backbone, DNA fragments, and clips can be 
performed either in cell extract of E. coli expressing recombination protein or through two-
step PCR to maintain high efficiency. 
The key highlight of this method is the direct assembly of existing DNA parts without further 
cloning and PCR amplification with the help of four single stranded oligonucleotides. 
Moreover, the four single stranded oligonucleotides, the half-clips, and the full clips can be 
stored and reused to the user’s convenience. This feature is a great advantage in automated 
DNA assembly processes.  
 
2.2. In vivo assembly based on homologous recombination 
A series of assembly methods based on in vivo homologous recombination have been 
developed. These include the transformation associated recombination (TAR) (Ma et al., 
1987), DNA Assembler (Shao et al., 2009), and mating-assisted genetically integrated cloning 
(MAGIC) (Li and Elledge, 2005), all of which take advantage of the endogenous homologous 
recombination machinery in biological cells (Table 1).  
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2.2.1. DNA Assembler 
Shao et al. developed a powerful assembly tool, named DNA assembler, which allows single-
step assembly of biochemical pathways in vivo (Shao et al., 2012; Shao et al., 2009). This 
method relies on the native homologous recombination machinery of S. cerevisiae to anneal 
multiple overlapping DNA sequences. The length of overlaps should be at least 40 bp to 
maintain high efficiency. In this approach, multiple target DNA fragments and a linearized 
vector are co-transformed into S. cerevisiae through electroporation (Figure 3a). The 
transformants are selected from amino acid dropout media according to the auxotrophic marker 
carried by the vector, and the correct constructs are confirmed by restriction digestion or 
sequencing. This method usually takes one more week than in vitro assembly because the 
assembled plasmids in yeast need to be retransformed to E. coli for DNA enrichment before 
being confirmed. However, because the assembly is conducted inside yeast cells, the power of 
S. cerevisiae homology recombination can be fully picked up, making the assembly accuracy 
and capacity significantly higher than any of the in vitro assembly methods. It has been 
demonstrated to construct a plasmid as large as 52 kb (Shao et al., 2013) although the upper 
limit could be far beyond as indicated in genome assembly based on the same principle. Shao 
et al. also described the versatility of this approach in manipulating large natural product gene 
clusters, including achieving heterologous expression, single or multiple point mutations, scar-
less gene deletion, synthesis of natural product derivatives (Shao et al., 2011; Shao et al., 2012) 
and artificial gene clusters refactoring (Luo et al., 2013; Shao et al., 2013). 
In addition, DNA assembler also enables direct chromosome-based assembly if the two 
outermost fragments are designed to anneal to the selected locus on the yeast chromosome 
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(Figure 3b). More of this technique in the context of combinatorial pathway assembly is 
described in the Section 4 of this appendix.  
 
 
 
Figure 3. DNA Assembler based on in vivo assembly: A) Vector-based assembly; B) 
Chromosome-based assembly. 
 
2.2.2. Genome assembly 
A key milestone in DNA assembly history was achieved in 2008 with the invention of the 
Gibson Assembly. Daniel Gibson  reconstituted the complete synthetic 583-kb genome of 
Mycoplasma genitalium (Gibson et al., 2008). The whole genome was split into 101 fragments 
with sizes ranging from 5 kb to 7 kb and overlapping regions ranging from 80 bp to 360 bp. 
Four quarter-genomes were individually assembled through Gibson Assembly, and then 
transferred to S. cerevisiae to reconstitute the whole genome in vivo. It is the yeast in vivo 
homologous recombination that ensures such a superior efficiency for large DNA fragment 
assembly when compared to in vitro assembly.  
In 2010, Gibson et al. further assembled the 1.08-Mb Mycoplasma mycoides genome and 
more importantly, transplanted it to the “shell” of Mycoplasma capricolum whose genome had 
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been removed(Gibson et al., 2010). The newly transplanted cell demonstrated the phenotype 
directed by the synthesized genome rather than the recipient cell and was capable of continuous 
self-replication. Beyond the numbers game, the significance of this achievement is, for the first 
time, life was synthesized purely based on chemical building blocks. It can be imagined that, 
in the future, valuable creatures can be digitally designed and created according to human 
desires, despite numerous bioethical controversies it will likely initiate.  
The most recent groundbreaking progress in genome assembly has been made through 
synthesizing the first eukaryotic chromosome, S. cerevisiae chromosome III, and moreover 
removing dispensable junk sequences to give a remarkable 14% reduction in chromosome size 
(Annaluru et al., 2014).  Starting off with the efforts of 60 undergraduate students enrolled in 
the “Build a Genome” project seven years ago, the project has quickly sparked a global 
collaboration, named Sc2.0. This initial success in minimizing one yeast chromosome without 
losing major functions will lead to the reconstruction of the other 15 yeast chromosomes. Once 
completed, Sc2.0 will push the boundaries of synthetic biology through creating synthetic yeast 
with a minimized genome that will bolster development of more efficient industry processes 
for producing biofuels, chemicals and vaccines. 
2.2.3. Non homology-based assembly  
Non homology-based assembly relies on type II restriction enzymes or serine integrases that 
recognize and cleave specific DNA molecules at fixed sites. This leads to 5’ or 3’ DNA 
overhangs with potentially infinite combination of nucleotides.  On the basis of this property, 
a series of pathway assembly tools have been built such as Golden Gate Assembly(Engler et 
al., 2009; Engler et al., 2008), Ordered Gene Assembly in Bacillus subtilis (OGAB) (Tsuge et 
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al., 2003), Serine integrase recombinational assembly (SIRA) (Colloms et al., 2014), 
GoldenBraid (Engler et al., 2008), and the pairwise selection assembly method (Table 1). 
2.2.4. Golden Gate Assembly 
The uniqueness of Golden Gate Assembly is the recognition sites of type II restriction enzymes 
which are removed during digestion, therefore allowing digestion and ligation to take place in 
the same pool (Engler et al., 2008). As shown in Figure 4, the fragments to be assembled are 
flanked with type II cleavage sites and the recognition sites. Incubation of these fragments with 
DNA ligase and a single type II restriction enzyme leads to an irreversible removal of the 
recognition sites. By designing unique overhangs, Golden Gate Assembly allows an orderly 
assembly of multiple fragments simultaneously. It has been shown that nine fragments were 
efficiently assembled into the recipient vector using Golden Gate method (Engler et al., 2009). 
More importantly, unlike homology-based assembly, Golden Gate Assembly has been proven 
to be particularly useful for building large genes or pathways with repeated sequences. For 
example, it was used to prepare transcription activator-like effector nucleases (TALENs) for 
genome editing, whereas homology-based assembly methods were useless because TALENs 
usually have 12-23 repeat modules (Weber et al., 2011b). 
  
211 
 
 
Figure 4: Golden Gate Assembly: The final desired plasmid is resistant to BsaI digestion. 
Blue elbow connectors show the BsaI restriction digestion sites. TF, target fragment. Number 
0 to 9 (including 0’ and 9’) denote any nucleotide sequence. 
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2.2.5. OGAB  
Besides E. coli and S. cerevisiae, other microorganisms possessing unique characters 
beneficial to DNA assembly have been subject of intense research (Cao et al., 2014; Gao et al., 
2014; Tsuge et al., 2003). Ordered Gene Assembly in Bacillus subtilis (OGAB) is one of these 
examples(Tsuge et al., 2003). Unlike E. coli, B. subtilis prefers to uptake linear-form DNA and 
has nucleases located on its cell membranes to process the attached double-stranded DNA 
(dsDNA) into single-stranded DNA (ssDNA). It can incorporate as many as 50 ssDNA per cell 
simultaneously. Once inside the cell, the single DNA strands will pair with their 
complementary fragments to form desired circular plasmids. This is highly facilitated by the 
endogenous recombination machinery in B. subtilis. In fact, within the ligation mixture, after 
type II enzyme and DNA ligase treatment, target fragments will line up according to sticky 
end matching, forming linear concatemers, with a much higher abundance compared to the 
circularized form. The ability of B. subtilis to uptake these linear concatemers and circularize 
them inside cells significantly increases assembly capacity. Using OGAB, it was shown that 
98 out of 100 examined colonies were correct when five gene cassettes were ligated with a 
linearized backbone.  
2.2.6. SIRA 
SIRA requires the recruitment of a serine integrase and a recombination directionality factor 
(RDF) to accomplish site-specific recombination. The serine integrase alone is able to cut DNA 
fragments at attB and attP sites in synchrony, and re-ligate them to form two new sites, attL 
and attR. However, the addition of RDF in assembly mixtures can completely reverse the 
reaction. To maintain efficient recombination, exact matching of 2-base pair overlaps of 
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adjacent fragments is required. Orthogonal recombination sites are necessary for ordered 
recombination of multiple fragments. 
High flexibility is the main advantage of this method. DNA fragments can be deleted from 
the recombined vectors or substituted by one or more fragments. A two-step replacement 
strategy was developed to improve the efficiency of fragment substitution and addition. In the 
first step, a target gene was replaced by an antibiotic resistance cassette through serine 
integrase- and RDF-dependent attL/attR recombination. Then, with serine integrase alone, 
three DNA fragments with the appropriate flanking sites replaced the antibiotic resistance 
marker. SIRA was also utilized to construct metabolic pathways, alter gene order to adjust to 
balance expression levels, and optimize synthetic genetic pathways (Colloms et al., 2014).      
 
3. Tools for Genetic Block Visualization 
The development of computational biology and bioinformatic tools has immensely aided the 
modeling and prediction of a myriad of intricate biological mechanisms. From computational 
genomics (Koonin, 2001) to evolutionary biology (Torday, 2012), cutting-edge computational 
tools allow scientists an in silico first approach to the design of wet-lab experiments, lowering 
the possibility of introducing the rather inevitable human errors. This is precisely what has 
been achieved with the visualization tools for pathway assembly. Nowadays, one can virtually 
manipulate DNA parts as building blocks with a friendly user interface program, allowing the 
elaboration of complex gene circuits and metabolic pathways. This also opens the door for the 
accurate design of intricate combinatorial pathway constructs, permitting to precisely keep 
track of restriction sites, homology regions, as well as to seamlessly design primers. Table 2 
contains the current most popular computational tools for design and visualization of DNA 
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circuits. Here we will pay special attention to j5 since it is a free, open-source web software 
that anyone can access from a computer with an Internet connection.  
 
Table 2: Computational tools for visualization and design of DNA constructs. 
 
Software Source Reference 
Vector NTI Life Technology (Lu and Moriyama, 2004) 
j5 http://j5.jbei.org (Hillson et al., 2012) 
GeneDesigner https://www.dna20.com/resources/genedesigner (Villalobos et al., 2006) 
GeneDesign https://genedesign.org (Richardson et al., 2006) 
Gene Composer http://www.genecomposer.net/ (Lorimer et al., 2009) 
 
 
j5 DNA assembly software was first introduced in 2012 by Hillson et al. with the goal of 
automating the design of scar-less multipart constructs (Hillson et al., 2012). This software 
was designed with the capability of adopting the requirements of common assembly techniques 
like isothermal Gibson (Gibson et al., 2008) and Golden Gate (Engler et al., 2008). A great 
feature enabled in this software is the cost-analysis algorithm that compares the cost of 
synthesizing a DNA fragment to laborious PCR assembly of the same fragment. This software 
also contains algorithms to create precise oligonucleotides to provide homology regions for 
the case of SLIC (Li and Elledge, 2007), Gibson (Gibson et al., 2009), and CPEC (Quan and 
Tian, 2009) (Table 1). One of the criteria for this design relies on avoiding the creation of 
fragments that share high similarity in order to prevent unspecific assemblies.  Moreover, for 
Golden Gate assembly, an algorithm built in the software allows the selection of appropriate 
overhang combinations to circumvent potential self-cohesive or off-target annealing events.  
j5 and other software like GeneDesig (Richardson et al., 2006) and Vector NTI (Lu and 
Moriyama, 2004) do not focus on the biological activity of the DNA fragments to be 
assembled. As a visualization tool, these software solely aid in the assembly design of the 
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genetic constructs. Nevertheless, tools like the RBS calculator, are great complementary tools 
since their main purpose is to generate DNA variants of regulatory fragments with tailored 
biological functionalities. The junction of software like these, together with robotics and 
microfluidics, open the door for the implementation of combinatorial approaches for assembly 
of pathways to exploit biological diversity. The concept of combinatorial design is introduced 
in the following section.  
 
4. Combinatorial Assembly 
Pathway assembly represents an important step in the engineering of microbes towards the 
production of value-added compounds. However, after introducing the heterologous genes into 
the host, an ample room for optimization remains available. Combinatorial pathway assembly 
is a concept that has been recently coined as the product of the desire to exploit variability in 
the components of a pathway. For example, this variability, commonly introduced by some 
types of mutagenesis, can be targeted to create libraries of promoters with different strengths. 
As a result, a more efficient pathway may be generated due to an optimal balance in gene 
expression.  
As it will be depicted, all of the combinatorial assembly techniques make use of the 
assembly methods mentioned in the previous section. It is in this case that the rapidness of 
assembly plays a very important role. Only the most efficient techniques, generally the ones 
that allow assembly with only a few steps, will permit the wide application of combinatorial 
design. Techniques limited by restriction digestion and multiple cloning steps may not be 
considered as an option when a combinatorial approach will be put in play. Table 3 displays 
the predominant combinatorial techniques described in this section. 
  
216 
This section will describe several approaches to assemble pathways for the production of 
diverse metabolites following combinatorial techniques. Also, an extension to the 
combinatorial approach towards production of natural products will be included. The intrinsic 
modularity of the pathways for natural product production allows combinatorial design to be 
exploited at its fullest. 
 
4.1. In vivo combinatorial assembly 
4.1.1. Cocktail assembly and chromosomal integration of metabolic pathways 
An interesting feature in the genomic DNA of S. cerevisiae is the presence of retrotransposon 
sequence denominated δ-site. This sequence has more than 100 copies spread out on the 
genome and has been used as recombination sites for the integration of heterologous genes in 
the yeast since 1990 (Sakai et al., 1990), and continues to be exploited for metabolic 
engineering studies (Lee and Da Silva, 1997; Shao et al., 2009; Yamada et al., 2010). In 2010, 
a technique denominated cocktail δ-integration was developed to introduce cellulose-
degrading genes from the fungus Trichoderma reesei into the δ sites of S. cerevisiae. T. reesei 
is a fungus known for possessing various enzymes capable of degrading cellulose (Yamada et 
al., 2010). Depending on the environment, this fungus can balance the expression of such genes 
to efficiently degrade cellulose (Stricker et al., 2008). The dynamic nature of this process has 
not permitted to discern the appropriate expression levels of the genes required in this process.   
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Table 3: Techniques for combinatorial pathway design. 
Combinatorial 
technique 
Assembly 
foundation Control level Applications 
δ-Cocktail 
Integration 
Integration of genes 
into δ-sequence in 
yeast genome 
 - Transcriptional 
(variability in integration 
events) 
 - Integration of cellulolytic enzymes in S. cerevisiae (Yamada et al., 
2010).  
 - Introduction of five-gene isobutanol pathway and eight-gene amorpha-
4,11-diene pathway in S. cerevisiae .  
COMPACTER DNA Assembler  - Transcriptional (promoter variants) 
 - Construction of an enhanced 3-gene xylose and a 2-gene cellobiose 
utilization pathway in S. cerevisiae controlled by a promoter library (Du et 
al., 2012). 
Single-Step 
Linker-Based 
Assembly 
Gibson Assembly 
 
 - Transcriptional 
(promoter variants) 
 - Enzyme variability  
 - Restoring the acetate utilization pathway in E. coli (Ramon and Smith, 
2011).  
Single Strand 
Assembly 
 - Transcriptional 
(promoter library) 
 - Translational (RBS 
library) 
 - Enzyme variability  
- Combinatorial assembly of variant promoters, RBS sequences, and 
reporter genes as proof of concept (Coussement et al., 2014).  
MoClo 
Golden Gate 
- Transcriptional  - Creation of an 11-transcription unit construct conformed by 44 individual basic units (Weber et al., 2011a).  
GB2.0  - Transcriptional   - Translational 
 - Standardized modular assembly method for gene expression in plants 
(Sarrion-Perdigones et al., 2013).  
ePathBrick BioBrick - Transcriptional - Translational 
 - Flavonoid production pathway in E. coli (Xu et al., 2012).  
 - Engineering of the fatty acid central metabolism in E. coli leading to the 
highest reported productivity (Peng et al., 2013).  
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The goal of cocktail δ -integration was to develop a S. cerevisiae strain capable of degrading 
cellulose more efficiently without knowledge a priori of the required balanced expression 
levels of the genes. They incorporated three genes, namely, endoglucanase (EG), 
cellobiohydrolase (CBH), and β-glucosidase (BGL) with different auxotrophic markers into 
multiple δ sites of the yeast. After only two rounds of integration they obtained a strain with a 
higher activity of degrading phosphoric acid swollen cellulose. This increase was merely due 
to a balanced expression of the three genes, as opposed to a strain that simply contained the 
three genes overexpressed which had 13% less activity than their resulting variant with a 
balanced expression.  
Recently, Yuan and Ching (Yuan and Ching, 2015) took the foundation of cocktail δ-
integration to engineer S. cerevisiae for the production of two metabolites of interest in the 
biorenewables field, namely, isobutanol (a potential biofuel) and amorpha-4,11-diene (a 
precursor for artemisinin, the potent antimalarial medicine). They modified the δ-integration 
technique by introducing two coding sequences (CDS) per integration cassette driven by a 
bidirectional promoter. Also, each cassette contained a gene for phleomycin resistance, 
allowing them to control the integration frequency by varying the antibiotic concentration.  
Proceeding with this idea they assembled 5 genes involved in isobutanol production into 
the yeast genomic DNA. After a single round of integration, they obtained a strain capable of 
producing 600 mg/L of isobutanol, an impressive increase, since the reference strain, 
containing the pathway in a multiple copy plasmid, was only able to produce around 6 mg/L. 
Following the same rationale, the mevalonate pathway consisting of 8 genes was integrated 
into the δ-sites with 100% efficiency (all randomly selected mutants contained the full 
219 
 
 
pathway). Although their final strain did not reach to the maximal level as reported in literature 
with a different yeast strain as the host (Newman et al., 2006; Tsuruta et al., 2009), they did 
consistently observe that the strain with higher amorpha-4,11-diene accumulation gave a low 
transcription abundance of the gene susceptible to cause feedback inhibition specific for this 
pathway. This allowed concluding that, indeed, their technique can go beyond what was 
originally shown in the DNA Assembler method for chromosome-based pathway assembly 
(Shao et al., 2009), and be utilized as a combinatorial way to fine tune the expression levels of 
individual genes to obtain more efficient phenotypes. 
The combinatorial rationale in the aforementioned technique pertains to balancing the 
expression of the genes constituting the pathway. Work like this can help decipher the ways in 
which the hosts are naturally able to produce the metabolite of interest balance the expression 
of their genes. Nevertheless, it is important to keep in mind that, in most cases, metabolic 
pathways have to be tailored to a specific host. That is, it is common that a pathway resulting 
from a combinatorial approach does not yield the same results when transferred between strains 
even if they are from the same species. Du and Yuan et al. (Du et al., 2012) demonstrated this 
when they engineered an efficient xylose- and cellobiose-utilization pathways in strains of S. 
cerevisiae with different genetic backgrounds. Similar to the cocktail integration technique, 
this group targeted combinatorial expression levels in their constructed pathways. However, 
unlike having multiple integrations into the yeast chromosomes, they created libraries of 
mutant promoters with confirmed varying strengths obtained by nucleotide analog mutagenesis 
(Ueda et al., 1995).  
The name of this combinatorial approach is COMPACTER, which stands for ‘customized 
optimization of metabolic pathways by combinatorial transcriptional engineering’ and it is 
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based on the DNA Assembler (Shao et al., 2009) technique described in the previous section. 
To analyze the colony variants, they developed a rigorous screening method that allowed them 
to select strains with higher pathway activity based on colony sizes. Subsequential refinement 
of the selected mutants helped rule out the possibility of background mutations and host 
adaptation to xylose or cellobiose. For each strain studied, they were able to obtain a mutant 
pathway that enabled optimal utilization of either xylose or cellobiose as sole carbon source.  
Translational optimization in combinatorial pathway design adds a second level of control 
to enhance heterologous production of biofuels and chemicals. This approach includes, but is 
not limited to, modulating the ribosome binding site sequences (RBS) (Levin-Karp et al., 2013; 
Salis, 2011), combining enzyme homologues (Kim et al., 2013), or implementing libraries of 
mutant enzymes. The following example demonstrates how an efficient xylose utilization 
pathway was constructed by exploring thousands of combinations of enzyme homologues with 
various features. This approach, again, took advantage of the DNA Assembler (Shao et al., 
2009) method discussed previously.   
There are multiple microorganisms that are capable of utilizing xylose as a carbon source. 
This invaluable feature is enabled by the presence of three key enzymes, XR, XDH, and 
xylulose kinase (XK). Although this set of enzymes share a certain level of homology among 
xylose-utilizing microbes, they all display differences in cofactor selectivity. These differences 
were explored by Kim et al.(Kim et al., 2013) through assembling around 8,000 xylose-
utilization pathway variants as a result of the combination of multiple enzyme homologues of 
the three enzymes originated from Scheffersomyces stipitis, a yeast well-known for its 
exceptional assimilation of xylose as a carbon source (Jeffries, 2006; Jeffries et al., 2007; 
Jeffries and Jin, 2004). Their pathway library consisted of 20 XR, 22 XDH, and 19 XK 
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homologues from various hosts, yielding a total of 8360 possible combinations. Also they 
tested the performance of the pathways in different S. cerevisiae strains, such as laboratory 
(InvSc1) and industrial (ATCC 4124) strains. Coupled with a screening method based on 
colony size, xylose consumption, and ethanol production, they were able to obtain 
combinations that allowed efficient xylose utilization compared to other highly efficient 
xylose-utilizing strains. It was observed that activities among the enzymes involved were, 
XKS>XDH>XR, represented by specific activities, which at least set a starting point for further 
understanding the optimal balance in expression level for this 3-gene pathway. They also 
proved that the performance of the pathway was strain dependent as well as carbon source 
dependent. Once again, it was proven that a combinatorial approach allows a fast way to exploit 
random combinations of pathway elements that yield better performances.  
 
4.2. In vitro combinatorial assembly 
The following examples show combinatorial pathway design based on in vitro assembly 
techniques. So far, we have shown how two levels of pathway assembly variability can be 
independently targeted by combinatorial techniques. Could it be possible to merge both into 
one to create an even larger pool of pathway variants?  
In 2010 Ramon and Smith (Ramon and Smith, 2011) developed a technique founded upon 
isothermal assembly (Gibson) (Gibson et al., 2009), which targeted the combinatorial assembly 
of promoters and gene cassettes. The fragments involved in the construct were flanked with 
40-bp unique linker sequences to drive the assembly in an orderly manner. This opened the 
combination at two control levels: one referring to the promoter strength and the other to the 
variable features displayed by homologue genes. The combinatorial assembly was done in vitro 
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and then transferred to the host organism, unlike the previous examples, in which the library 
of pathways was directly assembled and screened in the same organism. As an example to 
prove the functionality of their method, they restored the acetate assimilation pathway, 
consisting of the genes acetate kinase (ackA) and phosphotransacetylase (pta), into a mutant 
E. coli strain incapable of growing on acetate as sole carbon source. In total, they selected three 
different promoters and four homologues for each enzyme to yield a total of 144 combinations. 
They were able to select positive transformants from the plates containing acetate as sole 
carbon source. However, the distribution analysis of their mutants showed misrepresentation 
of some combinations that were later attributed to uneven concentrations of individual 
cassettes before the assembly. Predominance of some combinations could also be originated 
from better functioning pathways; showing again that combinatorial assembly can function as 
a tool to efficiently find promoters and gene homologues that display better performance in a 
multigenic pathway.  
Recently, Coussement et al. (Coussement et al., 2014) showed that targeting all three levels 
of pathway control in E. coli was feasible using fluorescent reporter gene as a proof of concept. 
The library of assembled modules contained variability in promoters, RBS sequences, and 
CDS. To enable this combinatorial approach, they relied on Gibson Assembly (Gibson et al., 
2009) of oligonucleotides encoding different regions of the construct. They named this 
approach as the single-stranded assembly technique (SSA). Since they targeted variability in 
all three elements of their target, they devised three ways in which their oligonucleotides could 
be assembled, and tested for the one yielding the highest efficiency. In their first case, a single-
very long oligonucleotide contained all three sections namely, promoter, RBS, and CDS. Their 
second scheme partitioned the sequence in three smaller oligos, while their last scheme 
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partitioned the sequence into two oligos of similar sizes. Their assembly analysis showed that 
the third scheme had the highest efficiency followed by the second scheme with almost 100% 
efficiency, while the first scheme had only around 25% efficiency.   
When implementing the third scheme into the combinatorial assembly with varying 
promoter and RBS, they were able to observe that the levels of fluorescence resulting from 
these combinations exceeded the values obtained when just the promoter or the RBS were 
individually subjected to variability. Finally, when incorporating two reporter genes in control 
of a promoter library, they observed good orthogonality in the expression of the genes. They 
were able to conclude that the method allows to independently and in parallel tune the 
transcript levels of the genes. However, even though their best scheme showed excellent 
assembly efficiencies, longer oligonucleotides may be required to assemble longer pathways, 
thus limiting the potential of this technique to small pathways, or to multiple steps of assembly, 
a common drawback of in vitro assembly techniques.  
Further, in vitro combinatorial techniques have originated from well-established assembly 
techniques. For example, the Golden Gate Assembly technique has allowed the origination of 
two combinatorial assembly techniques, namely MoClo (Weber et al., 2011a) and GoldenBraid 
(Sarrion-Perdigones et al., 2011). The main aim of these techniques is to standardize the way 
combinatorial pathways can be assembled. In MoClo and GoldenBraid, they subdivided all the 
genetic elements that will confer tiers or levels on their DNA composite, starting from level 
zero, which consists of individual genetic elements that can include, but are not limited to RBS, 
CDS, terminators, and signal peptides. In a series of one-pot assembly reactions, they combine 
the level-zero parts to form a level-one composite. Successively, the level-one constructs can 
be combined to form level-two assemblies. This is enabled by flanking each module with 
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fusion sites and type II restriction sites (BsaI and BpiI); destination vectors allowed for 
different selection methods of positive transformants. In 2013, an update to GoldenBraid was 
published and was denominated GoldenBraid 2.0 (GB2.0) (Sarrion-Perdigones et al., 2013). 
Similar to the two previous examples, the inventors of GB2.0 made an analogy of their 
technique to the foundation English grammar. Their level-zero parts function just like 
morphemes and grammemes as units in linguistics that allow the construction words to 
complete phrases. Mainly, GB 2.0 was developed as a standardized procedure to assemble 
pathways for plant metabolic engineering with combinatorial applicability. As an updated 
version of GoldenBraid, GB2.0 incorporates several new tools that simplify the overall 
assembly process. First, they introduced a BtgZI site into the entry vector. The ability of this 
enzyme to cut 10 nucleotides from its recognition site enables the capability of a “dual-release” 
option for each GBpart, speeding up the construction of multigenic assemblies. Also they have 
arranged a collection of standard parts compatible with their technique available as an open 
source, as well as web applications that allow a friendly interface for in silico pathway design. 
The authors envisioned their technique as a revolutionary method that will allow fine 
automation of the assembly process. They claimed that the use of their technique will 
potentialize the advancement in, not only plant synthetic biology, but also for microorganisms, 
since their method facilitates exchangeability of genetic parts.  
Natural products represent the perfect example for implementing a combinatorial approach 
to enable exploration of the vast pool of metabolite variants. Although the discovery of natural 
products is a topic of great importance, the intricate regulations embedded in gene clusters 
involved in the production of such secondary metabolites hamper quick advancement in this 
area. New DNA technologies have to be implemented to ease drug discovery and one of them 
225 
 
 
is fast combinatorial ways to assemble gene clusters or independent enzymes involved in 
secondary metabolism.  
A classic example of combinatorial assembly for natural products is the scrambling of 
enzymes belonging to the family of type I polyketide synthase (PKS). The enzymes involved 
in this family resemble an industrial assembly line in which each module carries out a specific 
reaction. This feature allows to easily apply the concept of combinatorial design, in which each 
module can be removed, mutated, or substituted by putative enzymes to finally yield the 
desired product or even create unnatural ones. Menzella et al. (Menzella et al., 2005) developed 
a combinatorial approach to assemble codon-optimized PKS modules to produce unnatural 
triketide lactones in E. coli. They designed 11 donor and 14 acceptor modules from which 72 
out of the 154 possible combinations were able to produce a potential unnatural triketide 
lactone. In addition, in 2007 Katsuyama et al. (Katsuyama et al., 2007) targeted type III PKS 
and produced a series of metabolites from the stilbene and flavonoid family by combining 
enzymes from different non-microbial sources. By mixing enzymes involved in precursor 
formation and post-PKS tailoring, the authors enabled the diversification of the originally 
targeted products and discivered 36 new secondary metabolites.   
Most of the research in this field has been done with the aid of classic DNA cloning 
methodologies, in which time-consuming steps limited the research to case-by-case scenarios. 
The development of new assembly techniques and synthetic biology tools, hence, represents a 
great potential for new natural product discovery. Even though there are only a few examples 
of applying such techniques in this area, it is not hard to foresee the great potential that they 
possess. For example, a recently developed synthetic biology strategy based on a plug-and-
play scaffold allowed for the heterologous production of spectinabilin in Streptomyces lividans 
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(Shao et al., 2013). This technique allowed the bypass of endogenous regulation by setting the 
expression of the genes in the cluster to constitutive promoters. Founded upon the DNA 
Assembler (Shao et al., 2009), this technique has also allowed the production of polycyclic 
tetramate macrolactams and the discovery of new derivatives from the same family (Luo et al., 
2013). 
The methods exemplified in this text have demonstrated vast improvements in terms of 
standardization, efficacy, and versatility. Nowadays the limitations do not solely rely on the 
assembly method of choice but rather on developing fast screening techniques that permit to 
easily explore the multiple phenotypes generated along the assembly process. Hence, to 
leverage rapid strain engineering enabled by combinatorial pathway assembly, high-
throughput screening techniques must be readily available.  
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